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Abstract  
Due to the universal lack of donor tissue, there has been emerging interest in engineering 
materials to stimulate living cells to restore the features and functions of injured organs. 
We are particularly interested in developing materials for corneal use, where the necessity 
to maintain the tissue’s transparency presents an additional challenge. Every year, there are 
1.5 – 2 million new cases of monocular blindness due to irregular healing of corneal 
injuries, dwarfing the approximately 150,000 corneal transplants performed. The large gap 
between the need and availability of cornea transplantation motivates us to develop a 
wound-healing scaffold that can prevent corneal blindness. 
 
To develop such a scaffold, it is necessary to regulate the cells responsible for repairing the 
damaged cornea, namely myofibroblasts, which are responsible for the disordered and non-
refractive index matched scar that leads to corneal blindness. Using in vitro assays, we 
identified that protein nanofibers of certain orientation can promote cell migration and 
modulate the myofibroblast phenotype. The nanofibers are also transparent, easy to handle 
and non-cytotoxic. To adhere the nanofibers to a wound bed, we examined the use of two 
different in situ forming hydrogels: an artificial extracellular matrix protein (aECM)-based 
gel and a photo-crosslinkable heparin-based gel. Both hydrogels can be formed within 
minutes, are transparent upon gelation and are easily tunable.  
 
Using an in vivo mouse model for epithelial defects, we show that our corneal scaffolds 
(nanofibers together with hydrogel) are well-tolerated (no inflammatory response or 
turbidity) and support epithelium regrowth. We developed an ex vivo corneal tissue culture 
vii 
 
model where corneas that are wounded and treated with our scaffold can be cultured while 
retaining their ability to repair wounds for up to 21 days. Using this technique, we found 
that the aECM-based treatment induced a more favorable wound response than the heparin-
based treatment, prompting us to further examine the efficacy of the aECM-based treatment 
in vivo using a rabbit model for stromal wounds. Results show that treated corneas have 
fewer myofibroblasts and immune cells than untreated ones, indicating that our corneal 
scaffold shows promise in promoting a calmer wound response and preventing corneal 
haze formation.  
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Chapter 1 
 
Introduction 
 
1.1 Tissue regeneration  
The field of regenerative medicine or tissue engineering uses various scaffold materials to 
stimulate living cells to restore injured organs and/or tissues, in hopes of reducing the need 
for organ replacement. The first attempt at tissue engineering is widely recognized as the 
effort of Dr. W.T. Green in generating new cartilage using chondrocytes seeded onto small 
pieces of bone in the early 1970s.1 In the 1980s, Drs. John Burke and Ioannis Yannas 
together developed the first commercially reproducible, synthetic human skin substitute 
using silicone and a matrix containing cow tendons and shark cartilage.2 It was not until 
the mid 1980s - early 1990s that scientists started designing biomimetic scaffolds, in 
contrast to seeding cells onto naturally occurring ones.3 Since then, the field of tissue 
engineering has grown exponentially, and it was estimated that $600 million was spent in 
tissue engineering research alone in 2001.4  
 
Recently, with increasing knowledge that cells acting to repair damaged tissues in vivo are 
bombarded with a multitude of molecular signals, there has been emerging interest to 
develop scaffolds with specific biochemical, mechanical and topographical cues to guide 
the regeneration of new tissue by these repair cells. For example, in the context of bone 
tissue and cartilage engineering, osteoblasts that are seeded on nanofibrous scaffolds have 
increased rates of proliferation, differentiation and mineralization5-7 and in nerve 
regeneration, controlled release of fibroblast growth factor enhances neurite extension of 
various types of neurons8-10. We are particularly interested in developing materials for the 
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cornea, which has a complex nanostructure that is necessary and essential for maintaining 
the transparency of the tissue (described below).  
 
In developing a corneal scaffold, we will gain a deeper understanding on how native 
corneal cells respond to their microenvironment. We envision that accumulation of such 
knowledge will provide new insight on central processes responsible for tissue repair and 
regeneration that can be extended to other organs, as well as possibly aid in the 
development of in vitro models for cancer metastasis. 
 
1.2 Corneal blindness  
As stated above, our focus is in creating materials for corneal applications. We are 
motivated by the fact that corneal blindness is the fourth leading cause of blindness 
worldwide (after cataracts, glaucoma and age-related macular degeneration), and impairs 
the vision of more than 10 million people worldwide.11 Currently, the only way to treat 
corneal blindness is by removing the injured tissue and replacing it with either a donor 
cornea or an artificial implant.  
 
Worldwide, there are 1.5 - 2 million new cases of monocular blindness per year, dwarfing 
the approximately 150,000 corneal transplants performed every year.11 According to the 
Eye Bank Association of America, there were approximately 68,000 donated corneas in 
the United States in 2012, of which only 38,496 (56%) were implanted into patients (Table 
1).12 Tissue suitability was the leading cause of tissue judged unsuitable for transplant. In 
addition, although the initial success rate of donor corneas can be quite high (~90% in the 
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first year post-transplant), this number decreases to around 75% after 5 years (i.e. 25% 
rejection rate).13 It is also estimated that the average cost of a corneal transplantation 
surgery is $14,000,14 not easily affordable for patients in developing countries.  
 
Synthetic artificial corneas have been developed to alleviate the need for donor tissues. The 
Boston Keratoprosthesis (Boston KPro) was developed under Dr. Claes Dohlman in the 
1960s, and was approved by the FDA in 1992.15,16 Its most recent design consists of a front 
plate, a piece of medical grade polymethylmethacrylate (PMMA), and a back plate; during 
assembly, the front and back plates snap together with the PMMA piece sandwiched in-
between to form a collar-button-like device. More recently, Chirila, Hicks and colleagues 
have developed the AlphaCor (approved by the FDA in 2003),17,18 which is made of a 
central transparent region made of poly(2-hydroxyethyl methacrylate) and a peripheral 
region with interconnecting pores that allow integration with surrounding corneal tissue. 
Despite these efforts, artificial corneas have not yet expanded the availability of corneal 
replacement due to the high incidence of severe complications (e.g., a 2009 study of Boston 
KPro found that 65% of patients suffered from postoperative complications19, while a 2011 
study of AlphaCor found that 9 out of 15 patients suffered “corneal melt” after 
implantation20). There are only approximately 1000 Boston KPro devices implanted every 
year21, and only ~300 AlphaCor devices have been implanted total (up to 2008)22. In 
addition, the AlphaCor implantation is a two-stage process over several months, and 
requires tremendous technical ability. Therefore, there still exists an urgent need to develop 
alternative approaches to treating corneal blindness that are not only effective, but easy for 
physicians to implement.  
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1.3 Structure of the cornea  
The human cornea is a 500-µm-thick transparent, dome-shaped layer in the front of the eye 
that covers the iris and pupil (Figure 1A), and is responsible for two-thirds of the eye’s 
total focusing power.23 The cornea can be separated into three main layers (Figure 1B): 
the outer epithelium (made up of multi-layers of epithelial cells), the middle stromal layer, 
and the inner endothelium (made up of a single layer of endothelial cells). The epithelium 
is regenerative (every 7 days), and provides protection for the eye against foreign materials 
(e.g. dust, bacteria). The endothelial cells making up the endothelium contain many 
metabolic enzymes that work to pump water from the cornea, thereby keeping it clear. If 
the endothelial cells become damaged, they do not regenerate, and corneal edema will 
ensue.  
 
The middle stromal layer makes up the bulk of the cornea (85-90% of the total corneal 
thickness) (Figure 1C).24 Its highly-ordered network of extracellular matrix (ECM) 
proteins and keratocytes (specialized fibroblasts that reside in the stroma) are crucial to 
maintaining corneal transparency. The stromal ECM is made up of mainly collagen and 
proteoglycans. Collagen fibers (25 - 35 nm in diameter) align parallel to each other at 
uniform distances to form a lamellae sheet. Over 300 lamellae sheets stack on top of each 
other at varying angles from 0 to 90 degrees to form the full thickness of the stroma (Figure 
1D). The proteoglycans in the stroma absorb and retain large amounts of water, therefore 
giving the stroma its hydrogel-like quality. They also act to regulate the uniform spacing 
between the collagen fibrils, thereby keeping the collagen fibrils at defined distances that 
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minimizes light scattering.25 Corneal keratocytes reside between the collagen lamellae with 
a flattened morphology (Figure 1E). In a healthy cornea, the keratocytes usually display a 
quiescent phenotype, are largely immobile and incapable of rapid rates of migration. 
Keratocytes continuously synthesize corneal crystallins, which are water-soluble 
cytoplasmic proteins that unify the refractive index within the cells, thereby minimizing 
light scattering. 
 
1.4 Corneal injury  
When minor abrasions occur on the surface of the cornea, healthy epithelial cells migrate 
and close the wound quickly. However, for deeper injuries that penetrate into the stroma, 
the healing process is much more intensive, and takes much longer.26 Keratocytes in the 
direct vicinity of the wound site undergo apoptosis, while adjacent keratocytes become 
activated and differentiate into repair phenotypes – fibroblasts and myofibroblasts. These 
repair cells migrate into the wound and actively secrete new ECM proteins. However, the 
newly synthesized collagen is disorganized and lacks the orderly structure that maintains 
corneal transparency (Figure 2).27 In addition, there is a decreased production of keratan 
sulfate proteoglycans and an increased expression of hyaluronan, which disrupts the 
spacing between newly deposited collagen fibrils. The myofibroblasts express alpha-
smooth muscle actin (αSMA), which organizes into stress fibers and generates high 
contractile forces that function to close wounds28,29, but also contributes to disrupting the 
smooth refracting surface of the cornea. Also, myofibroblasts have a decreased expression 
of corneal crystallins30, which renders them less transparent as quiescent keratocytes. To 
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prevent corneal blindness, it is essential to modulate the activation of myofibroblasts, 
thereby reducing the production of αSMA and disordered ECM proteins. 
 
1.5 Tissue-engineered approaches  
There have been significant efforts in developing a corneal scaffold, and they can be 
divided into two main categories: synthetic-polymer based scaffolds (Table 2) and protein-
based materials (Table 3). 
 
Synthetic polymers used include poly(ethylene glycol) (PEG), poly(acrylic acid) (PAA), 
polyvinyl alcohol (PVA) and poly(lactic-co-glycolic acid) (PLGA).31-36 One of the more 
successful attempts was developed by Curtis Frank,33,34 where he and his students created 
a hydrogel with an interpenetrating network of PEG and PAA, and demonstrated that the 
hydrogels are optically clear, highly permeable to glucose, and have high tensile strength 
despite having a high water content. However, they observed that epithelial wound closure 
over the hydrogel was not comparable to sham wounds in an organ culture model, possibly 
due to the lack of cell-binding domains in the hydrogel.  
 
Protein-based scaffolds have also been investigated, with a majority of them using collagen 
as the main material.37-45 Sheardown and colleagues developed a dendrimer-crosslinked 
collagen scaffold, which has favorable glucose permeability and mechanical properties, 
and also supported human corneal epithelial cell growth and adhesion.45 However, they 
observed that the optical transparency of the crosslinked gels was variable and highly 
dependent on the crosslinker used.  
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The most promising efforts have come from May Griffith’s work throughout the past 15 
years. In 1999, she published a pivotal paper where she isolated cells from different corneal 
layers and successfully constructed an artificial cornea by culturing the cells around a 
cellular scaffolding structure.46 More recently, she and her coworkers have developed a 
corneal substitute composed of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 
crosslinked recombinant human collagen and implanted the material into 10 patients using 
sutures to secure in place.47 They reported that two years after implantation, all 10 patients 
improved their vision to levels comparable that of patients who received donor corneas, 
but only when the patients also wore contact lens (the sutures impaired vision and needed 
to be smoothed by a contact lens). In addition, they observed that epithelial cells did not 
fully migrate over the implant, and instead halted at the sutures, causing discrete areas of 
corneal haze in those areas. 
 
1.6 Objectives and organization  
While alternatives to donor corneas are being developed, the large gap between the need 
and availability of cornea transplantation motivates us to take a different approach. 
Specifically, our goal is to develop a wound-healing scaffold that can prevent corneal 
blindness. An ideal corneal scaffold should have several basic qualities: (1) appropriate 
topological and biochemical cues that modulate myofibroblast phenotype, (2) suitable 
architecture that directs cell infiltration, (3) optical and mechanical profiles that match 
those of the native cornea, and (4) ability to form in situ to prevent the need for sutures.  
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The present thesis details our efforts in developing such a corneal scaffold. Chapter 2 
describes effects of electrospun gelatin nanofibers (different diameter and orientation) on 
corneal cell behavior (migration, phenotype). Chapter 3 describes effects of growth factors 
on myofibroblast phenotype. Chapter 4 details the development of a visible-light photo-
crosslinkable heparin-based hydrogel that is within the safety limits of corneal and retinal 
light exposure. Our composite scaffold (nanofibers together with hydrogel) was tested in 
vivo using a mouse model (Chapter 5), ex vivo (Chapter 6), and in vivo using a rabbit model 
(Chapter 7).  
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Figure 1. Structure of the eye and cornea. A) Schematic of the human eye. The cornea 
is the outermost part of the eye. B) The cornea can be separated into three main layers: 
epithelium, stroma and endothelium. C) Hematoxylin-and-eosin stained tissue section 
of a human cornea.48 D) Top-down view of the stroma: lamellae of collagen fibrils 
stack on top of each other.49 E) Cross-section of the stroma: keratocytes (K) are found 
in between layers of the collagen lamellae.49  
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Figure 2. Scanning electron micrographs of the stroma from wounded and healthy 
corneas.50 The collagen fibrils are disorganized at A) month 5, B) month 10, and C) 
month 16 after injury. D) In a normal cornea, the collagen fibrils are regularly spaced 
and uniaxially aligned inside the lamellae. Scale bar = 200 nm.  
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Table 1. Number of donor and transplanted corneas in the US and UK.  
 US (2012)12 UK (2013-2014)51 
Donated corneas  68,681 6,255 
Transplanted corneas 38,502 (56%) 3,597 (66%) 
Top reasons for tissue 
not being used  
17% tissue quality 14% tissue quality 
13% contamination   11% medical 
contraindications 
12% medical record or 
autopsy findings  
5% exceeded storage 
days 
4% bacterial/fungal 
contamination 
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Table 2. Synthetic polymer-based corneal scaffolds  
Description Authors Ref. 
Central core optical component made of a 
poly(ethylene) glycol, poly(acrylic acid) double 
network; peripheral skirt of poly(hydroxyethyl 
acetate) hydrogel; surface modified with collagen 
type I 
Myung, D. et al.  31 
Central core made of polyvinyl alcohol; skirt 
made of a nano-hydroxyapatite/polyvinyl alcohol 
hydrogel composite 
Xu, F. et al.  32 
Interpenetrating network of poly(ethylene glycol) 
and poly(acrylic acid) 
Hartman, L. et al. 
Myung et al.  
33 
34 
Electrospun poly(lactic-co-glycolic acid) 
scaffolds containing micropockets 
Ortega, I. et al.  35 
Corneal stromal cells mixed with non-woven 
polyglycolic acid fibers to form cell-scaffold 
construct  
Hu, X. et al. 36 
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Table 3. Protein-based corneal scaffolds  
Description Authors Ref. 
Silk films 
 
Lawrence, B.D. et 
al. 
Gil, E.S. et al.  
37 
 
38 
Fibroblast precursor cells combined with gelatin 
hydrogels  
Mimura, T. et al.  
 
39 
Corneal cells (epithelial cells, fibroblasts and 
endothelial cells) cultured on a fibrin-agarose 
scaffold to construct full-thickness corneal 
substitute 
Alaminos, M. et al.  
 
40 
Compressed collagen scaffolds with embedded 
corneal keratocytes and limbal stem cells 
Mi, S.; Connon, 
C.J.  
41 
Glucose-mediated UV crosslinkable collagen 
scaffolds 
Crabb, R.A.; 
Hubel, A.  
42 
Aligned polylactic acid nanofibers within a 
collagen hydrogel 
Wilson, S.L. et al. 
 
43 
Magnetically-oriented orthogonal collagen 
scaffolds 
Builles, N. et al. 44 
Dendrimer crosslinked collagen gels  Duan, X.; 
Sheardown, H.  
45 
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Chapter 2 
 
Effects of nanofiber diameter and orientation on corneal epithelial cells, fibroblasts 
and myofibroblasts 
 
2.1 Introduction 
In vivo, keratocytes in the corneal stroma reside between layers of lamellae, which have 
a distinctive nanometer scale morphology that includes aligned collagen fibrils. Thus, 
keratocytes are continuously exposed to a microenvironment containing oriented 
topological and biochemical signals. The present study builds upon recent advances in 
understanding how biophysical cues affect corneal cell behavior, especially by Murphy, 
Nealey and Russell, who have collectively demonstrated that topography can influence 
the corneal fibroblast-myofibroblast transformation in vitro.1-3 Substrate anisotropy 
(aligned pitches 400 - 4000 nm compared to planar controls)1-2 and compliance 
(polyacrylamine hydrogels 4-71 kPa compared to tissue culture plates >1GPa)3 
influence myofibroblasts to reduce αSMA expression. Orwin and coworkers further 
showed that scaffold composition (collagen compared to tissue culture plates)4 and 
structure (3D collagen sponge compared to 2D films)5 reduce αSMA expression in 
myofibroblasts. In addition, Guillemette and coworkers demonstrated that aligned 
surface grooves (1 - 10 microns) stimulate corneal fibroblasts to deposit new collagen 
that is also oriented.6 They found that the orientation of the first cell layer becomes a 
physical cue to induce other cell layers to orient and deposit collagen in a way that 
mimics the structure of the native cornea. These prior findings led us to hypothesize that 
nanofibers, reminiscent of those found in the native cornea both in dimension and 
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orientation, might promote orderly tissue repair. Therefore, we prepared nanofiber 
layers that could be used in a wound dressing and examined their influence on 
myofibroblast phenotype.  
 
We chose to use electrospinning to fabricate the nanofibers, since electrospinning is a 
versatile method that allows for the formation of continuous fibers using virtually any 
material and does not require specialized equipment.7,8 Pioneered by Dr. Darrell 
Reneker, during the electrospinning process (described in detail at the end of the 
chapter), high voltage is applied to the electrospinning solution (usually polymeric or 
protein-based), which leads to the formation of fibers that are deposited on a grounded 
collector.9,10 The dimensions and morphology of the fibers can be varied by changing 
the properties of the molecule itself (molecular weight, solubility), the properties of the 
solution (concentration, solvent), processing conditions (needle diameter, field strength, 
needle to collector distance, collector geometry) and ambient conditions (temperature, 
relative humidity).11-15 Here, we used gelatin as our material to fabricate nanofibers of 
different diameter (100 – 220 nm) and different orientation (isotropic, uniaxially 
aligned, radially aligned) that could be used in a wound dressing, and examined their 
influence on the native behavior of corneal cells. 
 
Our results show that the effect of nanofiber diameter in the range of 100 – 220 nm is 
weak; whereas, nanofiber orientation strongly affects the migration rate of corneal cells 
and αSMA expression of myofibroblasts in vitro. Surprisingly, the mechanism of the 
myofibroblast response is essentially integrin independent; rather, it appears to involve 
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mechanotransduction. In relation to potential clinical translation, the electrospun 
nanofiber substrates are transparent when wet, non-cytotoxic, and easy to handle 
without breaking. Thus, protein nanofiber mats may prove valuable in wound dressings 
for corneal injury that can orchestrate an orderly wound healing response, preventing 
corneal blindness.  
 
2.2 Methods 
Fabrication of nanofiber mats.  
Gelatin A (Sigma Aldrich, St. Louis, MO) was dissolved in a mixture of 5:3:2 acetic 
acid/ethyl acetate/distilled water at a concentration of 10-15% (w/w) and stirred 
overnight at 37oC. Electrospun nanofibers were fabricated from the gelatin solution 
using a 22-gauge needle at a voltage of +15kV (Universal Voltronics high voltage 
supply) and a needle to collector distance of 8 cm. Different fiber orientations were 
achieved using different grounded collectors: isotropic nanofibers were obtained using 
a metal ring (stainless steel back ferrule, 0.95 cm in diameter) placed on a flat aluminum 
plate; radially aligned nanofibers were collected on a metal ring nested on a copper 
frame with a centered copper point electrode, and uniaxially aligned nanofibers were 
made using a pair of split electrodes (0.95 cm apart). Electrospun fibers were crosslinked 
with glutaraldehyde (vapor phase) overnight, and sterilized with 70% ethanol prior to 
use. Details on nanofiber characterization are found in Supplementary Information.  
 
Characterization of fabricated scaffolds 
To visualize the nanofiber mats, they were labeled with either NHS-rhodamine or NHS-
fluorescein dye (Thermo Fisher, Rockford, IL). A stock solution was prepared by 
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dissolving the dye in dimethyl sulfoxide at a concentration of 10 mg/mL. The staining 
solution was made by diluting the stock solution with Dulbecco’s phosphate buffered 
saline (DPBS, GIBCO, Grand Island, NY) to a final dye concentration of 0.1 mg/mL. 
The nanofiber mats were immersed in the staining solution for 1 hour (at room 
temperature) on a rocker. To remove any residue dye, the nanofibers were rinsed in 
deionized water for a total of 1.5 hours, during which the water was replaced twice. 
Nanofiber mats were air dried prior to use. 
 
To characterize the morphology and diameter of the electrospun fibers, a field emission 
scanning electron microscope operating at an accelerating voltage of 5 kV was utilized 
(Zeiss 1550 VP). Samples were mounted onto aluminum SEM stubs using double-sided 
carbon tape and sputter-coated (Cressington 208HR) with a 10 nm layer of palladium 
prior to measurement to minimize electron charging effects. 3 pictures were taken for 
each scaffold, and 40 independent fibers were counted for each picture. Each scaffold 
was performed in triplicate, and the experiment was repeated three times on separate 
days.  
 
To examine the transparency of the nanofiber mats, the optical transmittance of the 
scaffolds was measured with a UV-VIS spectrophotometer (Beckman DU640) at a 
spectral range of 400-700 nm. The reference sample was an explanted porcine cornea 
alone, and the experimental sample consisted of a nanofiber mat placed in front of the 
porcine cornea. 
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Rabbit corneal fibroblast isolation and culture.  
Fibroblasts were isolated from young rabbit eyes (mixed gender, approximately 8-12 
weeks old, Pel-Freez, Rogers, AR) as described elsewhere.16 The isolated fibroblasts 
were passaged every 2-3 days when 95% confluence was reached. Cells from passages 
5-8 were used in the present study.  
 
Characterization of cell shape, orientation and viability.  
To examine cell shape and orientation, fibroblasts seeded on the nanofiber surfaces were 
imaged under an inverted phase contrast microscope with a 10x objective, and 3 random 
pictures were taken of each surface. To visualize the intracellular cytoskeleton, cells 
were first fixed with 4% paraformaldehyde in DPBS for 10 minutes, washed 3x with 
DPBS, and permeabilized with 0.1% Triton X-100 in DPBS for 10 minutes. Blocking 
was then performed with 1% bovine serum albumin in DPBS for 30 minutes at room 
temperature. The cells were incubated with 1:1000 rhodamine phalloidin (Invitrogen, 
Grand Island, NY) in 1% BSA for 60 minutes at room temperature, followed by 3x 
washes in DPBS. Cell nuclei were stained with Hoescht 33342 (Invitrogen, Grand 
Island, NY) at 0.5 µg/mL for 10 minutes at room temperature in the dark. Cells were 
then imaged with a confocal microscope (Zeiss LSM 510) using a 40x objective. Five 
random images were taken for each scaffold. Cell viability on the scaffolds was assessed 
using a LIVE/DEAD® cell viability assay following the manufacturer’s protocol using 
10µM ethidium homodimer-1 and 2µM calcein AM (Invitrogen, Grand Island, NY). 
 
In vitro study of cell migration.  
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Nanofiber mats were detached from collectors and placed onto circular gelatin hydrogel 
disks (15% gelatin A in DPBS, 9.5 mm diameter, 700 µm thick, crosslinked with 
glutaraldehyde, liquid phase, and rinsed in deionized water). A circular 
polydimethylsiloxane (PDMS) disk (4 mm diameter, 100 µm thick, prepared following 
manufacturer’s protocol, Dow Corning, Midland, MI) was placed at the center of the 
fiber mat, creating a three-layered structure. Cells were then seeded in each well (1x105 
cells/mL) and cultured to confluence (typically 24 hours following cell seeding). The 
PDMS disks were lifted with sterile tweezers, thereby creating a circular wound site. A 
gelatin hydrogel with no nanofiber mat was used as a control. Cell migration was tracked 
and imaged at regular time intervals using an inverted phase contrast microscope. 
Images were analyzed using Autostitch and ImageJ software (NIH). Each scaffold 
parameter was repeated at least 5 times. Cells of the same passage were used for each 
independent experiment. 
 
qPCR, Western blotting, immunocytochemistry.  
Nanofiber mats were detached from collectors and placed onto glass slides coated with 
an N-hydroxsuccinimide ester functionalized polymer layer (Nexterion Slide H, Schott, 
Louisville, KY). Glass slides spin-coated with gelatin (50 µm) were used as the planar 
control. Glass slides were then exposed to glutaraldehyde (vapor phase, 2 hours), 
followed by washing 3x in deionized water (30 minutes each). Corneal fibroblasts were 
seeded onto nanofibers (5x104 cells/mL). Transforming growth factor-beta (TGF-β, 1 
ng/mL) was added 24 hours post-seeding to induce the myofibroblast phenotype16,18, 
and cells were grown for 72 hours.  
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Quantitative PCR (qPCR).  
TGF-β induced myofibroblasts were lifted from the nanofiber surface and pelleted. RNA 
was extracted using the Qiagen RNeasy kit following the manufacturer’s protocol 
(Qiagen, Valencia, CA). RNA yield was determined using a Nanodrop 
spectrophotometer (Thermo Sci., Wilmington, DE). Gene expression was evaluated 
using qPCR with an EXPRESS One-Step SYBR® GreenERTM Universal kit 
(Invitrogen, Grand Island, NY) in an Eco Real-Time PCR system (Illumina, San Diego, 
CA). qPCR was carried out using 50 ng RNA per sample and commercially available 
primers for αSMA, GAPDH and β-actin in a total reaction volume of 10 µL per sample. 
GAPDH and β-actin served as references. Products were evaluated by melt curve 
analysis and sizing on agarose gels. Gene expression was normalized relative to the 
expression of mRNA from control surfaces (no nanofibers present) under the same 
culture conditions using the ΔΔCt method as described elsewhere.17 The mRNA from 
the control surface was given an arbitrary value of 1.0. qPCR reactions were run in 
triplicates per sample, and the experiment was repeated three times on separate days. 
 
Western blotting.  
TGF-β induced myofibroblasts were lifted from the nanofiber surface, pelleted and lysed 
with M-PER mammalian protein extraction reagent following the manufacturer’s 
protocol (Thermo Sci., Rockford, IL). Insoluble cellular debris was removed by 
centrifugation at 10k rpm for 10 minutes, and the supernatant was collected into new 
tubes. A bicinchroninic acid (BCA) protein assay (Thermo Sci., Rockford, IL) was 
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performed to determine the concentration of the extracted protein. Equivalent amounts 
of protein (10 µg per sample) were mixed with loading buffer, denatured by boiling for 
5 minutes and loaded onto a MINI-PROTEAN TGX precast gel (Bio-Rad, Hercules, 
CA). Gel electrophoresis was performed at 200V for 40 minutes. Protein bands were 
then transferred to a nitrocellulose membrane at 100V for 1 hour. The nitrocellulose 
membrane was blocked for 1 hour at room temperature in blocking solution (5% BSA, 
0.1% Tween-20 in DPBS). The membrane was then incubated with mouse anti-GAPDH 
antibody (Invitrogen, Grand Island, NY) at 1:2500 dilution in blocking solution for 1 
hour at room temperature. The blot was washed 3x (10 minutes each) in DPBS-T (DPBS 
+ 0.1% Tween-20), followed by incubation with AlexaFluor 647 goat anti-mouse 
secondary antibody (Invitrogen, Grand Island, NY) in blocking solution at 1:2500 
dilution for 1 hour in the dark. The blot was washed 3x (10 minutes each) in DPBS-T 
and incubated with FITC-conjugated mouse anti-αSMA antibody (Sigma Aldrich, St. 
Louis, MO) at 1:2500 dilution in blocking solution for 1 hour in the dark. After rinsing 
with DPBS-T, the blot was scanned using a Typhoon Trio Scanner (GE, Piscataway, 
NJ). Relative intensities of α-SMA bands were normalized with GAPDH bands. 
Immunoblotting was performed on samples from three independent experiments. 
 
Immunocytochemistry.  
TGF-β induced myofibroblasts were first washed 3 times with DPBS, and then fixed, 
permeabilized and blocked as detailed above. The cells were then incubated with 1:1000 
FITC-conjugated mouse anti-αSMA antibody (Sigma Aldrich, St. Louis, MO) in 1% 
BSA for 60 minutes at room temperature. Cells were washed 3 times with DPBS, and 
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cell nuclei were stained with Hoescht 33342 (Invitrogen, Grand Island, NY) at 0.5 
ug/mL for 10 minutes at room temperature in the dark. Cells were then stored in PBS 
until imaging with a Zeiss Axiovert 25CFL fluorescent microscope. For analysis of 
αSMA protein expression, 5 random images were taken of each scaffold using a 5x 
objective for both Hoescht and FITC fluorescence. Blue dots (Hoechst stained nuclei) 
were counted as total cells per image, while cells presenting a green signal (FITC) were 
counted as positive for αSMA. Immunocytochemistry was performed on samples from 
three independent experiments. 
 
siRNA transfection of human corneal fibroblasts.  
FAK, Raf-1, YAP and TAZ were knocked down in human corneal fibroblasts 
(ScienCell, Carlsbad, CA) using siRNAs targeted to the corresponding genes (all from 
Santa Cruz Biotechnology, Dallas, TX). Cells (P3, 60-70% confluent) were transfected 
with siRNA (60 nM) using siRNA transfection reagent (Santa Cruz Biotechnology, 
Dallas, TX) according to the manufacturer’s instructions. Control cells were transfected 
with FITC-conjugated control siRNA (Santa Cruz Biotechnology, Dallas, TX). The 
cells were incubated for 72 hours before collection. 
 
Statistical analysis.  
All results are reported as mean ± standard deviation. Differences between groups were 
assessed by two-tailed t-tests. P < 0.05 was considered as significant.  
 
2.3 Results  
Nanofiber substrates of different diameter and orientation were fabricated  
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Gelatin nanofibers were fabricated using electrospinning. By varying the concentration 
of the starting gelatin solution, we created nanofibers of three different diameters (10% 
solution: 105 nm; 12% solution: 155 nm; 15% solution: 220 nm) (Figure 1, Table S-1). 
By varying the grounded collector, we created nanofibers of three different orientations 
(planar collector: isotropic; pair of electrodes: uniaxially aligned; metal ring with central 
point electrode: radially aligned) (Figure 2). 
 
Corneal fibroblasts elongate and orient on radially and uniaxially aligned 
nanofibers  
Rabbit corneal fibroblasts (RCF) were seeded on nanofiber mats of different orientation: 
planar, isotropic, radially aligned and uniaxially aligned (Figure 3, left to right, FITC 
stained, false colored to red). Using a fluorescently-labeled phalloidin probe to visualize 
the cytoskeleton of seeded cells (Figure 3), we observed that cells on radial and uniaxial 
nanofibers are elongated and oriented along the same axis of the underlying nanofibers. 
Cells that were seeded on isotropic nanofibers showed no preferred orientation, and cells 
that were seeded on a planar surface showed few focal adhesions and the associated fan-
shaped morphology.  
 
Corneal fibroblasts migrate faster on oriented nanofibers  
To compare the rate of migration of corneal cells moving across nanofibers of different 
orientation, we carried out an in vitro mock wound-healing assay (Figure 4A). Relative 
to the sharp initial boundary (“wound edge”) between confluent cells and freshly 
exposed substrate, we observed that corneal fibroblasts migrated faster along the 
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direction of oriented nanofibers (Figure 4B). Relative to a planar surface, fibroblasts 
advanced less rapidly on isotropic nanofibers, more rapidly along radial nanofibers and 
along uniaxial nanofibers, and much slower orthogonal to the nanofibers. On radial 
nanofibers, the migration velocity increased as the surface concentration of nanofibers 
increased, leading to a faster overall migration velocity than along uniaxially-oriented 
nanofibers. Varying the nanofiber diameter did not significantly change the rate of 
fibroblast migration. In contrast to fibroblasts, when corneal epithelial cells were used, 
we observed that they migrated fastest on isotropic nanofibers, approximately twice as 
fast as on a planar substrate or migration along oriented nanofibers (radial or uniaxial) 
(Figure 4C). Migration orthogonal to nanofibers was slowest for both epithelial and 
fibroblast cells.  
 
Reduced levels of αSMA are observed in cells seeded on oriented nanofibers   
To study the response of myofibroblasts to nanofibers of different orientation, we 
transformed corneal fibroblasts into myofibroblasts by adding 1 ng/mL of TGF-β to the 
cell culture medium, and analyzed the αSMA expression of the transformed cells. 
Immunocytochemical staining indicated that the proportion of cells producing αSMA 
depends on the orientation distribution of nanofibers, with significantly fewer cells 
expressing αSMA on radial (20% decrease) and uniaxial (40% decrease) nanofibers 
compared with planar surfaces or randomly-oriented nanofibers (Figure 5, Figure 6A). 
Total mRNA was isolated from cells seeded on the four different substrates and analyzed 
using qPCR, which revealed a significant decrease in αSMA mRNA expression in cells 
grown on oriented nanofiber substrates (Figure 6B). Specifically, cells seeded on 
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uniaxially-aligned nanofibers (Dfiber = 155 nm) expressed the lowest levels of αSMA 
(40% decrease compared to cells on planar surfaces). For other nanofiber diameters, 
cells on uniaxially-oriented nanofibers consistently showed the lowest αSMA mRNA 
expression (approximately 40% reduction for Dfiber = 100 nm, 25% for Dfiber = 220 nm 
relative to planar control) (Figure S-2). Western blot analysis of αSMA protein content 
(normalized by GAPDH) in cells seeded on differently-oriented nanofibers showed that 
cells cultured on nanofiber surfaces have significantly lower αSMA protein expression 
(Figure 6C), with cells on uniaxial nanofibers showing the largest decrease (75%). A 
similar trend was observed at different nanofiber diameters (Figure S-3). 
 
TAZ/YAP may play a much stronger role than FAK/Raf-1 in transducing 
topological cues into cellular signals that modulate αSMA expression  
To investigate the molecular mechanism by which cells cultured on nanofiber surfaces 
demonstrate a reduced αSMA expression, we examined focal adhesion kinase (FAK), 
serine/threonine protein kinase Raf-1, transcription co-activator TAZ and Yes-
associated protein (YAP) by generating the corresponding knocked-down cells 
(transfected human corneal fibroblasts with the corresponding siRNA). These cells were 
then seeded onto uniaxially-aligned nanofibers, transformed into myofibroblasts with 
10 ng/mL TGF-β, and their αSMA protein expression was visualized using 
immunocytochemistry (Figure 7). Interestingly, knockdown of FAK or Raf-1 did not 
restore αSMA expression and cells looked similar to control cells on uniaxial nanofibers. 
In contrast, both TAZ and YAP knockdowns partially reversed nanofiber-dependent 
changes in αSMA expression: both siTAZ and siYAP cells express αSMA (labeled 
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green) at a level intermediate between control cells on planar surfaces and control cells 
on uniaxial nanofibers.  
 
2.4 Discussion 
Topological cues have emerged as important factors in affecting cellular behavior, 
attracting attention in the context of guided wound healing and tissue regeneration.19-21 
However, the role of length scale and biochemical functionality of the topological 
features is the subject of debate. In relation to the ocular cornea, Pot and colleagues 
studied the behavior of corneal keratocyte, fibroblast and myofibroblast cells cultured 
on uniaxial pitches (400 - 4000 nm), and found that while corneal stromal cells elongated 
and migrated favorably on large surface features (> 800 nm), cells failed to respond to 
topographic features close to the dimensions of their native environment.1 In contrast, 
Wray and Orwin demonstrated that nanofiber substrates as small as 50 nm in diameter 
promoted elongated morphologies of corneal fibroblasts.22 Both studies suggest that 
mechanical cues can induce significant changes in corneal cell behavior.   
 
Our motivation for studying the effects of nanofiber diameter and orientation on corneal 
fibroblasts is to pave the way to using such nanofiber mats as building blocks in a wound 
dressing for corneal injury. An ideal wound healing material would be a transparent, 
acellular scaffold containing topological and biochemical cues that first encourage 
healthy cells near the wound to infiltrate into the scaffold, and then promote orderly 
tissue repair or replacement. The central challenge in treating corneal wounds is 
mitigating the myofibroblast phenotype that is responsible for the disordered and non-
refractive-index-matched scar that leads to corneal blindness.23,24 Therefore, we 
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deliberately provoked corneal fibroblasts into myofibroblasts using TGF-β,5,18 and 
examined the effects of nanofiber diameter and orientation on the cellular phenotype.  
 
In this study, we used electrospinning to fabricate nanofibers with diameter in the range 
110 – 220 nm (Figure S-4). The upper limit was chosen to minimize light scattering of 
the material. The smallest diameter was the lowest for which we could fabricate fibers 
with a uniform diameter. In relation to potential clinical translation, we found that 
nanofiber mats with fiber diameter <100 nm were delicate, and tore during routine 
handling. By choice of the geometry of the collection electrode (Figure 2), we created 
radially-oriented nanofibers that might speed wound closure, and uniaxial nanofibers 
(reminiscent of collagen fibrils found in individual lamellae of the corneal stroma) that 
might promote orderly healing. Behavior of cultured cells on these two surfaces was 
compared to those on isotropic nanofibers with no preferred orientation and control 
substrates with no nanofibers.  
 
For the fabricated nanofiber mats to be used in corneal applications, they must first 
satisfy two important prerequisites: transparency and non-cytotoxicity. When we placed 
the nanofiber mats on an excised fresh cornea and measured the transmittance through 
the material, there was no measurable change in light transmission compared to a control 
cornea without nanofibers (Figure S-5). Also, using a LIVE/DEAD fluorescent assay 
to test for cell viability, we found cells plated at the same density onto nanofiber 
substrates and a control substrate with no nanofibers had indistinguishable and very high 
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cell survival rates (Figure S-6). Having fulfilled these two requirements, the behavior 
of the corneal fibroblasts cultured on the different nanofiber surfaces was examined.  
 
When corneal fibroblasts are seeded on oriented nanofibers (radial or uniaxial), they 
elongate in the direction of the axis of the underlying nanofibers. This observation is in 
agreement with Wray and Orwin’s results that corneal fibroblasts are able to respond to 
topological and biochemical cues presented by electrospun collagen nanofibers in the 
50-300 nm range.22 Wray and Orwin’s hypothesis that nanofibers in this size range 
affects cells in part through patterned cell binding ligands applies equally to the present 
study and may reconcile our observations with those of Pot and coworkers, who found 
that oriented topography with periodicity less than 400 nm did not alter cell morphology 
when the ligand distribution was uniform.1 In addition, literature suggests that oriented 
corneal fibroblasts deposit newly-synthesized protein along the same direction of their 
orientation.6,25 This is of interest, in the context of remodeling an injured cornea, because 
the layers of aligned, uniformly-spaced collagen fibrils are essential to maintaining the 
transparency of the cornea.  
 
Toward the goal of recruiting cells into the scaffold, we examined the effects of 
nanofiber diameter and orientation on the rate of migration of corneal fibroblasts. The 
presence of oriented nanofibers enhances the rate of migration of corneal fibroblasts in 
the direction parallel to the fibers, and inhibits it in the direction orthogonal to the fibers. 
The migration velocity parallel to the fibers to that perpendicular to the fibers is 
approximately 3 (i.e. 35 µm/hour parallel, 12 µm/hour perpendicular, Figure 2) for 
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corneal fibroblasts independent of fiber diameter. The parallel/perpendicular velocity 
ratio here is similar to that observed by Pot et al. for >1200 nm pitch size (and contrasts 
with their finding that this ratio approaches 1 for pitch <800 nm).1 Relative to the 
uniaxially aligned nanofiber substrate, one that has a radial pattern further enhances the 
rate of cell migration (~45 μm/h). We speculate that fibroblasts migrate faster on radial 
nanofibers than on uniaxial nanofibers because the surface concentration of fibers, and 
hence the density of cell binding domains available, increases as the cells move closer 
to the center of the radial pattern (Figure S-7).  
 
Interestingly, corneal epithelial cells migrate more rapidly on randomly-oriented 
nanofibers than along aligned ones (radial or uniaxial) with the same fiber diameter and 
density (Tables S3-4). While there are prior studies that report epithelial cell migration 
being faster along uniaxial oriented nanofibers,26,27 we did not find any studies that 
compared randomly-oriented nanofibers to oriented ones. While epithelial migration on 
aligned nanofibers is faster than on planar substrates, it is not faster than on randomly-
oriented nanofibers (Figure 2C). This characteristic of epithelial cells is different from 
skin fibroblasts28, glioma cells29 and aggressive metastatic breast cancer cells30. To our 
knowledge, this is the first report of a cell type that migrates faster on randomly-oriented 
nanofibers than on aligned nanofibers.  
 
We speculate that the unusual response of epithelial cells to nanofiber orientation may 
be due to the distinctive mode of wound closure used by epithelial cells when closing 
around small circular wounds: “cables of actin filaments appear to extend from cell to 
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cell forming a ring around the wound circumference… [perhaps] as a contractile ‘purse 
string’ to facilitate wound closure.”31 While fibroblasts move primarily by cell crawling, 
epithelial cells at the concave edges of migrating cell sheets exhibit purse-string healing 
in addition to cell crawling.32 Indeed, purse-string healing is the predominant mode of 
closing small round wounds in the corneal epithelium. Perhaps purse-string healing is 
adversely affected by aligned nanofiber substrates, although further investigation would 
be required to test this hypothesis. In relation to corneal wound dressings, the different 
responses of epithelial cells and fibroblasts suggest that a top layer of isotropic 
nanofibers might promote epithelial wound closure, and uniaxial nanofibers in the bulk 
of the dressing might enhance fibroblast recruitment.  
 
As alluded to previously, a key feature of a successful corneal scaffold is its ability to 
modulate the myofibroblast phenotype. Myofibroblasts lead to corneal haze and loss of 
transparency, both due to their refractive index mismatch with respect to the stroma 
(insufficient expression of corneal crystallins and expression of αSMA stress fibers) and 
due to the disordered extracellular matrix proteins they produce.33-36 The present results 
show that nanofiber substrates are capable of mitigating the myofibroblast phenotype: 
compared to planar controls, there is a decreased expression of αSMA mRNA and 
protein in TGF-β-transformed myofibroblasts cultured on oriented nanofibers (Figure 
3 and 4).  
 
The molecular mechanism by which myofibroblasts perceive microenvironmental cues 
and relay information to initiate a cellular response is still unclear. Based on two 
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prevailing hypotheses regarding the mechanisms of cell response to the extracellular 
matrix, we designed siRNA experiments to discern whether myofibroblasts respond to 
nanofibers 1) through integrin-dependent signaling pathways, and/or 2) by direct 
mechanotransduction.  
 
Integrin-dependent signaling is mediated by non-receptor tyrosine kinases, most notably 
focal adhesion kinase (FAK).37,38 Integrin binding to underlying extracellular matrix 
components activates FAK, which subsequently influences cellular transcription events 
through phosphorylation of downstream signaling molecules. One of the most-studied 
pathways downstream of FAK is the extracellular signal-regulated kinase (ERK) 
cascade, which modulates cellular differentiation and directional migration.39,40 One of 
the important gatekeepers in the ERK pathway is Raf-1.41 Therefore, we chose FAK and 
Raf-1 as two targets for gene silencing that would reveal a possible role of integrin-
dependent signaling (i.e., if silencing them blocks myofibroblast response to 
nanofibers).  
 
Alternatively, direct mechanotransduction is initiated when cells pull on the 
extracellular matrix and develop cytoskeletal tension. This tension then leads to 
subsequent post-translational modifications of downstream targets that regulate gene 
transcription. Recently, YAP and TAZ have been suggested to play an important role in 
relaying to the nucleus cytoskeletal changes caused by substrate stiffness.42,43 In relation 
to the cornea, Vijay and coworkers speculate that YAP and TAZ are involved in 
regulating contact guidance in corneal epithelial cells.44 Therefore, we chose YAP and 
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TAZ as two targets for gene silencing that would reveal a possible role of mechano-
transduction.  
 
We generated knockdown cells by transfecting human corneal fibroblasts with one of 
the corresponding siRNAs (FAK, Raf-1, YAP or TAZ) (Figure S-8), and cultured them 
on uniaxially-aligned nanofiber substrates. We found that inhibition of myofibroblast 
character persisted despite knockdown of FAK or Raf-1, suggesting that integrin-
dependent signaling does not seem to play a significant role in the present system. In 
contrast, knockdown of TAZ and YAP both partially restored αSMA expression, 
suggesting that mechanotransduction is involved in mitigating the myofibroblast 
phenotype in this system. We speculate that myofibroblasts cultured on aligned 
nanofibers orient their cytoskeleton in the direction of the underlying substrate, and 
develop greater cytoskeletal tension than they do on planar substrates or isotropically 
distributed nanofibers. In the view of the complexity of intracellular signaling, 
mechanotransduction may be one of a number of pathways modulating the 
myofibroblast phenotype.  
 
To our knowledge, this is the first study which examines the role of TAZ and YAP in 
cellular protein expression in response to underlying substrate orientation. Previously, 
TAZ and YAP have only been studied as mediators of mechanical cues in the context 
of substrate stiffness. Since the composition, crosslinking and diameter of individual 
nanofibers, and the density of the fiber mats are almost identical for each mat of different 
orientation (isotropic, radial and uniaxial), we expect the stiffness of the fiber mats to 
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be similar. Thus, TAZ and YAP appear to be involved in transduction of information 
regarding anisotropic orientation distribution of fibrils (e.g., collagen) in the 
extracellular matrix.  
 
Taken together, our results demonstrate that nanofiber substrates are well-suited for 
corneal wound healing scaffolds due to their transparency, non-cytotoxicity, ability to 
promote cell migration, and ability to modulate the myofibroblast phenotype. In 
particular, our findings suggest that an ideal scaffold would be composed of a top layer 
of isotropic nanofibers to expedite wound closure by epithelial cells, and aligned 
nanofibers in the bulk to mitigate the myofibroblast wound response.  
 
 
2.5 Conclusions 
Taken together, our results demonstrate that nanofiber substrates are well-suited for 
corneal wound healing scaffolds due to their transparency, non-cytotoxicity, ability to 
promote cell migration and ability to modulate the myofibroblast phenotype. In 
particular, our findings suggest that an ideal scaffold would be composed of a top layer 
of isotropic nanofibers to expedite wound closure by epithelial cells, and aligned 
nanofibers in the bulk to mitigate the myofibroblast wound response. Interestingly, 
integrin-dependent signaling plays a minor role (if any) in myofibroblast response to 
oriented nanofibers, while mechano-transduction plays a significant role.  
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Figure 1. Scanning electron micrographs demonstrate ability to electrospin nanofibers of 
different diameter by choice of gelatin concentration in the electrospinning solution (for 
15kV and 8cm needle to collector distance):  10% w/w gave 108 nm (left), 12% w/w gave 
159 nm (middle) and 15% w/w gave 221 nm (right). 
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Figure 2. Nanofiber mats were fabricated by electrospinning. (A) Schematic of 
electrospinning apparatus. (B) Different grounded collectors used to electrospin isotropic 
(B, left, planar electrode with a ring used to recover the fiber mat), radially aligned (B, 
middle) and uniaxially aligned (B, right) nanofibers.  
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Figure 3. Nanofiber orientation influences cell shape and orientation. Phase contrast 
micrographs (top row) show that corneal fibroblasts (P5) are elongated when exposed to 
uniaxial and radial nanofibers compared to either a planar surface or isotropic nanofibers. 
Immunostaining (second to bottom row) demonstrates that cells orient along the same axis 
of the underlying nanofibers. Nanofibers were labeled using NHS-FITC (false color to red 
for consistency with Figure 3); cell nuclei, Hoescht stain (blue); F-actin cytoskeleton, 
phalloidin-Rhodamine (false color to yellow to avoid confusing with the αSMA in Figure 
3). Nanofiber diameter = 155 nm. 
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Figure 4. Nanofiber orientation affects the rate of cell migration. (A) Schematic of in vitro 
mock wound healing assay (after cells grow to confluency, a 4 mm dia. 
polydimelthylsiloxane, PDMS, mask is lifted to expose the substrate). (B) Corneal 
fibroblasts migrate faster along oriented nanofibers, both radial and uniaxial, compared 
with isotropic nanofibers. Green dashed line indicates fibroblast migration rate on a control 
planar surface. Solid red lines in schematic diagram below indicate initial cell boundary. 
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P-values are in Supplementary Tables 1-2. (C) Epithelial cells migrate faster on isotropic 
nanofibers than on oriented ones (radial or uniaxial). *: p-value < 0.05; **: p-value < 0.001 
compared to isotropic nanofibers. Cells between passages 5-8 were used in these 
experiments. 
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Figure 5. Representative images of corneal fibroblasts (P5) transformed to myofibroblasts 
with 1 ng/mL TGF-β on nanofibers of different orientation. Relative to planar control, there 
are fewer cells positive for αSMA on oriented nanofibers. Nanofibers were labeled using 
NHS-Rhodamine (red); cell nuclei, Hoechst stain (blue); αSMA, anti-αSMA-FITC (green). 
Nanofiber diameter = 155 nm.  
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Figure 6. Relative to Planar control, TGF-β (1 ng/mL) induced myofibroblasts grown on 
nanofiber surfaces demonstrated (A) fewer α-SMA positive cells (analysis of images of 
Figure 3), (B) significantly lower levels of α-SMA mRNA, and (C) significantly lower α-
SMA protein expression based on Western blot analysis of cell lysates, quantified by the 
ratio of α-SMA protein signals normalized by GAPDH. Passage 5 cells were used in all 
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experiments.  Nanofiber diameter = 155 nm. **: p-value < 0.001 compared to planar 
controls.   
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Figure 7. Human corneal fibroblasts (P5) were transfected with the indicated siRNA 
(control, FAK, Raf-1, TAZ, YAP), seeded on uniaxially-aligned nanofibers and 
transformed to myofibroblasts with 10 ng/mL TGF-β. (The greater concentration used for 
human cells compared to rabbit cells in Figures 3-4 was selected to provide visible αSMA 
expression in the control.) Cell nuclei, Hoechst stain (blue); αSMA, anti-αSMA-FITC 
(green). Red arrows indicate direction of the underlying nanofibers. Nanofiber diameter = 
155 nm.  
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Additional information  
Electrospinning  
The basic setup of an electrospinning apparatus consists of three main components: a 
high-voltage supply, a syringe needle and a grounded collector (Figure). The 
electrospinning solution (usually polymeric or protein-based) is fed through the syringe 
needle. During the electrospinning process, a high voltage (usually in the range of 10 - 
30 kV) is applied to the solution, and the droplet of fluid coming out from the needle 
becomes highly charged. The droplet experiences two major electrostatic forces: the 
electrostatic repulsion between surface charges in the droplet, and the Coulomb forces 
exerted by the external electric field. These interactions cause the droplet to deform 
into a conical shape, known as the Taylor cone. When the electrostatic forces pass a 
certain critical value and are able to overcome the surface tension of the droplet, a 
charged liquid jet is ejected from the tip of the Taylor cone, and the jet undergoes an 
unstable whipping process. The solvent evaporates as the liquid jet is accelerated 
towards the counterelectrode, leading to the formation of continuous thin fibers. The 
fibers are deposited onto the grounded collector as a randomly-oriented, non-woven 
mat. By changing the type of grounded collector, we can obtain nanofiber substrates of 
different orientation.  
 
How aligned fibers are formed 
To fabricate uniaxially-aligned nanofibers, we used a pair of split electrodes as the 
grounded collector. We can explain the formation of aligned fibers on split electrodes 
using Coulombic interactions and electrostatic forces.45 When a fiber is deposited 
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across the gap between the split electrodes, it does not discharge immediately, and is 
affected by fibers already present. The Coulomb force generated by the newly-
deposited fiber is  
𝐹𝐹 =  𝑘𝑘𝜆𝜆2
𝑟𝑟2
 
where k is the Coulomb’s constant, λ is the linear charge density of the fiber, and r is 
the distance between two interacting fibers. In Figure S-1, when r1<r2 (as in the top 
region of the newly deposited fiber), F1 will be stronger than F2, and thus, the top of 
the fiber is pushed towards fiber 2. At the same time, the bottom region of the fiber 
experiences forces of the opposite effect, and therefore, the overall fiber is 
preferentially aligned with the other fibers. In addition, fibers also prefer to arrange 
perpendicularly to the split electrodes, because this configuration possesses the lowest 
electrostatic energy (Figure 19-B).  
    
Figure S-1. (A) Coulombic interaction between electrospun fibers (B) Relationship 
between the electrostatic potential between the split electrodes (ε) and the angle 
between the fiber and the electrode (Θ).45  
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Isolation of corneal fibroblasts from rabbit eyes  
10-15 eyeballs from young rabbits were purchased from Pel-Freez and used 
immediately upon delivery. Excess fat and connective tissue was trimmed from the 
eyeballs. Cold RPMI media was used to wash the surface of the eye. For each eyeball, 
the epithelium layer was scraped off using a scalpel. The cornea (with 5 mm scleral rim 
for handling) was cut from the eyeball. The cornea was then placed upside down on a 
sterile petri-dish. The iris was then removed and the endothelial layer was removed 
with a sterile cotton-tipped applicator. The middle portion of the cornea (now without 
the epithelium and endothelium) was punched out using a corneal punch (8 mm 
diameter). The stromal buttons were then placed in a cell culture dish filled with fresh 
RPMI media. This process was repeated until all the eyeballs were processed. All 10-
15 stromal buttons were then placed in a 14 mL round-bottom tube with 10 mL digest 
media (0.5 mg/mL hyaluronidase, 2 mg/mL collagenase, 0.02% Pen/Strep/Fungizone 
in DMEM). The tube was then placed in the cell culture incubator (5% CO2, 37oC) 
overnight. The next day, the solution was pipetted up and down to make a 
homogeneous solution (debris will be observed at the bottom of the tube). The 
suspension was transferred to a 50 mL conical tube and was diluted with 20 mL culture 
medium. The mixture was centrifuged at 1,500 rpm for 5 minutes, and the supernatant 
was removed. The cell pellet was resuspended in 2 mL culture medium, and the cells 
were plated in 100 mm cell culture dishes at a density of 2.5 x 104 cells/cm2. The cell 
medium was replaced every 2 days until the cells were 90% confluent. The cells were 
then either passaged or frozen. 
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Figure S-2. TGF-β induced myofibroblasts grown on nanofiber surfaces of (A) 103 nm 
and (B) 219 nm show a similar trend in α-SMA mRNA expression to that of 155 nm 
(Figure 4), with cells seeded on uniaxially-aligned nanofibers consistently expressing the 
lowest levels of α-SMA mRNA.  
*: p-value < 0.01 compared to planar controls. **: p-value < 0.001 compared to planar 
controls. 
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Figure S-3. TGF-β induced myofibroblasts grown on nanofiber surfaces of (A) 103 nm 
and (B) 219 nm show a similar αSMA protein expression trend to that of 155 nm (Figure 
4), with cells seeded on uniaxially-aligned nanofibers expressing the lowest levels of α-
SMA when normalized to GAPDH. **: p-value < 0.001 compared to planar controls. 
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Figure S-4. Optical transmittance of various nanofiber mats placed on an explanted porcine 
cornea after application of PBS drops demonstrates that the nanofibers do not significantly 
reduce light transmission through the cornea.  
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Figure S-5. LIVE/DEAD cell viability assay confirms that corneal fibroblasts seeded on 
nanofiber surfaces show no cytotoxicity issues. Green signal: live cells; Red signal: dead 
cells. Two days after seeding P5 cells. Scale bar is 100 µm.  
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Figure S-6. In the mock wound-healing assay using a 4mm initial diameter ‘wound,’ the 
remaining wound area (i.e., not yet infiltrated with cells) is correlated with the rate of cell 
migration. Corneal fibroblasts that are cultured on radially-aligned nanofibers increase 
their rate of migration with time (i.e. as they move closer to the center of the radial pattern), 
while those that are on uniaxial and isotropic maintain a constant rate of migration.  
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Figure S-7. Validation that silencing RNA did indeed reduce the expression of the 
corresponding protein.  Top: Western Blot (WB) and antibody staining of the 
corresponding protein band for each case. Bottom: GAPDH band shows that gel loading 
was consistent.  
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Table S-1. Varying the nanofiber orientation by changing the grounded collector does not 
significantly influence the average fiber diameter at each protein concentration. 
 10% gelatin 12% gelatin 15% gelatin 
Isotropic 107.9 ± 10.7 nm 158.8 ± 18.7 nm 221.2 ± 22.2 nm 
Radial 106.0 ± 14.1 nm 152.9 ± 16.1 nm 218.4 ± 27.3 nm 
Uniaxial 103.2 ± 12.8 nm 155.3 ± 17.1 nm 219.3 ± 23.5 nm 
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Table S-2. P-values from two-tailed t-test show that nanofiber orientation (diameter fixed) 
significantly affects the rate of corneal fibroblast migration (Figure 4). Fields shaded in 
orange highlight results with relatively large p-values (0.01 or greater) that are still of 
significance (p < 0.05). 
105 nm Isotropic Radial Uniaxial // 
Uniaxial 
⊥ 
Isotropic  < 0.001 0.001 0.002 
Radial < 0.001  0.007 < 0.001 
Uniaxial // 0.001 0.007  < 0.001 
Uniaxial ⊥ 0.002 < 0.001 < 0.001  
 
155 nm Isotropic Radial Uniaxial // 
Uniaxial 
⊥ 
Isotropic  < 0.001 0.02 0.003 
Radial < 0.001  0.01 < 0.001 
Uniaxial // 0.02 0.01  < 0.001 
Uniaxial ⊥ 0.003 < 0.001 < 0.001  
 
220 nm Isotropic Radial Uniaxial // 
Uniaxial 
⊥ 
Isotropic  0.01 0.03 0.03 
Radial 0.01  0.02 0.001 
Uniaxial // 0.03 0.02  0.004 
Uniaxial ⊥ 0.03 0.001 0.004  
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Table S-3. P-values from two-tailed t-test show that nanofiber diameter (orientation fixed) 
does not affect the rate of corneal fibroblast migration (Figure 4).  Fields shaded in red 
show p values that exceed the threshold for significance ( p> 0.05). 
Isotropic 105 nm 155 nm 220 nm 
105 nm  0.4 0.05 
155 nm 0.4  0.6 
220 nm 0.05 0.6  
 
Radial 105 nm 155 nm 220 nm 
105 nm  0.4 0.5 
155 nm 0.4  0.9 
220 nm 0.5 0.9  
 
Uniaxial // 105 nm 155 nm 220 nm 
105 nm  0.9 0.2 
155 nm 0.9  0.3 
220 nm 0.2 0.3  
 
Uniaxial ⊥ 105 nm 155 nm 220 nm 
105 nm  0.9 0.9 
155 nm 0.9  1.0 
220 nm 0.9 1.0  
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Table S-4. Varying the nanofiber orientation by changing the grounded collector does not 
significantly influence the average fiber density. 
 Dfiber = 155 nm  
Isotropic 0.42 ± 0.06  
Radial 0.41 ± 0.05 
Uniaxial 0.41 ± 0.04 
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Chapter 3 
Effects of growth factors on corneal myofibroblast phenotype 
3.1 Introduction 
The wound-healing cascade is complex, involving multiple processes such as cell 
proliferation, differentiation and migration.1-3 These events act to repair and replace 
injured tissue, and are mediated by cytokines released from cells upon injury. In relation 
to the cornea, the repair response mainly involves epithelial regrowth, keratocyte-
myofibroblast differentiation and new matrix deposition by myofibroblasts.2,3 As 
described in Chapter 2, the central challenge to treating corneal wounds is mitigating 
the myofibroblast phenotype to reduce the production of α-smooth muscle actin (αSMA) 
that pulls on wound edges and disordered ECM proteins that lead to corneal blindness.4,5 
Identification of growth factors that modulate the myofibroblast phenotype may 
promote an orderly wound-healing response to recover the transparency of the cornea.  
 
Growth factors influence cell decisions by binding to cell-surface receptors, which then 
become activated to initiate signaling cascades that affect gene transcription. Much 
progress has been made in identifying growth factors that influence corneal wound 
healing. For example, Yu and coworkers have shown that endogenous heparin-binding 
epidermal growth factor (HB-EGF) is essential for epithelial wound closure.6 Also, 
epidermal growth factor (EGF) has been shown to increase migration and proliferation 
of keratocytes.7 Jester and coworkers demonstrated that cells treated with fibroblast 
growth factor (FGF) exhibit a reduced expression of αSMA8, a cell marker for 
myofibroblasts. In addition, Kim and coworkers found that the addition of platelet-
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derived growth factor (PDGF) induces keratocyte elongation without the formation of 
stress fibers and promotes the deposition of ECM proteins that closely resemble those 
of the native cornea.9,10  
 
Building on their findings, we chose to examine the role of EGF, FGF and PDGF on 
myofibroblast phenotype in the present study. Specifically, we systematically varied the 
concentration of each growth factor (0.1 - 100 ng/mL) in the cell culture medium of 
TGF-β transformed myofibroblasts and analyzed their αSMA expression. Our results 
show that each growth factor is capable of reducing αSMA expression in 
myofibroblasts, with a strong dependence in the growth factor concentration. Gene-
silencing experiments suggest that one of the pathways in which growth factors regulate 
αSMA expression is through the ERK signaling cascade. In relation to potential clinical 
translation, the addition of growth factors (at their optimal concentrations) may prove 
valuable to orchestrate an orderly wound-healing response. 
 
3.2 Methods 
Rabbit corneal fibroblast isolation and culture. Fibroblasts were isolated from young 
rabbit eyes (mixed gender, approximately 8-12 weeks old, Pel-Freez, Rogers, AR) as 
described elsewhere.11 The isolated fibroblasts were passaged every 2-3 days when 95% 
confluence was reached. Cells from passages 5-8 were used in the present study. Corneal 
fibroblasts were seeded in 6-well plates (5x104 cells/mL). Transforming growth factor-
beta (TGF-β, 1 ng/mL) was added 24 hours post-seeding to induce the myofibroblast 
phenotype11,12, and cells were grown for 72 hours. The cell culture medium was then 
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removed and replaced with fresh medium containing growth factors (EGF, FGF, PDGF 
at 0 – 100 ng/mL). Cells were grown in growth-factor-rich medium for 72 hours prior 
to assays.  
 
Identification of αSMA producing cells using immunocytochemistry   
Myofibroblasts treated with growth factors were first washed 3 times with DPBS, and 
fixed in 4% paraformaldehyde (in DPBS) for 10 minutes. Fixed cells were then washed 
3x with DPBS and permeabilized with 0.1% Triton X-100 in DPBS for 10 minutes. 
Blocking was performed with 1% bovine serum albumin in DPBS for 30 minutes at 
room temperature. The cells were then incubated with 1:1000 FITC-conjugated mouse 
anti-αSMA antibody (Sigma Aldrich, St. Louis, MO) in 1% BSA for 60 minutes at room 
temperature. Cells were washed 3 times with DPBS, and cell nuclei were stained with 
Hoescht 33342 (Invitrogen, Grand Island, NY) at 0.5 ug/mL for 10 minutes at room 
temperature in the dark. Cells were then stored in PBS until imaging with a Zeiss 
Axiovert 25CFL fluorescent microscope. For analysis of αSMA protein expression, five 
randomly-selected locations on each scaffold were imaged using a 5x objective for both 
Hoescht and FITC fluorescence. Blue dots (Hoechst stained nuclei) were counted as 
total cells per image, while cells presenting a green signal (FITC) were counted as 
positive for αSMA. Immunocytochemistry was performed on samples from three 
independent experiments. 
 
Quantitative PCR (qPCR)  
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Myofibroblasts treated with growth factors were lifted using 0.05% TRED and pelleted 
by centrifuging at 900 rpm for 3 minutes. RNA was extracted using the Qiagen RNeasy 
kit following the manufacturer’s protocol (Qiagen, Valencia, CA). RNA yield was 
determined using a Nanodrop spectrophotometer (Thermo Sci., Wilmington, DE). Gene 
expression was evaluated using qPCR with an EXPRESS One-Step SYBR® GreenERTM 
Universal kit (Invitrogen, Grand Island, NY) in an Eco Real-Time PCR system 
(Illumina, San Diego, CA). qPCR was carried out using 50 ng RNA per sample and 
commercially-available primers for αSMA, GAPDH and β-actin in a total reaction 
volume of 10 µL per sample. GAPDH and β-actin served as references. Products were 
evaluated by melt curve analysis and sizing on agarose gels. Gene expression was 
normalized relative to the expression of mRNA from control cells (grown under the 
same culture conditions without added growth factors) using the ΔΔCt method as 
described elsewhere.13 The mRNA from control untreated cells was given an arbitrary 
value of 1.0. qPCR reactions were run in triplicates per sample, and the experiment was 
repeated three times on separate days. 
 
Western blotting 
Myofibroblasts treated with growth factors were lifted, pelleted (as described above) 
and lysed with M-PER mammalian protein extraction reagent following the 
manufacturer’s protocol (Thermo Sci., Rockford, IL). Insoluble cellular debris was 
removed by centrifugation at 10k rpm for 10 minutes and the supernatant was collected 
into new tubes. A bicinchroninic acid (BCA) protein assay (Thermo Sci., Rockford, IL) 
was performed to determine the concentration of the extracted protein. Equivalent 
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amounts of protein (10 µg per sample) were mixed with loading buffer (Laemmli sample 
buffer, Bio-Rad, Hercules, CA), denatured by boiling for 5 minutes, and loaded onto a 
MINI-PROTEAN TGX precast gel (Bio-Rad, Hercules, CA). Gel electrophoresis was 
performed at 200V for 40 minutes. Protein bands were then transferred to a 
nitrocellulose membrane at 100V for 1 hour. The nitrocellulose membrane was blocked 
for 1 hour at room temperature in blocking solution (5% BSA, 0.1% Tween-20 in 
DPBS). The membrane was then incubated with mouse anti-GAPDH antibody 
(Invitrogen, Grand Island, NY) at 1:2500 dilution in blocking solution for 1 hour at room 
temperature. The blot was washed 3x (10 minutes each) in DPBS-T (DPBS + 0.1% 
Tween-20), followed by incubation with AlexaFluor 647 goat anti-mouse secondary 
antibody (Invitrogen, Grand Island, NY) in blocking solution at 1:2500 dilution for 1 
hour in the dark. The blot was washed 3x (10 minutes each) in DPBS-T and incubated 
with FITC-conjugated mouse anti-αSMA antibody (Sigma Aldrich, St. Louis, MO) at 
1:2500 dilution in blocking solution for 1 hour in the dark. After rinsing with DPBS-T, 
the blot was scanned using a Typhoon Trio Scanner (GE, Piscataway, NJ). Relative 
intensities of α-SMA bands were normalized with GAPDH bands. Immunoblotting was 
performed on samples from three independent experiments. 
 
siRNA transfection of human corneal fibroblasts. FAK, Raf-1, YAP and TAZ were 
knocked down in human corneal fibroblasts (ScienCell, Carlsbad, CA) using siRNAs 
targeted to the corresponding genes (all from Santa Cruz Biotechnology, Dallas, TX). 
Cells (P3, 60-70% confluent) were transfected with siRNA (60 nM) using siRNA 
transfection reagent (Santa Cruz Biotechnology, Dallas, TX) according to the 
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manufacturer’s instructions. Control cells were transfected with FITC-conjugated 
control siRNA (Santa Cruz Biotechnology, Dallas, TX). The cells were incubated for 
72 hours before collection. 
 
Statistical analysis. All results are reported as mean ± standard deviation. Differences 
between groups were assessed by two-tailed t-tests. P < 0.05 was considered as 
significant.  
 
3.3 Results  
Growth factors can reduce the number of αSMA-expressing myofibroblasts  
To study the response of myofibroblasts (induced from corneal fibroblasts using 72 hour 
exposure to medium with TGF-β at 1 ng/mL) to growth factors at different 
concentrations (0.1 - 100 ng/mL), we added growth factors to the cell culture medium 
and counted the number expressing αSMA.  
 
Myofibroblasts treated with 0.1 ng/mL EGF showed a measurable reduction in the 
number of αSMA producing cells (15%, p-value < 0.001); the effect increased to 80% 
reduction upon increasing EGF concentration to 1 ng/mL, and the effect remained at 
that level for concentrations up to 100 ng/mL (Figure 1).  
 
For FGF-treated cells, the number of cells producing αSMA was not significantly 
changed by concentrations of 0.1 and 1 ng/mL (>90% cells expressed αSMA), and 
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decreased similarly for concentrations of 10 ng/mL or more (65%, 70% and 85% 
reductions for 10, 50 and 100 ng/mL) (Figure 2).  
 
For PDGF-treated cells, we observed a non-monotonic effect on the number of αSMA-
producing cells (Figure 3). The lowest concentration (0.1 ng/mL) and the highest 
concentration (50 and 100 ng/mL) reduced the number of αSMA-producing cells by 
80% or more. However 10 ng/mL PDGF had relatively little effect.  
 
Growth factors can inhibit αSMA gene and protein expression  
Total mRNA was isolated from cells treated with different growth factors at 50 or 100 
ng/mL (based on largest decrease in αSMA-producing cells as described above) and 
analyzed using qPCR. Consistent with their effects on the number of αSMA-producing 
cells, 100 ng/mL concentrations strongly reduce αSMA-mRNA (Figure 4). Western 
blot analysis of αSMA protein content (normalized by GAPDH) in cells treated with 
different growth factors showed significantly lower αSMA protein expression compared 
to untreated cells (Figure 5), with cells treated with 100 ng/mL growth factor showing 
the largest decrease (30 - 40% in all cases).  
 
Growth factors can mitigate myofibroblasts cultured on oriented nanofibers  
In Chapter 2, we observed a reduction of αSMA expression in TGF-β myofibroblasts 
cultured on oriented nanofibers. To investigate whether the addition of growth factors 
could further mitigate the myofibroblast phenotype, we added EGF, FGF or PDGF (50 
or 100 ng/mL) in the cell culture medium of myofibroblasts seeded on uniaxially-
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aligned nanofibers and visualized the αSMA expression of the cells. The myofibroblasts 
were transformed from fibroblasts using 10 ng/mL TGF-β (a greater concentration was 
used here compared to Figures 1-5 to provide visible αSMA expression in the control). 
We confirmed that the addition of growth factors reduces αSMA expression in 
myofibroblasts cultured on oriented nanofibers (Figure 6).  
 
FAK/Raf-1 play a role in modulating αSMA expression 
To investigate the molecular mechanism by which cells treated with growth factors 
demonstrate a reduced αSMA expression, we examined focal adhesion kinase (FAK), 
serine/threonine protein kinase Raf-1, transcription co-activator TAZ and Yes-
associated protein (YAP) by generating the corresponding knocked-down cells 
(transfected human corneal fibroblasts with the corresponding siRNA). These cells were 
then transformed into myofibroblasts with 10 ng/mL TGF-β, treated with EGF, FGF or 
PDGF at 100 ng/mL, and their αSMA expression was visualized using 
immunocytochemistry (Figure 7). Knockdown of FAK and Raf-1 partially reversed 
growth-factor-dependent changes in αSMA expression: both siFAK and siRaf-1 cells 
expressed αSMA (labeled green) at a level similar to control untreated cells. 
Interestingly, siTAZ and siYAP cells also expressed αSMA, but at a much lower 
intensity than control untreated cells. 
 
3.4 Discussion 
When the cornea encounters trauma, quiescent keratocytes transition into hyperactive 
myofibroblasts that proliferate and produce disordered intercellular and extracellular 
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proteins to repair the wound.4,5 This repair response is a complex biological process, 
which involves many signaling cascades initiated by ligand-receptor binding. In 
particular, the use of peptide growth factors has emerged as an effective way to enhance 
corneal wound healing.14-17 However, the type and concentration of growth factors that 
can produce such effects is still unclear. In the present study, we examined the effects 
of three growth factors (EGF, FGF and PDGF) on myofibroblast phenotype. The 
concentration range studied was between 0.1 to 100 ng/mL based on past literature.16,18 
The rationale for choosing each growth factor and a discussion on our experimental 
findings are detailed in separate sections below. 
 
Effect of EGF on myofibroblast phenotype 
EGF has been extensively studied for its effects on stimulating migration of both normal 
and cancer cells, including keratinocytes19, prostate carcinoma cells20, etc. In relation to 
the cornea, EGF has been shown to promote epithelial cell proliferation, fibroblast 
migration and endothelial cell mitosis in vitro21,22, and accelerate reepithelialization of 
corneal surface injuries in vivo23. Based on these studies, we hypothesized that the 
addition of EGF to our wound-healing scaffold would encourage epithelial regrowth. 
Since EGF released from the scaffold may diffuse into other parts of the cornea, we 
were interested in examining effects of EGF on myofibroblast behavior as well. 
 
We observed that EGF modulates the myofibroblast phenotype (Figures 1, 4-5). By 
adding 1 ng/mL of EGF to the cell culture medium of TGF-β transformed 
myofibroblasts, there were significantly fewer cells expressing αSMA compared to 
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untreated control cells. This effect was also observed at higher EGF concentrations of 
10 - 100 ng/mL (highest tested). These results contrasts those of He and Bazan, who 
reported that EGF (5 - 200 ng/mL) synergizes with TGF-β to induce fibroblast-
myofibroblast differentiation.24 It may be possible to explain this discrepancy by the 
difference in the order in which EGF was added into the culture medium. In He’s 
experiment, EGF was added simultaneously with TGF-β; whereas, in our experiment, 
we first induced myofibroblast transition with TGF-β, then replaced the culture medium 
with fresh medium containing EGF. Indeed, Kimura and coworkers observed that when 
cells were first cultured with TGF-β (3 days) and then cultured with EGF (3 days) after 
TGF-β removal, there was a decreased expression of αSMA compared to samples 
without EGF.25 In the skin, it has been observed that there is a burst of active TGF-β 
immediately after wounding (9-fold increase 1 hour after wounding), which declines 
within 24 hours (to a level slightly above that of normal skin and surrounding tissue).26 
It is possible that TGF-β expression in corneal wound healing follows a similar trend; 
thus, sequential addition of TGF-β and EGF may be an accurate in vitro representation 
of the therapeutic situation.   
 
Effect of FGF on myofibroblast phenotype 
FGF has been widely studied for its effects on promoting proliferation in a broad range 
of cell types, including keratinocytes27, osteoblasts28 and endothelial cells29. In relation 
to the cornea, FGF has been shown to stimulate proliferation of epithelial cells and 
stromal fibroblasts, and to enhance healing after an epithelial scrape injury in vivo.30,31 
In addition, Maltseva and coworkers demonstrated that corneal myofibroblasts cultured 
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in the presence of FGF (20 ng/mL) and heparin (5 μg/mL) have reduced αSMA 
expression.32 Although they found that the addition of FGF alone did not produce such 
effects, it has been suggested that raising the concentration of FGF (to 50 ng/mL) may 
eliminate the requirement of heparin.33 Based on these findings, the present study 
examines the effects of FGF alone (0.1 - 100 ng/mL) on myofibroblast phenotype.   
 
We observed that FGF reduces αSMA expression in myofibroblasts in a dose-dependent 
manner (Figure 2, 4-5). At low FGF concentrations (0.1 - 1 ng/mL), myofibroblasts 
express αSMA at levels that are indistinguishable from untreated control cells. We first 
see effects of FGF at a concentration of 10 ng/mL (65% fewer αSMA-expressing cells). 
Further increasing FGF concentration led to a larger decrease in αSMA-expressing cells 
(70% fewer at 50 ng/mL; 85% fewer at 100 ng/mL compared to untreated cells). Jester 
and Ho-Chang observed the addition of FGF did not induce αSMA expression in 
fibroblasts.8 Here, we further proved that FGF can decrease αSMA expression in 
myofibroblasts after TGF-β induction. In addition, we confirmed that the presence of 
heparin is not required (for FGF concentrations >10 ng/mL) in modulating the 
myofibroblast phenotype. 
 
Effect of PDGF on myofibroblast phenotype 
Etheredge and coworkers found that PDGF stimulates corneal fibroblasts to synthesize 
collagen (type I) and proteoglycans (keratan sulfate and chondroitin sulfate) that closely 
resemble normal corneal composition.34 This result suggests that PDGF is involved in 
the restoration of normal ECM following injury and that the addition of PDGF to a 
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corneal wound dressing can promote orderly tissue remodeling. Furthermore, Jester and 
Ho-Chang observed that PDGF (100 ng/mL) induced keratocytes to differentiate into 
fibroblasts that were negative for aSMA expression.8 On the contrary, Wilson and 
coworkers reported that PDGF promotes the differentiation of αSMA-positive 
myofibroblasts from keratocytes, which contribute to the development of corneal haze.35 
To clarify this discrepancy, we cultured myofibroblasts with PDGF (0 - 100 ng/mL) and 
analyzed their αSMA expression. 
 
We observed that PDGF was effective in reducing αSMA expression in myofibroblasts 
at very low concentrations (0.1 ng/mL) (Figures 3-5). However, the effects of PDGF 
diminished as PDGF concentration increased from 0.1 to 10 ng/mL. Interestingly, when 
PDGF concentration was further increased to 50 and 100 ng/mL, there was a drastic 
decrease in cells expressing αSMA. These results suggest that the effects of PDGF on 
αSMA expression is dose-dependent. Indeed, this dose-dependency in PDGF signaling 
has been observed in NIH3T3 fibroblasts, where cells switch from a migrating to a 
proliferating phenotype with increasing concentrations of PDGF.36 The hypothesis by 
De Donatis and coworkers that different PDGF concentrations lead to different 
endocytotic routes of the PDGF receptors may also hold true for the present study, 
although further investigation would be required to test this hypothesis. 
 
Different extent to which the number of αSMA-producing cells, αSMA mRNA and 
αSMA protein expression were affected by growth factors 
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It is noted that for each growth factor studied, they influence αSMA mRNA and protein 
levels, as well as the number of αSMA-producing cells, to different extents. For each 
growth factor at a given concentration, the number of αSMA-producing cells have a 
larger fold-change compared to that of αSMA mRNA changes, with the smallest fold-
change observed in the αSMA protein levels (e.g. for EGF at 50 ng/mL, compared to 
cells that received no EGF, there was a 65% decrease in cells positive for αSMA, but 
only a 25% decrease in αSMA mRNA expression and a 20% decrease in αSMA protein 
expression).  
 
It is possible that the number of αSMA-producing cells is underrepresented based on the 
method of quantitation. Here, we used immunostaining to label αSMA in growth factor 
treated and untreated myofibroblasts, and took photographs under the fluorescence 
microscope. The photographs were imported into ImageJ, and cells that showed 
fluorescence above a certain threshold were considered positive for αSMA expression. 
It is possible that additional cells are producing αSMA at levels that are either below the 
set threshold or not detectable by immunostaining. The αSMA protein in these cases 
would be detectable in our Western Blotting experiments (since protein is extracted from 
all cells in the culture dish), which may explain the discrepancy between the decrease 
in αSMA producing cells and the decrease in αSMA protein expression.  
 
The different extent to which αSMA mRNA and protein levels are affected by growth 
factors may be explained in the differences between mRNA and protein turnover rates. 
It has been shown that TGF-β induced myofibroblasts have relatively long-lived αSMA 
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protein: the organization of SMA into stress fibers make αSMA more stable against 
degradation.37 It is possible that growth factors affect downstream signaling molecules 
that decrease αSMA mRNA stability, which leads to a decrease in αSMA mRNA levels 
detected by qPCR experiments. However, since αSMA protein has a slow turnover rate, 
the decrease in αSMA protein levels is not as large as the decrease in αSMA mRNA 
levels. In addition, the regulation of αSMA expression has been shown to be controlled 
at multiple levels in transcription and translation38, further complicating the relationship 
between αSMA mRNA and protein levels. 
 
FAK and Raf-1 play a stronger role than TAZ and YAP in growth-factor-
dependent signaling that modulates αSMA expression 
We observed that EGF, FGF and PDGF are each able to mitigate the myofibroblast 
phenotype in a dose-dependent manner. The molecular mechanism by which these 
growth factors initiate signaling cascades that ultimately influence aSMA expression is 
still unclear. 
 
The differentiation of myofibroblasts from keratocytes is initiated when TGF-β binds 
and activates TGF-β receptors, which then recruits and phosphorylates downstream 
regulatory Smad proteins.39,40 Phosphorylated Smad proteins then translocate into the 
nucleus and regulate αSMA expression by targeting the Smad-binding sequence in its 
promoter region. 
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There are several hypotheses on the mechanism by which growth factors can inhibit 
αSMA expression (Figure 8). EGF, FGF and PDGF all activate the Raf/MEK/ERK 
signaling pathway41-43, which has been shown to suppress Smad transcriptional 
activities and induce expression of TGIF (a known Smad repressor),44 thereby 
negatively regulating levels of αSMA. In addition, it has been shown that focal adhesion 
kinase (FAK) is necessary for regulating the ERK pathway.45 Activated FAK increases 
cell-surface expression of growth factor receptors, which in turn increases activation of 
the ERK pathway. Therefore, we chose FAK and Raf-1 as two gene-silencing targets to 
investigate the role of ERK signaling in αSMA expression. 
 
Alternatively, it has been shown that TAZ and YAP promote the activity of TGFβ-
activated Smad complexes.46 In addition to being activated through substrate stiffness 
(as described in Chapter 2), TAZ and YAP can also be activated through other signaling 
pathways such as the Hippo cascade.47 It is possible that growth factors can inhibit 
downstream signaling molecules in these pathways. Indeed, it has been demonstrated 
that there is crosstalk between growth factor receptors and G-protein coupled receptors 
activated in the Hippo pathway.48 Therefore, we chose TAZ and YAP as two gene-
silencing targets to investigate their role in αSMA expression. 
 
We generated knockdown cells by transfecting human corneal fibroblasts with one of 
the corresponding siRNAs (FAK, Raf-1, TAZ or YAP) and cultured them in presence 
of a growth factor (EGF, FGF or PDGF at 100 ng/mL) (Figure 7). Knockdown of FAK 
and Raf-1 partially reversed αSMA expression to levels that were similar to control 
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untreated cells, suggesting that the ERK pathway plays a strong role in regulating αSMA 
expression. In contrast, siTAZ and siYAP cells expressed αSMA at a minimal level, 
suggesting that TAZ and YAP play a lesser role in the growth factor dependent reduction 
of αSMA expression. In the view of the complexity of intercellular signaling, it is 
possible that these are just two of the possible pathways with which growth factors 
influence αSMA expression. 
 
3.5 Conclusions 
We explored the use of growth factors in modulating the myofibroblast phenotype in 
vitro. Specifically, there were >80% fewer cells expressing αSMA (a cell marker of 
myofibroblasts) when treated with EGF, FGF or PDGF at a concentration of 100 ng/mL. 
Gene-silencing experiments suggest that the ERK signaling pathway plays an important 
role in propagating growth factor-receptor interactions into downstream molecular 
signals that affect αSMA expression.   
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Figure 1. Myofibroblast response to epidermal growth factor (EGF). A) Representative 
images of TGF-β (1 ng/mL) transformed myofibroblasts (P5) treated with EGF at 
different concentrations. Cell nuclei, Hoescht stain (blue); αSMA, anti-αSMA-FITC 
(green). B) Relative to control untreated cells, EGF treatment (>1 ng/mL) led to fewer 
αSMA-positive cells (analysis of images in A).  
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Figure 2. Myofibroblast response to fibroblast growth factor (FGF). A) Representative 
images of TGF-β (1 ng/mL) transformed myofibroblasts (P5) treated with FGF at 
different concentrations. Cell nuclei, Hoescht stain (blue); αSMA, anti-αSMA-FITC 
(green). B) Relative to control untreated cells, FGF treatment at high concentrations (10 
– 100 ng/mL) led to fewer αSMA-positive cells (analysis of images in A).  
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Figure 3. Myofibroblast response to platelet-derived growth factor (PDGF). A) 
Representative images of TGF-β (1 ng/mL) transformed myofibroblasts (P5) treated 
with PDGF at different concentrations. Cell nuclei, Hoescht stain (blue); αSMA, anti-
αSMA-FITC (green). B) Relative to control untreated cells, PDGF treatment at high 
concentrations (50 – 100 ng/mL) led to fewer αSMA-positive cells (analysis of images 
in A).  
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Figure 4. Relative to control untreated cells, TGF-β (1 ng/mL) transformed 
myofibroblasts (P5) treated with growth factors (EGF/FGF/PDGF at 50 or 100 ng/mL) 
demonstrated significantly lower levels of αSMA mRNA.  
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Figure 5. Relative to control untreated cells, TGF-β (1 ng/mL) transformed 
myofibroblasts (P5) treated with growth factors (EGF/FGF/PDGF at 50 or 100 ng/mL) 
demonstrated significantly lower αSMA protein expression. Results plotted here are 
based on Western blot analysis of cell lysates, quantified by the ratio of αSMA protein 
signals normalized by GAPDH.   
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Figure 6. Representative images of TGF-β (1 ng/mL) transformed myofibroblasts (P5) 
cultured on uniaxially-aligned nanofibers. Cells were treated with EGF/FGF/PDGF (50 
or 100 ng/mL) for 3 days, and their αSMA expression was visualized. Red arrows 
indicate direction of underlying nanofibers. Cell nuclei, Hoescht stain (blue); αSMA, 
anti-αSMA-FITC (green). 
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Figure 7. Human corneal fibroblasts (P5) were transfected with the indicated siRNA 
(control, FAK, Raf-1, TAZ, YAP) and transformed to myofibroblasts (10 ng/mL TGF-
β; greater concentration was used for human cells compared to rabbit cells in Figures 1-
7 to provide visible αSMA expression in the control). Cells were then treated with 
EGF/FGF/PDGF (100 ng/mL) for 3 days, and their αSMA expression was visualized. 
Cell nuclei, Hoescht stain (blue); αSMA, anti-αSMA-FITC (green). 
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Figure 8. Possible mechanisms by which growth factors regulate αSMA expression: 1. 
through activation of the ERK pathway that inhibits Smad activity and/or 2. by 
inhibiting TAZ/YAP translocation to the nucleus. Intermediate signaling molecules 
have been omitted for simplicity.  
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Table 1. Summary of prior literature on using GFs to influence corneal cells 
Growth 
factors 
Findings  Authors Ref 
Epidermal 
growth factor 
(EGF) 
Essential for epithelial wound closure Yu et al.  6 
Promotes epithelial cell proliferation, 
fibroblast migration and endothelial 
cell mitosis  
Watanabe et al.  
Kruse et al.  
 
Accelerates reepithelialization of 
corneal surface injuries in vivo  
Fabricant et al.  23 
Induces fibroblast-myofibroblast 
differentiation 
He et al.  24 
Decreases expression of αSMA  Kimura et al.  25 
Fibroblast 
growth factor 
(FGF) 
Reduced expression of αSMA in 
fibroblasts  
Jester et al.   8 
Stimulates proliferation of corneal 
cells  
Hu et al.  30 
Reduced αSMA expression in 
myofibroblasts in conjunction with 
heparin  
Maltseva et al.  32 
Platelet-
derived growth 
factor (PDGF) 
Induces keratocyte elongation without 
formation of stress fibers  
Kim et al. .  9 
Stimulates corneal fibroblasts to 
synthesize collagen and proteoglycans 
that closely resemble normal corneal 
composition 
Etheredge et al.   34 
Induced keratocytes to differentiate 
into fibroblasts that were negative for 
αSMA  
Jester et al.  8 
Promotes differentiation of αSMA –
positive myofibroblasts from 
keratocytes  
Wilson et al.  12 
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Chapter 4 
 
Development of a heparin-based hydrogel for corneal injury 
 
4.1 Introduction 
Regenerative medicine aims to promote tissue regeneration and remodeling, which can 
be achieved through drug delivery or controlling the biological environment 
surrounding injured tissues, among others. This in turn influences cell decisions such as 
replication, differentiation, proliferation and migration.1,2 Regenerative medicine 
provides an alternative to organ transplantation that relieves demand for transplant 
organs and avoids complications associated with immune responses against allografts. 
The use of hydrogels in regenerative medicine is appealing since they provide a three-
dimensional framework that can present stimuli to promote and direct formation of new 
tissue.3-5 Moreover, in situ forming hydrogels can be combined with living cells or 
bioactive molecules, such as growth factors, and be delivered to injured tissue in a 
minimally invasive manner.6,7  
 
A variety of synthetic and naturally-derived materials have been used for hydrogel 
formation. Among the synthetic polymers, end-functionalized polyethylene glycol 
(PEG) is widely used to prepare hydrogels under mild conditions8-9, and has progressed 
to the clinic as a component in a number of FDA-approved formulations for in-situ 
forming hydrogels (Matrix VSG™, ProGEL™, ReSure® to name a few). However, 
synthetic polymers do not present inherent biochemical cues or binding sites for 
bioactive molecules. Naturally-derived materials, such as collagen and hyaluronic acid, 
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have been used as a hydrogel because of their bioactivity and natural occurrence in the 
human body.10-13 Naturally-derived materials present challenges in controlling and 
tuning their hydrogel properties due to the materials’ heterogeneity. Hybrid hydrogels 
are promising because they take advantage of the benefits of each type of material and 
combine the tunable characteristic of synthetic material with the bioactivity of naturally-
derived materials.14,15  
 
Heparin is an anionic polysaccharide found naturally in the body, and is best known for 
its anticoagulant properties.16 A variety of proteins, including many growth factors, have 
heparin-binding domains.17 Incorporating heparin into hydrogels therefore provides an 
efficient way to sequester growth factors without loss of activity. Tae et al. have 
developed a heparin-based hydrogel that forms by reacting thiolated heparin (Hep-SH) 
and poly(ethylene glycol) diacrylate (PEG-DA) through a Michael-type addition.18 The 
addition of PEG-DA allows for easy control of physical properties of the hydrogel by 
varying the concentration and architecture of the crosslinker. Tae has demonstrated that 
his heparin-based hydrogel is well-suited for the cultivation of hepatocytes19 and 
chondrocytes20, as well as the regeneration of cartilage in vivo21. More recently, in situ 
forming hydrogels based on heparin have been extended to maleimide functionalized 
heparin and thiolated PEG with glutathione–sensitive crosslinks22; peptide-heparin 
networks23 and starPEG-heparin hydrogels.24  
 
To increase the gelation rate and provide spatial and temporal control of gelation, photo-
polymerization of hydrogels has been widely used, particularly with the photoinitiator 
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Irgacure 2959.25-28 In the context of heparin-based hydrogels, Tae demonstrated gelation 
within minutes when the precursor solution was exposed to ultraviolet (UV) light (365 
nm, 18 W/cm2).29,30 However, UV light can compromise cytocompatibility due to 
production of cytotoxic free radicals that damage cellular proteins and DNA.31 Also, it 
has been shown that certain cell types (osteoblasts and corneal epithelial cells) are very 
sensitive to UV exposure.32 Therefore, we have developed a variation of the heparin-
based hydrogel that can be cured using visible light. Specifically, we replaced Irgacure 
2959 with eosin Y (EY).  The maximum absorbance of EY is at 524 nm, and therefore 
is activated by green light.  Since the 1990s, EY with TEOA as a coinitiator has attracted 
interest because, even in direct contact with cells, it permits photopolymerization with 
very low toxicity,33,34 and is used in an FDA-approved  lung sealant (FocalSeal).35  The 
ability to encapsulate cells in photopolymerized hydrogels using EY as the initiator has 
since been used by the Lin group to embed hepatocytes in thiol-acrylate PEG 
hydrogels36,37 and by the West group to study endothelial morphogenesis in laminin 
functionalized PEGDA hydrogels.38  
 
The present visible light initiated formulation permits gelation within minutes, 
comparable to the Irgacure-containing hydrogels, using a light dose that conforms with 
Group 1 eye safety threshold (no hazard). Thus, the current formulation opens the way 
to applications of heparin-based hydrogels on and in the eye. Relationships between gel 
formulation and irradiation conditions, and properties are described. The visible light 
photo-crosslinking is shown to be well-suited for use as a cell carrier, as well as a 
scaffold for growth-factor delivery.  
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4.2 Methods 
Preparation of heparin-based hydrogels  
Thiol-functionalized heparin (Hep-SH) was synthesized by modifying 40% of the 
carboxyl groups of heparin, following established protocols.18 In heparin, each 
disaccharide repeat has one carboxylate group, so the functionalized polymer has one 
thiol group per 1500 g/mol of heparin at 40% modification. The amount of thiol groups 
in Hep-SH was determined using Ellman’s reagent and measurement of molar 
absorptivity at 412 nm. In this study, 40 ± 2.5% thiolated heparin was used for all of the 
experiments. PEG macromers (PEG-DA or 4-arm PEG) and Hep-SH were sequentially 
dissolved in either PBS or DMEM (thiol:acrylate = 1:1 – 1:0.25 molar ratio). 0.005 – 
0.01% (w/v) eosin Y as a photo-initiator and 0 – 0.5% (v/v) TEOA as an electron donor 
were added via stock solutions ([EYstock] = 0.5%; [TEOAstock] = 5%) to the precursor 
solution. The pH of the reaction mixture was adjusted to 7.0 – 8.0 with 1 N HCl and/or 
NaOH. Precursor solutions were used within 1 hour of preparation and stored in the dark 
at 4oC prior to use. Prepared precursor solution was photo-polymerized under green 
LED light (5 – 100 mWcm2) exposure. The LED emission wavelength is 525 ± 15 nm. 
 
Micropatterning 
1. Preparation of release layer on the glass slide. 
In order to enable controlled retrieval of micropatterned heparin-based hydrogels from 
their substrate, one of the glass slides is treated to provide an initially-adhesive surface 
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that can be subsequently “switched” to release the gel in a stimuli-response manner.30 
Specifically,  a layer by layer (LbL) technique was used to deposit a (PLL-HA)2 
multilayer, as described previously.30 Finally, a capping layer of methacrylate-
functionalized chitosan (GMA-Chi) (5 kDa) is adsorbed to provide sites for anchoring 
the hydrogel to the system. Additional experimental details can be found in the 
Supplementary Information. Glass substrates bearing this multilayer are denoted as 
(PLL-HA)2-(GMA-Chi). 
 
2. Micropatterning of heparin-based hydrogel on multilayer-adsorbed glass 
slide. 
For each formulation investigated, 30 μL of the corresponding hydrogel precursor 
solution was pipetted on the (PLL-HA)2-(GMA-Chi) glass slide and covered with a bare 
cover slip using a 320 µm spacer to provide a uniform thickness. A photomask was put 
on the cover slip prior to irradiation using green light. After irradiation, the photomask 
and coverslip were carefully removed. The coverslip and glass slide were rinsed with 
PBS and imaged. The presence of heparin in the micropatterned hydrogel structures was 
visualized by toluidine blue O staining, as previously reported.30,39 
 
Cell culture and live-dead assay 
To encapsulate 3T3 fibroblast (NIH 3T3) cells in the heparin-based hydrogel, cells were 
detached from standard cell culture plates and re-suspended in the prepared hydrogel 
precursor solution in DMEM. A gel precursor solution (30 μL) containing cells (2x106 
cells/mL) was pipetted on a (PLL-HA)2-(GMA-Chi) modified glass slide, and hydrogels 
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were formed following the same micropatterning procedure as described above. Cell-
laden hydrogels were maintained in the DMEM containing 10% FBS, 200 U/mL 
penicillin, and 200 μg/mL streptomycin at 37°C in a humidified 5% CO2 incubator with 
a medium change every 2 days. The viability of fibroblasts inside the hydrogel was 
analyzed using a double-staining live-dead assay procedure. Briefly, cell-laden 
hydrogels were rinsed with PBS and then incubated in a medium with 0.67 μM AO and 
7.5 μM PI for 30 minutes. After rinsing again with PBS, stained cells were imaged using 
a confocal microscope (FV1000, Olympus, Center Valley, PA). The percentage of 
viable cells was calculated by counting the number of green (live) cells and dividing by 
the total number of cells including red (dead) cells. The average viability was obtained 
from 4 independent preparations of precursor solutions. 
 
Rheological measurements  
Moduli of hydrogels were determined using oscillatory shear. For gelation studies, a 
rheometer (AR-1000, TA Instruments, New Castle, DE) fitted with a custom-built 
photo-crosslinking setup (Figure S1) was used to perform simultaneous irradiation and 
rheological measurements. Measurements were performed in the linear viscoelastic 
regime (Figure S2). 30 μL of gel precursor solution was pipetted onto the rheometer 
and the 8 mm parallel plate geometry was set to a gap of 500 μm. A 10-minute time 
sweep (an angular frequency of 1 rad/s and a stress of 50 Pa) was carried out for 
monitoring hydrogel gelation. The hydrogel precursor solution was irradiated with a 525 
nm green light at 5 mW/cm2 for the first 2.5 minutes of the time sweep, and the green 
light was then turned off for the remainder of the time. The experiment was repeated 
4-7 
 
four times for each precursor solution. To measure the modulus after swelling, hydrogels 
were separately prepared and swollen in PBS (pH 7.4) for 2 days at 37oC. Swollen 
hydrogels were then cut to fit the 8 mm parallel plate geometry. An angular frequency 
of 1 rad/s and a strain of 2% was used in these studies (ARES-RFS, TA Instruments, 
New Castle, DE). The experiment was repeated four times for each precursor solution. 
 
Swelling measurements  
To measure the wet-to-dry mass ratio of the hydrogels, we first prepared the hydrogels 
and immersed them in PBS (pH 7.4) for 2 days at 37oC. Fully-swollen hydrogels were 
dabbed gently with a Kimwipe to remove excess PBS and weighed immediately to 
obtain the wet-mass weight (Ws). The hydrogels were then lyophilized and weighed to 
obtain the dry-mass weight (Wd). The fully-swollen:dry-mass ratio was calculated by 
Ws/Wd (n = 4).  The dry mass includes salts from PBS, which could represent 10-15% 
of the dry mass.  None of the conclusions are affected by this uncertainty in the dry 
mass.  
 
Heparin incorporation  
A toluidine blue assay was used to quantify the amount of heparin retained in hydrogels 
after swelling.40 The hydrogels were prepared as described above and placed in PBS for 
2 days. 1 mL of 0.04% (w/v) toluidine blue in aqueous 0.01 N HCl/0.2% (w/v) NaCl 
was then added to each hydrogel. The mixture was gently shaken for 6 hours, during 
which heparin-toluidine blue complexes were formed. The mixture was then centrifuged 
at 1,000 x g for 10 minutes to remove excess toluidine blue solution. The amount of 
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toluidine blue in the heparin-toluidine blue complex (i.e. the amount of toluidine blue 
in the hydrogel) was determined by first rinsing the hydrogel with aqueous 0.01 N 
HCl/0.02% (w/v) NaCl and then adding a solution of 4:1 (v/v) mixture of ethanol and 
aqueous 0.1 N NaOH until all the heparin-toluidine blue complex was dissolved. The 
absorbance of the resulting solution was measured at 530 nm. A standard curve was 
carried out using the same procedure with solutions of heparin at known concentrations. 
To rule out the possibility that EY is responsible for some of the signal at 530 nm 
(attributed to heparin), the assay was performed on heparin-free hydrogels (replacing 
heparin with gelatin) photocured using EY. When the heparin-free hydrogels were 
subjected to the same heparin incorporation analysis, no significant reading was 
measured. The experiment was repeated 4 times for each precursor solution.  
 
In vitro EGF release from hydrogels  
Loading of the hydrogels was achieved by adding EGF to the hydrogel precursor 
solution with a final EGF concentration of 100 ng/mL. 50 μL of gel precursor solution 
was pipetted into a well in a 96-well plate and irradiated for 2.5 minutes at 5 mW/cm2 
using a 525 nm green light. After gelation, 200 μL of PBS (pH 7.4) was added to the 
well as release buffer and samples were kept at 37oC in a humidified 5% CO2 incubator. 
The release buffer was collected and replaced with fresh buffer each day. Collected 
samples were stored frozen prior to analysis. The released EGF at different time points 
was analyzed with a human EGF ELISA kit (Life Technologies, Carlsbad, CA). 
Absorbance was measured using a microplate reader at 450 nm (Tecan, Männedorf, 
Switzerland). The experiment was repeated 4 times for each precursor solution.  
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Cell culture assay of EGF bioactivity  
Bioactivity of EGF released from hydrogels was assayed using scratch wound assay.41 
3T3 fibroblasts (NIH 3T3) were grown in a 24-well plate in a humidified incubator (5% 
CO2) at 37oC in DMEM containing 10% FBS, 200 U/mL penicillin, and 200 μg/mL 
streptomycin. When the cells were confluent, a sterile pipette tip was used to scrape the 
cell monolayer, thereby creating a ‘mock wound.’ The initial wound boundaries were 
imaged with an inverted phase contrast microscope (Zeiss Axiovert 25CFL). The cell 
medium was then replaced with fresh media containing either no growth factor (negative 
control), 20 ng/mL of as-received EGF (positive control) or 20 ng/mL released EGF. 
The mock wound area was imaged every 12 hours. The experiment was repeated 4 
times.  
 
4.3 Results  
We have developed a visible-light photo-crosslinking formulation of a heparin-based 
hydrogel (Figure 1), using green light (525 nm) to photocrosslink thiolated-heparin and 
acrylate-ended poly(ethylene glycol) (PEG) in the presence of eosin Y as the 
photoinitiator and triethanolamine as the electron donor.  
 
Effect of concentration on gelation kinetics and micropatterning gelation time  
With a higher concentration of heparin and PEG, holding thiol:acrylate ratio fixed at 
1:1, gelation occurred faster and a higher final modulus was achieved (Figure 2A). 
Doubling the heparin concentration from 1.66% to 3.33% while keeping the 
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thiol:acrylate ratio and all other solution conditions constant, increased the storage 
modulus more than an order of magnitude (from 550 ± 110 Pa to 6900 ± 800 Pa).  
 
When placed in a large volume of PBS, the as-prepared gels swell, taking in an 
additional 50 to 75% of water (e.g. the solids content of the as prepared 1.67% heparin 
hydrogel is 5%, corresponding to an initial wet:dry mass ratio of 20, which increases to 
30.5 after 2 days in PBS). The increase in water content is accompanied by a decrease 
in modulus by a factor of 2 to 3 (Table 1). A small fraction of heparin diffused out from 
the gel, particularly for the lowest crosslinking density (1.67% heparin gel loses 13% of 
its heparin to the bath). 
 
In the micropatterning experiment, decreasing the heparin concentration led to an 
increase in the time required for spatially-resolved gelation from 4 minutes at 3.33% to 
10 minutes at 1.67% (Figure 2B). In contexts in which higher intensity is acceptable, 
increasing the light intensity can be used to significantly decreased gelation time (e.g. 
from 10 minutes at 5 mW/cm2 to 2.5 minutes at 100 mW/cm2 for 1.67% heparin). 
 
Effect of gel formulation on gelation kinetics and micropatterning gelation time  
To investigate the effect of gel formulation on hydrogel formation, we varied the pH, 
TEOA concentration and EY concentration. Even small changes in pH strongly affect 
gelation kinetics and modulus. Increasing pH from 7.0 to 8.0 provided a 3-fold increase 
in the modulus (Figure 3A, top) and a 3-fold decrease in the micropatterning time 
(Figure 3B, top).  
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Increasing the TEOA concentration from 0.05% to 0.1% enhanced gelation rate (Figure 
3A, middle) and shortened the time required for micropatterning (Figure 3B, middle). 
However, further increase of the TEOA concentration did not have a significant effect: 
both G’(t) and optimal photo-patterning exposure were virtually indistinguishable for 
0.1% and 0.5% TEOA. 
 
Increasing the photo-initiator (EY) concentration from 0.005% to 0.01% increased 
gelation rate (Figure 3A, bottom) and  shortened the time required for micropatterning 
(Figure 3B, bottom). Interestingly, further increasing the EY concentration to 0.02% 
resulted in the incomplete formation of a hydrogel (the side that was irradiated formed 
a gel, but a liquid layer was observed on the dark side).  
 
Equilibrium swelling correlates with as-prepared gel modulus (Table 2), in accord with 
trends observed as a function of heparin concentration (Table 1). All gels that had an 
as-prepared modulus of 1400 Pa or more had higher retention of heparin (93% or more). 
Gel formulations that gave low modulus (1150 Pa or less) exhibited relatively high 
equilibrium swelling (wet:dry mass ratio > 27), low modulus of equilibrium swollen 
gels (530 Pa or less) and low heparin retention (< 80%). 
 
Effect of crosslinking stoichiometry for linear PEG and 4-arm PEG on gelation 
kinetics and micropatterning gelation time  
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To study the effects of the acrylate-containing crosslinker on hydrogel formation, we 
varied the molar ratio of thiol to acrylate groups in the gel formulation, as well as the 
crosslinker architecture. Increasing the thiol:acrylate ratio from 1:1 to 1:0.3 (effectively 
decreasing the amount of crosslinker) while keeping the heparin concentration and all 
other solution conditions fixed, slowed the gelation rate (Figure 4A, top) and increased 
micropatterning time (Figure 4B, top). The modulus of the resulting gel decreased from 
1800 ± 80 Pa at 1:1 thiol:acrylate to 270 ± 50 Pa at 1:0.3 thiol:acrylate, which correlated 
the increase in both swelling ratio and extractables with decreased crosslinking of 
hydrogels (Table 3). 
 
Replacing linear PEG-DA (6 kDa) with its 4-arm counterpart (13 kDa) led to faster 
gelation and higher moduli (Figure 4A), and a shorter irradiation dose for optimal 
patterning (Figure 4B). These effects could be systematically modulated by increasing 
the thiol:acrylate ratio from 1:1 to 1:0.25 (keeping the heparin concentration and all 
other solution conditions fixed) to slow the gelation rate (Figure 4A, bottom) and 
increase the micropatterning time (Figure 4B, bottom).  
 
In vitro release of bioactive growth factors  
Hydrogels with encapsulated EGF (100 ng/mL) were formed as described in Methods 
and 200 µL of PBS as release medium was collected daily. Over the first two days, 
~30% of EGF was released from the heparin-based hydrogel (Figure 5). To validate the 
bioactivity of released EGF, we carried out a mock wound assay.33 It has been well-
established that EGF promotes cell migration in a variety of cell types.42-44 We collected 
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EGF that had been released from hydrogels (EGFrel) and compared it to native EGF by 
observing its effect on 3T3 fibroblasts at a concentration of 20 ng/mL. The migration 
rate of 3T3 fibroblasts into a ‘mock wound’ was indistinguishable for cells exposed to 
EGFrel and cells exposed to native EGF, and both move much faster than control samples 
without EGF (Figure 6). 
 
4.4 Discussion 
To reduce phototoxicity in vivo during in situ photo-crosslinking of heparin-based 
hydrogels developed by Tae,19-21 a visible-light activated formulation is demonstrated. 
Previously, photo-polymerization of the heparin-based hydrogels used Irgacure 2959 as 
the photoinitiator, activated by UV light (365 nm at 18 mW/cm2). To enhance the 
biocompatibility of the photo-crosslinking procedure, we replaced Irgacure 2959 with 
eosin Y (EY), a photoinitiator that can be activated by visible light, and has been shown 
to be biocompatible in several biomedical applications.33,34 EY is a type II photo-
initiator, which requires a co-initiator to generate sufficient radicals for photo-
polymerization. Hubbell et al. demonstrated hydrogel photocrosslinking using TEOA 
as the co-initiator with EY and found minimal toxicity.45 More recently, Lin and 
coworkers have used EY and visible light in photo-polymerizable thiol-acrylate 
hydrogels.36,37,46,47 They show that TEOA can be replaced by N-vinyl pyrrolidone 
(NVP), which becomes covalently incorporated during photo-polymerization and that 
cells encapsulated in the formulation remain viable. In the present study, we chose 
TEOA as the co-initiator because it has a higher median lethal dose (LD50) than NVP, 
e.g. LD50 (rabbit-dermal) for NVP is 560 mg/kg48 while that for TEOA is >22.5 g/kg49. 
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When a precursor solution of Hep-SH, PEG-DA, EY and TEOA is irradiated with green 
light (525 nm), a transparent hydrogel forms (Figure 1). 
 
Two different methods were used to study the gelation process of the visible light 
activated heparin-based hydrogel: oscillatory photo-rheology and micropatterning. The 
former provides information on the parameters that control gelation kinetics and the 
modulus of the gel, and the latter provides a useful platform for creating 3-D cell-
encapsulated hydrogel microstructures for cell therapy applications.29,50,51 Indeed, the 
motivation for using (PLL-HA)2-(GMA-Chi)-treated substrates is to pave the way to 
selectively retrieve cell-laden microgels, which can then be used as tissue building 
blocks in a bottom-up approach to assemble full tissue constructs.52  
 
We monitored hydrogel formation using a custom optical rheometer with the ability to 
perform simultaneous irradiation and rheological measurements (Figure S-1). During 
oscillatory shear with a parallel plate geometry, the hydrogel precursor solution was 
irradiated with green light at 5 mW/cm2 for 2.5 minutes. The light was then turned off 
for the remainder of the experiment. The gelation rate is characterized by the rate of 
increase of the storage modulus during irradiation. The short irradiation time was chosen 
because we intend to use this hydrogel for wound-healing applications where short 
gelation times are clinically desirable. Likewise, the modest light intensity was chosen 
based on clinical considerations (see Table 4).  
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In the micropatterning experiments, the observed outcomes fell into three groups 
(Figure S-3): “insufficient exposure” was associated with incomplete arrays of gel on 
the treated glass slides, “sufficient exposure” provided a complete array of uniform gel 
disks, and “excessive exposure” was manifested by the formation of gel in the dark 
regions that interconnected the microgel disks. The onset of “excessive exposure” 
occurred at approximately 2-3x the onset of “sufficient exposure.” Therefore, we simply 
show the latter when comparing the effect of material parameters and irradiation 
conditions on the “micropatterning gelation time.” In these micropatterning 
experiments, light intensities of up to 100 mW/cm2 were tested. This relatively high light 
flux was chosen to test the feasibility of forming microgels using short light exposure 
times (< 1 minute) for high throughput applications (such as microfluidics).  
 
Using these methods, we first studied the effect of heparin concentration on gelation 
time and gel stiffness. As expected, using a higher heparin concentration resulted in 
hydrogels that had a higher final modulus. Clinically, the gels will be in contact with an 
open system. Therefore, it is of interest to know the physical properties and heparin 
content of the hydrogels after equilibrating with a large bath (Table 1). We observed 
that the hydrogels swell when placed in PBS and a small fraction of heparin diffused out 
from the gels. A high swelling ratio and high level of extractables (water-soluble solids 
that can be readily extracted from a hydrogel when it is swollen in excess liquid) are 
both characteristic of a hydrogel system of low crosslinking density.53,54 A relatively 
high fraction of heparin remained in the hydrogel, representing an efficient crosslinking 
reaction in our case. 
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We then studied the effects of gel formulation on gelation time and gel stiffness. We 
speculate that TEOA plays a role in the increase of gelation rate at higher pH, similar to 
observations of Valdebenito et al.55, who attribute the effect of increase in pH near 
TEOA’s pKa of 7.74 to change the ionization of TEOA that facilitates electron transfer 
and, thus, increases the rate of polymerization. Interestingly, corresponding effects 
could not be achieved by increasing TEOA concentrations.  
 
The effect of EY concentration shows the usual trade-off between availability of photo-
initiator and penetration of light through the sample.56 For each EY concentration, there 
is a specific optical penetration depth (Lp, also known as extinction length) for light of 
a particular wavelength, at which the light intensity has attenuated by 1/e.57 The 
photoinitiator EY is the only species in the present formulation that absorbs light 
significantly; thus, the light intensity profile in the sample can be approximated by:  
𝐼𝐼(𝑧𝑧) =  𝐼𝐼𝑜𝑜𝑒𝑒−𝐶𝐶𝐶𝐶𝐶𝐶 
where I(z) is the light intensity at depth z, Io is the incident light intensity, ε is the molar 
absorptivity of EY, and c is the concentration of EY in the sample (Figure S-4). Using 
UV-VIS spectroscopy to measure the absorbance of EY at different concentrations, we 
calculated ε for EY at 525 nm to be 1.09 x 105 M-1cm-1 from Beer’s Law. For the EY 
concentrations considered here, the extinction lengths are approximately 1200 µm 
(0.005% EY), 600 µm (0.01% EY) and 300 µm (0.02% EY). For the first two, light 
penetrates through the entire sample thickness (500 µm on the rheometer and 320 µm 
for micropatterning); therefore, the increase in concentration of photo-initiator leads to 
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an increase in the rate of gelation (Figure 3A, top) and a shorter micropatterning 
gelation time (Figure 3B, bottom). However, for the highest of these concentrations, 
gelation occurs mainly on the irradiated side of the formulation. Due to the presence of 
a liquid layer on the dark side of the gap, the rheometer fails to detect an increase in 
modulus and the micropattern fails to adhere to the treated glass slide (it is observed on 
the cover slip instead, Figure S-3).   
 
The well-known method of using 4-arm PEG instead of linear PEG to increase formation 
of elastically-effective junctions also works in the present system.58 Replacing linear 
PEG-DA with its 4-arm counterpart resulted in faster gelation. In addition, the final 
moduli of hydrogels can be systematically modulated by varying the thiol:acrylate ratios 
(changing the ratio from 1:1 to 1:0.25 resulted in a softer gel).  
 
Thiol-acrylate photo-polymerization occurs through a mixed-mode mechanism, i.e., a 
combination of chain-growth and step-growth reactions.59,60 When a thiol-acrylate 
system is photo-polymerized, a competition exists between the chain-growth 
homopolymerization of acrylate groups and the step-growth thiol-ene coupling. 
Bowman and Anseth et al. have demonstrated that the reaction of a thiyl radical with a 
carbon-carbon double bond is almost 10x faster than that of a carbon-based radical with 
the same double bond.61,62 In accord with their findings, we observe a strong propensity 
to form SH – acrylate bonds (high levels of heparin incorporation) and negligible 
acrylate polymerization rates (as evidenced by failure to gel when Hep-SH was replaced 
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with heparin under matched concentration and irradiation conditions 5 mW/cm2, 2.5 
minutes). 
 
Our motivation for developing a visible light photo-crosslinking formulation is for 
application of heparin gels in guided wound-healing of corneal injuries. In this context, 
the irradiation conditions are limited by damage thresholds for the cornea and retina. 
Therefore, we performed calculations for a computational eye model of the eye using 
ZEMAX ray-tracing software (geometry shown in Figure S-5).  
 
In the EY/vis ZEMAX simulations, we allowed for a relatively long exposure (10 
minutes) of visible light from a single LED (32o viewing angle) placed 2 cm away from 
the cornea on axis. Under conditions that give a 5 mW/cm2 flux at the apex of the cornea, 
the maximum retinal irradiance using these parameters was found to be ~6.9 mW/cm2. 
Assuming that EY absorbs 50% of the incident light and using the retinal photochemical 
hazard-weighting function, the maximum flux of green light at the retina appears to be 
compatible with Group 1 and 2 Ophthalmic Instruments (ISO-15004-2:2007): 6.9 
mW/cm2 at 525 nm is approximately half the Group 1 threshold and is only 0.6% of the 
Group 2 threshold (Table S-1). In the Irgacure/UV case for heparin-based hydrogel 
formation, simulations were not required because the 18 W/cm2 flux at 365 nm for 
photo-gelation is 5,000x over the threshold for corneal damage (which has a much 
greater damage threshold than the retina). In more common Irgacure/UV 
photopolymerization applications, the light flux used is between 5 and 20 mW/cm2, with 
exposure times ranging from 1 to 30 minutes.25-28 Taking a median value of 10 mW/cm2 
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flux and 10 minutes exposure time, the exposure level of the UV light is 2.75x over the 
threshold for corneal damage (far in excess of the threshold for retinal damage). The 
results for EY/vis suggest that the treatment might be compatible with a Group 1 device 
(no hazard), and indicate the treatment is well within the safety limit for the category of 
Group 2 devices (Table S-1).  
 
The goal of using these heparin-based hydrogels as cell carriers or scaffolds is to display 
and deliver growth factors to nearby cells. Therefore, we confirm that they can be 
formed using EY/vis at physiological conditions without cytotoxicity and retain their 
ability to release growth factors. We tested the gelation time and final swollen moduli 
of hydrogels prepared at both 25oC and 37oC, and observed no significant differences 
between the two temperatures (Figure S-6). High levels of TEOA have been linked to 
cell toxicity.63 To test cell viability, we encapsulated 3T3 fibroblasts in the hydrogels 
and subjected the samples to live/dead staining using acridine orange (AO) and 
propidium iodide (PI). We found that the addition of up to 0.1% w/v TEOA to the gel 
formulation did not measurably affect cell survival relative to TEOA-free controls 
(Figure S-7). Increasing the light intensity from 5 mW/cm2 to 100 mW/cm2, varying 
the crosslinking stoichiometry, and changing from linear PEG to 4-arm PEG also had 
no effect on 3T3 viability (Table S-2, Figure S-7). Encapsulated cells in all samples 
tested were over 96% viable.  
 
To compare the present visible-light photocure system with the previously-reported UV 
cure with respect to growth factor delivery, we studied the release profile of epidermal 
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growth factor (EGF) from our hydrogel. We chose an EGF encapsulation concentration 
of 100 ng/mL based on studies that showed EGF to be effective in stimulating cell 
growth at concentrations of 0.1 – 100 ng/mL.64,65 
 
The fraction of growth factor released (~30% in 2 days) is somewhat greater than that 
of hepatocyte growth factor (HGF) released from Tae and coworkers’ original Michael-
addition formulation over the same time period19, and comparable to that of heparin-
binding epidermal growth factor (HB-EGF) from a UV-activated chitosan hydrogel of 
Ishihara et al.66, and that of encapsulated fibroblast growth factor (FGF) from a heparin-
containing hydrogel reported by Nie et al.58. The time profile of release, with most of 
the release within the first day, is also similar to that of Ishihara et al.66. The in vitro 
EGF release profiles were not affected by the heparin content of the present gels, 
consistent with the small amount of EGF (~16 nM) loaded compared to the amount of 
heparin (~1 – 3 mM). The hydrogel has the capacity to carry a much greater amount of 
EGF, or to carry multiple growth factors in addition to EGF. To test the hypothesis that 
incomplete EGF release is due to a fraction of EGF becoming covalently bound to the 
hydrogel during photo-polymerization, we performed experiments in which EGF was 
loaded after photo-crosslinking. Approximately 60% of the EGF was released in that 
case. Thus, approximately half of the retained EGF may be covalently incorporated into 
the gel. EGF retained in the gel can act continuously on encapsulated cells or even 
promote the migration of external cells into the hydrogel.67 To validate the bioactivity 
of released EGF, we carried out a mock wound-healing assay. Our results indicate that 
the EGF released from the heparin-based hydrogel has similar efficacy in promoting 
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fibroblast migration as native EGF, thereby confirming that its bioactivity is retained 
after hydrogel formation. 
 
4.5 Conclusions 
We have developed a visible-light photo-crosslinking formulation of a heparin-based 
hydrogel. Thiolated-heparin reacts with acrylate-ended poly(ethylene glycol) when 
green light (525 nm) is used to excite Eosin Y as a photoinitiator with triethanolamine 
as an electron donor. The hydrogel forms quickly (< 5 minutes), and is easily tunable in 
terms of both the mechanical properties and gelation kinetics by choice of the precursor 
concentration, crosslinker architecture and irradiation conditions (light intensity and 
exposure time). In addition, we successfully fabricated micropatterned cell-laden 
hydrogels, where the encapsulated fibroblasts remained viable after gelation. The 
incorporation of heparin in the hydrogel allows for the binding and release of a variety 
of growth factors. In vitro characterization of EGF as a model growth factor revealed 
that EGF retained its bioactivity after release from the hydrogel, indicating that our 
method of growth factor delivery protects the growth factors against damage. The 
irradiation conditions for gelation of the EY/vis formulation are compatible with safety 
standards for corneal and retinal exposure, opening the way to application of heparin-
based hydrogels as cell or growth factor scaffolds for ocular tissue engineering.  
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Figure 1. Schematic representation of visible-light activated heparin-based hydrogel 
formation. Thiol-functionalized heparin (Hep-SH) reacts with poly(ethylene glycol) 
diacrylate (PEG-DA) when green light (525 nm) is used to excite Eosin Y (EY) as a 
photoiniator with triethanolamine (TEOA) as an electron donor.  
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Figure 2. Effect of concentration on (A) gelation kinetics and (B) micropatterning gelation 
time for a fixed molar ratio of heparin to linear PEG (thiol:acrylate 1:1 mol, equivalent to 
Hep-SH:PEG-DA 1:2 mass ratio) in PBS (pH 7.8) with 0.01% EY and 0.1% TEOA. 
Concentrations are given in terms of heparin weight percent to emphasize the bioactive 
component. (A) Storage modulus of gel solution during irradiation with 525 nm green light 
at 5 mW/cm2 for 2.5 minutes (shaded green area) and afterward for a total of 10 minutes. 
(B) Optimal irradiation time to achieve spatially-resolved gelation using 525 nm green light 
at 100 mW/cm2.  
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Figure 3. Effects of pH for [TEOA] = 0.1% and [EY] = 0.01% (top), TEOA concentration 
with pH = 8.0 and [EY] = 0.01% (middle), and EY concentration for pH 8.0 and [TEOA] 
= 0.1% (bottom) on (A) gelation kinetics and (B) micropatterning gelation time for fixed 
concentrations of heparin (2.33% w/v) and heparin-to-linear-PEG molar ratio thiol:acrylate 
1:1, equivalent to Hep-SH:PEG-DA 1:2 mass ratio, in PBS (pH 7.8). Compositions listed 
in Table 2. (A) Storage modulus of gel solution during irradiation with 525 nm green light 
at 5 mW/cm2 for 2.5 minutes (green shaded area) and afterward for a total of 10 minutes. 
(B) Optimal irradiation time to achieve spatially-resolved gelation using 525 nm green light 
at 100 mW/cm2. 
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Figure 4. Effects of crosslinking stoichiometry for linear PEG (top) and 4-arm PEG 
(bottom) on (A) gelation kinetics and (B) micropatterning gelation time for fixed 
concentrations of heparin (2.33% w/v), EY (0.01%) and TEOA (0.1%) in PBS (pH 7.8). 
Compositions listed in Table 3. (A) Storage modulus of gel solution during irradiation with 
525 nm green light at 5 mW/cm2 for 2.5 minutes (green shaded area) and afterward for a 
total of 10 minutes. (B) Optimal irradiation time to achieve spatially-resolved gelation 
using 525 nm green light at 100 mW/cm2. Note that thiol:acrylate = 1:0.25 was 
characterized for both linear and 4-arm PEG; it is not shown in (top) because it did not gel 
under any of the irradiation conditions shown.  
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Figure 5. In vitro release profiles of epidermal growth factor (EGF) from heparin-based 
hydrogels at different heparin concentration. Hydrogels were prepared in PBS (pH 7.8) 
with 0.01% EY, 0.1% TEOA and 100 ng/mL EGF. [Heparin] = 2.33% w/v, [PEG-DA] = 
4.67% w/v. 
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Figure 6. Effect of EGF on cell migration of 3T3 fibroblasts in a wound-healing assay: (A) 
representative pictures taken using phase contrast microscopy and (B) quantified results. 
EGF released from the heparin-based hydrogel (EGFrel) promotes cell migration at a rate 
similar to native EGF. Cells exposed to EGF or EGFrel migrate faster than control samples 
without EGF exposure.  
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Table 1. Effect of heparin concentration on gel properties.  
Heparin 
(%) 
PEG-DA 
(%) 
G’ (Pa) as 
prepared(a) 
G’ (Pa) 
after 
swelling 
Wet : dry 
mass 
ratio(b) 
Fraction of 
heparin 
retained 
1.67% 3.33% 550 ± 110 200 ± 20 30.5 ± 1.6 0.87 ± 0.03 
2.33% 4.67%   1800 ± 80   900 ± 120 25.2 ± 1.0 0.94 ± 0.03 
3.33% 6.67%     6900 ± 800 4350 ± 240 17.5 ± 2.1 0.96 ± 0.02 
 
(a) Hep-SH (12 kDa) and linear PEG-DA (6 kDa), thiol:acrylate mole ratio 1:1 (hence 1:2 mass ratio Hep-
SH:PEG-DA), 25oC, pH 7.8, [EY] = 0.01%, [TEOA] = 0.1%, 5 mW/cm2 at 525 nm for 2.5 minutes. (b) 
Note that the dry mass may contain 10-15% of salts introduced with the PBS buffer. 
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Table 2. Effect of gel formulation on gel properties.  
pH TEOA EY G’ (Pa) as prepared(a) 
G’ (Pa) 
after 
swelling 
Wet : 
dry mass 
ratio(b) 
Fraction of 
heparin 
retained 
7.0 
0.1% 0.01% 
 680 ± 50    480 ± 80 30.1 ± 1.3 0.71 ± 0.10 
7.4   1150 ± 120    530 ± 80 27.4 ± 0.6 0.77 ± 0.06 
7.8   1800 ± 80  900 ± 120 25.2 ± 1.0 0.94 ± 0.03 
8.0   2110 ± 140 980 ± 110 23.9 ± 1.0 0.96 ± 0.01 
8.0 
0.05% 
0.01% 
    760 ± 60   340 ± 20 27.7 ± 0.7 0.66 ± 0.01 
0.1%   1800 ± 80   900 ± 120 25.2 ± 1.0 0.94 ± 0.03 
0.5% 3580 ± 580 1550 ± 190 17.2 ± 1.0 0.96 ± 0.02 
8.0 0.1% 
0.005% 1440 ± 220   860 ± 210 25.1 ± 0.6 0.93 ± 0.03 
0.01%  1800 ± 80 900 ± 120 25.2 ± 1.0 0.94 ± 0.03 
 
(a) [Heparin (12 kDa)] = 2.33%, linear [PEG-DA (6 kDa)] = 4.67%, thiol:acrylate molar ratio 1:1 
(equivalent to 1:2 mass ratio Hep-SH:PEG-DA), 25oC, 5 mW/cm2 at 525 nm for 2.5 minutes. (b) Note that 
the dry mass may contain 10-15% of salts introduced with the PBS buffer. 
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Table 3. Effects of crosslinking stoichiometry and architecture on gel properties   
Molar 
Ratio 
(thiol:acryl) 
PEG PEG (%) 
G’ (Pa) as 
prepared(a) 
G’ (Pa) 
after 
swelling 
Wet : 
dry mass 
ratio(b) 
Fraction of 
heparin 
retained 
1:1 Linear 4.67% 1800 ± 80  900 ± 120 25.2 ± 1.0 0.94 ± 0.03 
1:0.5 Linear 2.33% 1100 ± 60    310 ± 50 30.7 ± 0.9 0.80 ± 0.04 
1:0.3 Linear 1.40%   270 ± 50  80 ± 10 34.0 ± 1.6 0.50 ± 0.07 
1:1 4-arm 5.06%   11630 ± 520   4530 ± 170 13.4 ± 1.0 0.97 ± 0.01 
1:0.5 4-arm 2.52%  4510 ± 350   1650 ± 200 19.7 ± 1.4 0.77 ± 0.02 
1:0.3 4-arm 1.51% 1080 ± 70     320 ± 50 30.1 ± 1.2 0.69 ± 0.07 
1:0.25 4-arm 1.26%  450 ± 40     160 ± 70 35.2 ± 0.8 0.61 ± 0.09 
 
(a) Hep-SH (12 kDa), linear PEG-DA (6 kDa), 4-arm acrylate-terminated PEG (13 kDa), 25oC, [Heparin] = 
2.33%, [EY] = 0.01%, [TEOA] = 0.1%, 5 mW/cm2 at 525 nm for 2.5 minutes. (b) Note that the dry mass 
may contain 10-15% of salts introduced with the PBS buffer. 
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Additional Information  
Preparation of release layer on the glass slide. 
In order to enable controlled retrieval of micropatterned heparin-based hydrogels from their 
substrate, one of the glass slides is treated to provide an initially-adhesive surface that can 
be subsequently “switched” to release the gel in a stimuli-response manner.1 Specifically, 
a layer-by-layer (LbL) technique was used to deposit a (PLL-HA)2 multilayer followed by 
an adhesive-capping layer. First, the glass slides were cleaned by ultrasonication in 
isopropanol and deionized water for 10 minutes in each. The glass slides were dried with 
filtered nitrogen and exposed to an oxygen plasma (YES-R3, San Jose, CA, USA) for 5 
minutes. The polyelectrolytes were adsorbed on the glass using the usual layer-by-layer 
technique immersing the substrate alternately in the polycation and the polyanion solutions 
with rinsing in between.  Specifically, the glass slide is first placed in a PLL (0.5 mg/ml) 
solution for 5 minutes, followed by rinsing with PBS, then it is placed in a HA (0.5 mg/ml) 
solution, followed by rinsing with PBS. This procedure was repeated one more time to 
create a (PLL-HA)2 multilayer. As the last adsorption step, acryl-functionalized chitosan 
(GMA-Chi, 30% acrylation) (5 kDa) was adsorbed by immersing in a GMA-Chi (30% 
acrylation, 2 mg/ml) solution for 30 minutes, followed by rinsing with PBS. GMA-Chi was 
synthesized as previously reported.2 Modified glass slides were placed in a desiccator until 
further use. The glass substrates bearing this multilayer are denoted as (PLL-HA)2-(GMA-
Chi). 
1 Gwon, K.; Kim, M.; Tae, G. Integr. Biol. 2014, 6, 596-602. 
2 Kim, J. Y.; Choi, W. I.; Kim, Y. H.; Tae, G.; Lee, S. Y.; Kim, K.; Kwon, I. C. J. Controlled 
Release 2010, 147, 109-117. 
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Figure S-1. A) Diagram of photo-rheology apparatus. The green LED cluster is mounted 
on a ventilated heat sink that removes heat generated from the LED to prevent the sample 
from heating when the LED is on.  The LED assembly is mounted beneath the transparent 
bottom plate of the rheometer, used in a parallel plate geometry The hydrogel (“Sample,” 
shown in red) is prevented from drying by surrounding the sample with a wet sponge during 
the experiment. Photographs of the rheometer (without sample and environmental control) 
when the LEDs are turned off (B) and turned on (C).  
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Figure S-2. Results of A) a stress sweep from 1 to 100 Pa in oscillatory rheology at 1 rad/s 
on the photorheometry apparatus based on a stress-controlled rheometer (AR 1000) and B) 
a strain sweep from 0.1 to 10% on the strain-controlled rheometer that was used to measure 
the storage modulus of swollen hydrogels (ARES RFS).  The results confirm that all of the 
oscillatory conditions used in this study are in the linear viscoelastic range: The red arrows 
show the stress amplitude used during photorheometry experiments and the strain 
amplitude used for subsequent analysis after cure.  
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Figure S-3. A) Schematic representation of the micropatterning process. The hydrogel 
precursor solution is applied onto the (PLL-HA)2-(GMA-Chi)-modified glass slide, 
bounded by a 320micron thick Teflon spacer.  A cover slip is placed over the gel, and a 
photomask is placed on top of it.  Thus, irradiation is performed from the side in contact 
with an untreated glass surface.  The LED source is placed over the sample and turned on 
for the desired irradiation time.  Then, the mask and coverslip are removed (in cases of 
insufficient exposure, small islands of gel are on the coverslip).  The (PLL-HA)2-(GMA-
Chi)-modified glass slide is rinsed with PBS, and then stained.  B) Representative 
photographs of microgels formed using different light intensities and exposure times. 
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Images indicative of insufficient exposure are outlined in blue; images indicating that gels 
had undergone “excessive exposure” are outlined in red. C) Graphical representation of the 
minimum exposure that produces a well-defined pattern on the (PLL-HA)2-(GMA-Chi)-
modified glass slide (black curve), corresponding to “sufficient exposure” in the body of 
the manuscript and the upper bound on exposure time so that disks of gel are separate (red 
curve).  [Heparin] = 3.33%, linear [PEG-DA] = 6.67%, [EY] = 0.01%, [TEOA] = 0.1%, in 
PBS (pH 7.8). 
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Figure S-4. Intensity profiles calculated using the molar absorptivity of EY (1.09 105 M-
1cm-1) for thickness up to that of the thickest samples used in this study (rheometry samples 
were 500 microns thick, while the micropatterning samples were 320 microns thick).  The 
fraction of incident light that reaches the back of the sample depends on the concentration 
of the photo-initiator EY. The optical penetration depth, Lp, defined as the depth at which 
the initial light intensity is attenuated by 1/e (dotted line), which decreases from 1200 
microns for 0.005% EY to 300 microns for 0.02% EY.   
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Figure S-5. Computational eye model using ZEMAX ray-tracing software. (A) A single 
LED (32o viewing angle, 525 nm) was placed 2 cm away from the cornea on axis. The 
number of rays from the light source was set at 10 million. A corneal irradiance of 5 
mW/cm2 (B) corresponds to a retinal irradiance of 6.9 mW/cm2 (C).  
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Figure S-6. Gelation kinetics and final gel moduli of hydrogels prepared at different 
crosslinking conditions using linear PEG (A) and 4-arm PEG (B), other parameters held 
fixed in PBS (pH 7.8). There is no significant difference in gelation time or final swollen 
modulus between hydrogels prepared at 25oC and 37oC. Gel solution was irradiated with a 
525nm green light at 5 mW/cm2 for 2.5 minutes. 
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Figure S-7. Cell viability of 3T3 fibroblasts (2 x 106 cells/mL) encapsulated inside heparin-
based hydrogels at different (A) TEOA concentration, (B) light intensities, (C) crosslinking 
densities and (D) PEG architecture. Live cells are stained green, and dead cells are stained 
red. Cell viability in all cases was ≥ 96%. Unless otherwise noted, hydrogels were prepared 
with 2.33% heparin (w/v), thiol:acrylate 1:1, 0.01% EY and 0.1% TEOA in PBS (pH 7.8) 
with linear PEG and 5 mW/cm2 irradiation. 
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Table S-1. Comparison of visible and UV photo-gelation conditions to eye safety 
thresholds  
 EY/vis Irgacure/UV 
Wavelength 525 nm 365 nm 
Flux 5 mW/cm2 10 mW/cm2 
Exposure time 10 minutes 10 minutes(d) 
Hazard weighting function(a) A(λ:525 nm) = 0.031 S(λ:365 nm) = 1.1 x 10-4 
Group 1(b) safety limit 220 µW/cm2 0.4 µW/cm2 
Calculated irradiance 110 µW/cm2 1.1 µW/cm2 
% of threshold for Group 1 50% (ret.) 275% (cor.) 
Group 2(c) safety limit 10,000 mJ/cm2 3 mJ/cm2 
Calculated exposure 64 mJ/cm2 0.66 mJ/cm2 
% of threshold for Group 2 0.6% (ret.) 22% (cor.) 
 
(a) Hazard weighting functions represent the relative spectral sensitivity of the human eye to light hazards. 
For visible light the retinal photochemical hazard weighting function A(λ) is used because the light dose is 
far below the threshold for corneal damage. For UV light, the corneal UV radiation hazard weighting 
function S(λ) is used. The UV conditions are far in excess of the safety threshold of the retina.  
(b) Group 1 devices are those for which no potential light hazard exists. See text for description of ZEMAX 
calculations. For visible light, Group 1 limit refers to weighted retinal irradiance. For UV light, corneal 
threshold is reached for UV (far in excess of retinal damage threshold).  
(c) Group 2 devices are those for which a potential light hazard exists. For visible light, Group 2 limit refers 
to the weighted retinal radiant exposure. For UV light, Group 2 limit refers to the weighted corneal UV 
radiant exposure (much greater than the threshold for retina damage).  
(d) The lower the light intensity, the longer the exposure time.  
(ret.) indicates retinal photochemical threshold, see (a); (cor.) indicates corneal UV radiation threshold, see 
(a).  
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Table S-2. Cell viability of 3T3 fibroblasts encapsulated inside heparin-based hydrogels 
(2 x 106 cells/mL) at different conditions. 
Condition Cell viability 
[TEOA](a) 0% TEOA 96.2 ± 1.1% 0.1% TEOA 97.2 ± 1.0% 
Light intensity(b)  5 mW/cm2 97.6 ± 0.4% 100 mW/cm2 97.2 ± 1.0% 
Thiol:acrylate ratio(c) 1:1 97.2 ± 1.0% 1:0.3 99.6 ± 0.2% 
PEG architecture(d)  Linear 99.6 ± 0.2% 4-arm 99.4 ± 0.7%  
 
(a)  [Hep-SH (12 kDa)] = 2.33%, linear [PEG-DA (6 kDa)] = 4.67%, thiol:acrylate = 1:1, 25oC, pH 7.8, 
[EY] = 0.01%, 100 mW/cm2 for 2 minutes for 0% TEOA and 1.5 minutes for 0.1% TEOA. 
(b)  [Hep-SH (12 kDa)] = 2.33%, linear [PEG-DA (6 kDa)] = 4.67%, thiol:acrylate = 1:1, 25oC, pH 7.8, 
[EY] = 0.01%, [TEOA] = 0.1%. Irradiation time was 7 minutes at 5mW/cm2, and 1.5 minutes at 100 
mW/cm2. 
(c)  Hep-SH (12 kDa), linear PEG-DA (6 kDa), 25oC, [Heparin] = 2.33%, [EY] = 0.01%, [TEOA] = 0.1%, 
100 mW/cm2 for 1.5 minutes for 1:1 ratio and 3 minutes for 1:0.3 ratio. 
(d) Hep-SH (12 kDa), PEG-DA (6 kDa) thiol:acrylate 1:0.3, Hep-SH:4-arm acrylate-terminated PEG (13 
kDa) thiol:acrylate 1:0.25, 25oC, [Heparin] = 2.33%, [EY] = 0.01%, [TEOA] = 0.1%, 100 mW/cm2 for 
3 minutes for linear PEG, and 2 minutes for 4-arm PEG.  
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Chapter 5 
 
In vivo study of corneal scaffold in a mouse epithelial defect model 
 
5.1 Introduction 
In Chapter 2, we demonstrated that nanofiber substrates show great potential to be used 
in a scaffold for promoting orderly corneal wound healing. They are easy to fabricate 
and handle, transparent, and non-cytotoxic. In addition, we have shown that isotropic 
nanofibers (with no preferred orientation) can promote epithelial cell migration and that 
uniaxially aligned nanofibers can enhance fibroblast cell migration and modulate the 
myofibroblast phenotype by decreasing αSMA expression.  
 
In Chapter 4, we developed a visible-light photo-crosslinking formulation of a heparin-
based hydrogel. We showed that these hydrogels are suitable for corneal applications 
due to their transparency and non-cytotoxicity, and that the irradiation conditions for 
gelation (5 mW/cm2 for 5 minutes) are compatible with safety standards for corneal and 
retinal exposure. In addition, these hydrogels form quickly (< 5 minutes), are easily 
tunable (by choice of precursor concentration, crosslinker architecture or irradiation 
conditions), and allow the binding and release of bioactive growth factors. 
 
Taken together, we envision that an ideal corneal scaffold would consist of layers of 
nanofibers inside a transparent hydrogel, thereby containing the necessary topological 
and biochemical cues for orderly wound repair. Here, in addition to the heparin-based 
hydrogel described above, we also investigated the use of artificial extracellular matrix 
(aECM) protein-based hydrogels as an alternative.   
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Developed by Professor David Tirrell at Caltech, aECM proteins allow for systematic 
control of biochemical cues, as well as easily tunable degradation rates by proteolytic 
processes.1,2 The Tirrell group have demonstrated that aECM proteins can be chemically 
crosslinked to form transparent films3 or can be formed into injectable hydrogels 
through physical interactions of leucine zippers4. Furthermore, they showed that aECM 
proteins are favorable for collective cell migration5, and promote endothelial cell 
adhesion and spreading6-8. The aECM protein chosen for this study was derived from 
elements of fibronectin and elastin, and can be crosslinked with four-armed 
poly(ethylene glycol) with end-terminated succinimidyl glutarate groups to form a 
transparent hydrogel. We hypothesize that the RGD cell-binding sites present in aECM 
are favorable for promoting cell infiltration.  
 
Although live/dead staining results show that the nanofibers and hydrogel do not affect 
cell viability in vitro, it is important to validate the safety and biocompatibility of our 
scaffold in vivo. For clinical translation, we are also interested in testing the feasibility 
of our treatment protocol (e.g. how much time is needed to treat each eyeball? Is it easy 
to apply the treatment? etc.) 
 
Mice corneas are very thin (~ 170 microns)9, so it is not possible to create reproducible 
deep wounds without the risk of puncturing through the cornea. However, the mouse 
model is good for testing the biocompatibility of our scaffold. Indeed, studies have used 
alkali burns or sutures to induce corneal neovascularization and examined the efficacy 
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of different treatments in alleviating ocular damage.10-13 Here, we use a less harsh 
method (by debriding the corneal epithelium with a corneal knife) to test our scaffold in 
treating epithelial defects.  
 
The goal of this in vivo study is to answer the following questions:  
1. Is the treatment transparent when placed on the mouse cornea? 
2. Does the treatment remain in the wound following the procedure? 
3. Does the treatment induce inflammation? 
4. Does the treatment hinder re-epithelialization over the wounded area? 
 
This study will yield significant insights regarding the biocompatibility of our scaffold. 
Observations made will allow us to optimize (and re-examine, if necessary) the 
properties of our scaffold with respect to corneal healing, prior to carry out experiments 
in rabbits where deeper wounds are possible.  
 
5.2 Methods 
Fabrication of scaffold  
Fabrication of nanofibers 
Gelatin (type A, porcine, Sigma Aldrich, St. Louis, MO) was dissolved in a mixture of 
2:3:5 distilled water/ethyl acetate/acetic acid at 12% w/w and stirred overnight at 37oC. 
Electrospun nanofibers were fabricated from the gelatin solution using a 22-gauge 
needle, +15 kV voltage and 8 cm needle to collector distance. Isotropic nanofibers were 
collected on a metal ring (6 mm diameter) placed on a planar electrode. 
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Characterization of nanofibers 
To visualize the nanofibers, they were labeled with NHS-fluorescein (Thermo Fisher, 
Rockford, IL). The nanofiber mats were immersed in the staining solution (0.1 mg/mL 
NHS-fluorescein, 1% DMSO, PBS) for one hour at room temperature. Residual dye was 
removed by rinsing the nanofibers with deionized water three times (15 mins each). 
Nanofiber mats were air-dried prior to use. To characterize the fiber diameter, samples 
were mounted onto aluminum stubs using double-sided carbon tape and sputter-coated 
(Cressington 208HR) with a 10 nm layer of palladium. Prepared samples were then 
observed in a field emission scanning electron microscope (SEM, Zeiss 1550 VP) at an 
accelerating voltage of 5 kV.  
 
Fabrication of aECM-PEG hydrogels  
Artificial extracellular matrix proteins (aECM, 34.6 kDa) were synthesized and 
characterized using established protocols described elsewhere. To fluorescently label 
aECM proteins (aECM-f), aECM protein (2.5 mg/mL in PBS) was mixed with NHS-
rhodamine (7 molar excess) for one hour at room temperature. Excess dye was removed 
by fluorescent dye removal columns (Thermo Scientific). aECM-f proteins were then 
lyophilized for storage until use. aECM protein solutions were prepared by dissolving 
aECM in PBS (34% aECM, 2% aECM-f w/v) overnight at 4oC. Four-arm poly(ethylene 
oxide) terminated with succinimidyl glutarate groups (PEG-S, Polymer Source, 
Montreal, Canada) was dissolved in PBS (25% w/v) just prior to hydrogel fabrication. 
The aECM solution and PEG-S solution were mixed together in a 1:1 ratio to prepare 
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the aECM-PEG precursor solution (final concentration: 18% aECM, 12.5% PEG-S). 
The precursor solution was used immediately after preparation.  
 
Characterization of aECM-PEG hydrogels  
Moduli of aECM-PEG hydrogels were determined using oscillatory shear. 
Measurements were performed in the linear regime (Figure S-5). 30 uL of gel precursor 
solution was pipetted onto the rheometer (ARES-RFS, TA Instruments, New Castle, 
DE), and the 8 mm parallel plate geometry was set to 500 μm. A 60-minute time sweep 
(angular frequency of 1 rad/s and a strain of 2%) was carried out to monitor hydrogel 
gelation. Hydrogels were separately prepared and swollen in PBS (pH 7.4) for 2 days at 
37oC. Swollen hydrogels were cut to fit the 8 mm parallel plate geometry, and a 
frequency sweep (2% strain) was used to measure their moduli after swelling. A 
temperature sweep (angular frequency 1 rad/s, 2% strain) was carried out to examine 
the stability of hydrogels between 25 - 37oC.  
 
Preparation of heparin-based hydrogels 
Thiol-functionalized heparin (Hep-SH) was synthesized by modifying 40% of the 
carboxyl groups of heparin, following established protocols.14 In heparin, each 
disaccharide repeat has one carboxylate group, so the functionalized polymer has one 
thiol group per 1500 g/mol of heparin at 40% modification. The amount of thiol groups 
in Hep-SH was determined using Ellman’s reagent and measurement of molar 
absorptivity at 412 nm. In this study, 40 ± 2.5% thiolated heparin was used for all of the 
experiments. Poly(ethylene glycol)-diacrylate (PEG-DA) and Hep-SH were 
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sequentially dissolved in either PBS or DMEM (thiol:acrylate = 1:1 molar ratio). 0.01% 
(w/v) eosin Y as a photo-initiator and 0.1%  (v/v) TEOA as an electron donor were 
added via stock solutions ([EYstock] = 0.5%; [TEOAstock] = 5%) to the precursor solution. 
The pH of the reaction mixture was adjusted to 8.0 with 1 N HCl. Precursor solutions 
were used within 1 hour of preparation and stored in the dark at 4oC prior to use. 
Prepared precursor solution was photo-polymerized under green LED light (5 mWcm2) 
exposure. The LED emission wavelength is 525 ± 15 nm. 
 
Animal experiments  
The experiments in a mouse model were performed according to the Association for 
Research in Vision and Ophthalmology Statement of Use for Animals, and were 
approved by the Institutional Animal Care and Use Committee of the University of Utah 
(aECM-PEG hydrogels) or the California Institute of Technology (heparin-based 
hydrogels). All drugs used were pharmaceutical-grade ophthalmic solutions. All 
scaffold components were sterilized as follows prior to use. Nanofiber mats were first 
immersed in 70% ethanol (twice, 10 minutes each) and then placed under UV light for 
30 minutes (sufficient for all ethanol to evaporate from the present mats, which are less 
than 50 microns thick). Hydrogel precursor solutions were sterile filtered through a 0.2 
micron filter. All mouse procedures were carried out in a sterile laminar flow hood, 
equipped with a dissecting microscope.  
 
Epithelial debridement in mice 
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Mice (BALB/c, female, 20 - 30 g) were anesthetized with ketamine (100 mg/kg) and 
xylazine (10 mg/kg) through intraperitoneal injection. One drop of Proparacaine (0.5% 
solution, topical anesthetic) and one drop of Tropicamide (1% solution, pupil dilator) 
were applied to each eye. An alcohol pad (80% ethanol, 1.5 mm diameter) was placed 
on the cornea for 60 seconds to weaken the epithelium. The weakened epithelium was 
then removed by scraping with a sterile Tooke corneal knife, and the initial wound area 
was imaged. For each mouse, the left eye was untreated to serve as a control while the 
right eye was treated with our scaffold. For treated eyes, 1 µL of hydrogel solution 
(either aECM-PEG or heparin-based hydrogel) was pipetted onto the wound area, and a 
layer of nanofibers was placed on top; for control eyes, 1 µL of phosphate-buffered 
saline (PBS) was pipetted onto the wound area. The mice were allowed to recover from 
surgery, and their eyes were observed daily for signs of inflammation. Six mice were 
used in each experimental group.  
 
Tracking epithelium regrowth following procedure 
The surface area of the epithelial defect was assessed daily. For mice experiments, 
treated mice were anesthetized with 2% isoflurane (in oxygen), and one drop of 
proparacaine was applied to each eye. To observe the wound boundary, 1 µL of 
fluorescein solution (0.25% in PBS) was pipetted onto the surface of each eye. Excess 
fluorescein solution was rinsed with 0.9% sodium chloride solution and removed by 
gently touching a sterile cotton swab to the side of the eye. The wound area was then 
imaged under blue LED lights, and the extent of wound closure was analyzed using 
ImageJ.  
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Staining and immunolabeling of corneal sections  
Mice were euthanized following wound closure, and their corneas were harvested. 
Frozen sections were prepared by first fixing the excised corneas with 4% 
paraformaldehyde for 2 hours, and then placing in two sucrose solutions (10% for 2 
hours, 30% overnight). The corneas were then embedded in OCT medium and sectioned 
using a cryotome to 7 micron thick sections. The presence of the nanofibers and 
hydrogel were confirmed in treated animals by observing the sections using a 
fluorescence microscope. Paraffin sections were prepared by fixing excised corneas 
with 4% paraformaldehyde for 2 hours, dehydrating them through a graded ethanol 
series, and finally embedding them in paraffin. Sections were cut (7 microns) and 
processed for hematoxylin-eosin (H&E).  
 
Hematoxylin & eosin staining  
The tissue sections were deparaffinized in xylene (20 minutes) and rehydrated in a 
graded series of ethanol (100% to 70%, 5 minutes each). The slides were then rinsed 
with distilled water (5 minutes) and placed in hemotoxylin (3 minutes). The slides were 
rinsed with distilled water (5 minutes) and placed in acid alcohol (1 minute, Thermo 
Scientific Anatom Path Clarifier 1). They were then placed in 100% ethanol (1 minute), 
then in bluing reagent (1 minute, Thermo Scientific Richard-Allen Scientific Bluing 
Reagent) and eosin (3 minutes). The samples were then dehydrated in a graded series of 
ethanol (70% to 100%, 2 minutes each) and placed in xylene (two washes of 5 minutes 
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each). The slides were then mounted with Cytoseal (Fisher Scientific), cover-slipped 
and left to dry for 24 hours prior to imaging.  
 
5.3 Results  
The safety and biocompatibility of our scaffold were evaluated using a mouse model for 
epithelial debridement (Figure 1). Two types of materials were investigated. Nanofiber 
mats were tested in conjunction with a hydrogel that has already been proven to be 
compatible with the cornea (aECM-PEG). A heparin-based hydrogel that had not been 
tested for corneal compatibility was investigated separately.  
 
Nanofiber scaffolds are well-tolerated in treating mice epithelial defects 
In conjunction with experiments in which we used aECM-PEG hydrogel at pH 7.0 to 
support nanofiber attachment on the debrided area of the cornea, a control experiment 
was performed using only the aECM-PEG hydrogel at pH 7.0, and the effect of pH on 
the ease of handling the hydrogel was examined by including aECM-PEG hydrogel at 
pH 8.0. Five animals were used in each of these three groups, and the fellow eye served 
as the untreated control.  
 
All three treatments were transparent after application. (Figure 2A). When observed 
immediately after and approximately 15 – 18 hours after the procedure, the mice (in all 
three experimental groups) showed no inflammation (free of conjunctival redness and 
swelling) (Figure 2B). The following day after the procedure, mice showed no signs of 
distress (they moved about the environment, ate and drank normally). Our treatment 
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also supported epithelial regrowth at rates comparable to control eyes (Figure 3): the 
rate of wound closure in treated eyes was not statistically different from that in untreated 
control eyes. Corneal epithelial defects usually heal quickly and without incident15-17; 
thus, our results show that our treatment did not hinder the re-epithelialization process.  
 
Four days after the procedure, the mice were sacrificed, and their corneas were harvested 
and sectioned. To determine whether our treatment remained in the wound during the 
healing process, tissue sections were viewed under a fluorescence microscope, and both 
the fluorescein-labeled nanofibers (Figure S-1) and rhodamine-labeled aECM-PEG 
hydrogel (Figure S-2) were seen in the wound bed (Figures 4 and S-3). To observe the 
corneal morphology following wound closure, the tissue sections were stained with 
hematoxylin and eosin (H&E) using standard protocols (Figures 3 and S-4). H&E 
staining showed that the regenerated epithelium in untreated eyes was thicker than the 
epithelium of unwounded eyes (wounded but untreated cornea: 85.4 ± 2.4 µm thick; 
unwounded cornea: 50.5 ± 3.1 µm thick). Corneas that were treated with nanofibers and 
the hydrogel had an epithelial thickness (48.4 ± 1.6 µm) similar to that of a healthy 
cornea while the two experimental groups that received only the hydrogel treatment had 
an epithelial thickness similar to that of an untreated cornea (pH 7.0: 81.7 ± 4.0 µm; pH 
8.0: 81.8 ± 3.6 µm). 
 
Heparin-based treatment supports epithelial regrowth 
To evaluate compatibility of heparin-based hydrogels with the cornea, we examined four 
groups (six mice per group) with successively more components of the envisioned 
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treatment (Table 1): Group 1: irradiated with green light only; Group 2: heparin-based 
hydrogel photo-polymerized with green light; Group 3: addition of a layer of isotropic 
nanofibers on top of hydrogel and photo-polymerized; Group 4: addition of epidermal 
growth factor (EGF) to the Group 3 treatment.  
 
As was observed for aECM-PEG treated mice, the mice (in all four experimental groups) 
showed no inflammation, and the cornea and hydrogel were transparent 15 minutes after 
the procedure (Figure 5A). (In contrast to the aECM-PEG case, the cornea briefly 
exhibited haze that was visible at the time that the mice were placed on the heating pad 
after surgery, and it resolved itself within 15 minutes.) The following day, no 
inflammation was found, and the mice showed no signs of distress. Using fluorescein 
staining to visualize wound closure, we observed that heparin-based hydrogel treatment 
supported epithelial regrowth at rates that were not distinguishable from control eyes 
(Figure 6). The application of green light, hydrogel, nanofibers or epidermal growth 
factor did not hinder the ability of the injured cornea to regrow its epithelial layer.  
 
Two weeks after the procedure, the mice were sacrificed, and their corneas were 
harvested, sectioned and stained with hematoxylin and eosin (H&E) using standard 
protocols. The pronounced increase in epithelial layer thickness after wound healing 
(wounded but untreated cornea: 83.4 ± 4.0 µm thick; unwounded cornea: 53.0 ± 4.2 µm 
thick) is also observed for mice that received only green light or green light and hydrogel 
as treatment (Group 1: 84.6 ± 7.6 µm; Group 2: 74.4 ± 5.0 µm). Interestingly, both 
treatment groups that received nanofibers on top of the hydrogel recovered with an 
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epithelial thickness closer to corneas that had never been injured (Group 3: 62.9 ± 3.3 
µm; Group 4: 66.2 ± 5.2 µm). Fluorescence micrographs confirmed that the treatment 
remained in the wound during the healing process; fluorescein-labeled nanofibers 
(Groups 3-4) and rhodamine-labeled heparin-based hydrogel (Groups 2-4) were 
observed in the wound bed 14 days after the procedure (Figure 5B).  
 
5.4 Discussion 
Here, we developed two different corneal scaffolds (made of protein nanofibers and 
either an aECM-PEG based hydrogel or a heparin-based hydrogel) and confirmed their 
safety and biocompatibility in vivo using a mouse model for corneal epithelial defects. 
Furthermore, we observed that the regenerated epithelium of mice treated with 
nanofibers (on both types of hydrogel) had a thickness and morphology that was more 
similar to an unperturbed corneal epithelium than those that did not receive any 
nanofibers.  
 
The motivation for using nanofibers in our corneal scaffold stems from our observations 
that gelatin nanofibers can enhance cell migration and influence cell phenotype in vitro 
(Chapter 2). In this study, we use isotropic nanofibers because they promote wound 
closure by epithelial cells in vitro relative to uniaxial or radially-oriented nanofibers. In 
addition, nanofibers (mean diameter 155 nm) were used because they are transparent 
upon wetting, easy to handle, and non-cytotoxic. Gelatin (as opposed to synthetic 
polymers) was our material of choice since it contains integrin binding sites that support 
cell migration.18,19  
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The hydrogel component of both scaffolds match the properties (mechanical and 
optical) of the native cornea. Thomasy and colleagues measured the elastic modulus of 
the anterior stroma of a rabbit cornea to be 1.1 ± 0.6 kPa.20 Here, the two hydrogel 
formulations used have moduli in the range of 1 – 2 kPa. It is noted that the rabbit cornea 
and the human cornea have different stiffness (elastic modulus of the anterior stroma of 
a human cornea: 33.1 ± 6.1 kPa21). Here, we chose to use the rabbit cornea as a starting 
point, in preparation for in vivo experiments in rabbit models to validate the efficacy of 
our scaffold (Chapter 7). The two hydrogel formulations are tunable (by varying either 
the composition or gelation conditions), so stiffer gels can easily be made if needed for 
future studies. Both types of hydrogel are transparent upon gelation and adhere the 
nanofibers to the wound bed.  
 
aECM-PEG-based treatment 
The motivation for using an aECM-PEG hydrogel is that it presents cell-binding sites in 
addition to those on the nanofibers. The modular protein design of aECM affords 
systematic control of biochemical and proteolytic degradation. The particular aECM 
protein that we have chosen to use in this study (Figure S-2) is derived from elements 
of natural ECM proteins (fibronectin and elastin), which supports collective cell 
migration in vitro and reepithelialization when an inlay is implanted in the cornea of a 
rabbit model in vivo.  
 
For gelation in situ, we use 4-armed NHS-functionalized poly(ethylene glycol) (PEG-
S) as the crosslinker, which couples to lysine amino groups in aECM proteins. The 
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crosslinking kinetics are pH-dependent (optimal range pH 7 – 9), with slow kinetics at 
low pH due to protonation of amino groups.22 At high pH, NHS-esters are quickly 
hydrolyzed, which competes with crosslinking. Constrained to pH ≤ 8 for corneal safety, 
we studied the gelation kinetics of aECM-PEG at pH 7.0, 7.6 and 8.0 using oscillatory 
rheology (Figure S-5). The gelation rate and final modulus of hydrogels formed at pH 
7.6 were indistinguishable from those formed at pH 7.0. At pH 8.0, gelation was faster 
and the resulting gel was softer than those formed at lower pH values, as expected due 
to hydrolysis. In view of these results, we selected pH 7.0 and 8.0 aECM-PEG 
formulations for in vivo studies.  
 
The epithelium closed equally well over aECM-PEG for both pH 7.0 and pH 8.0 
formulations. The main difference between them was that during surgery, it was much 
harder to handle the pH 8.0 hydrogel due to the relatively short gelation time. 
Application of unoriented nanofibers over the aECM-PEG (and over heparin-based gels, 
below) led to reepithelialization with a thickness and number of cell layers that was 
closer to that of an unwounded cornea.  
 
Heparin-based treatment 
To our knowledge, this is the first in vivo test of heparin-based gels in the cornea and 
the primary objective is to assess inflammatory reactions and possible opacification. 
Because photo-crosslinking is used, in vivo experiments are needed to determine 
whether or not the dose of visible-light is well-tolerated. Using eosin Y (EY) as the 
photoinitiator and triethanolamine (TEOA) as a co-initiator, thiolated heparin reacts 
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with poly(ethylene glycol) diacrylate under green light (525 nm, 5 mW/cm2) to form a 
transparent gel within a few minutes of irradiation (Chapter 4). In vitro, we have shown 
that encapsulated fibroblasts remain viable following gelation (Chapter 4). Furthermore, 
our calculations show that the irradiation conditions for gelation of the EY/vis 
formulation (2.33% heparin, 1:1 thiol: acrylate molar ratio, 0.01% EY, 0.1% TEOA in 
PBS pH 8.0, 5 mW/cm2 irradiation for 5 minutes) are compatible with safety standards 
for corneal and retinal exposure (Chapter 4). These favorable in vitro results provided 
the basis for the present experiments on the ability of epithelium to close over the 
heparin-based gel in a mouse model.  
 
Using a Teflon cylinder to give a consistent distance from the LED to the cornea 
provided a readily-sterilizable tool to easily align the light source over the mouse cornea 
and ensure a consistent light flux at the cornea. The present results demonstrate that a 
5-minute exposure to green light (525 nm) at 5 mW/cm2 did not cause any cytotoxicity: 
normal epithelial regrowth was observed in all four experimental groups. Corneas 
treated with nanofibers (Groups 3 and 4) had a regenerated epithelium where the 
thickness and the layer of cells were more similar to an unwounded cornea compared to 
those that did not receive any nanofibers, as also observed for aECM-PEG-treated mice.  
 
Building on the observation that heparin-based hydrogel and the irradiation conditions 
were well-tolerated by the eye, we proceeded to examine the possibility of using 
heparin’s natural binding sites as a reservoir for growth factors. We demonstrated in 
vitro that epidermal growth factor (EGF) can be loaded into the heparin-based hydrogel 
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and retains its bioactivity after release (Chapter 4). The incorporation of EGF (100 
ng/mL) in the heparin gel formulation had no adverse effect on the response of the eye 
(no inflammatory response and no turbidity). Due to the very rapid closure of the mouse 
epithelium (all had closed within 18 hours), the present experiments cannot speak to the 
possibility that the addition of EGF might increase the rate of epithelial wound closure23 
(comparing Groups 3 and 4).  
 
In the current study, H&E staining provided information on the overall morphology of 
the regenerated epithelium (i.e. thickness and approximate number of cell layers). The 
observed differences in epithelial thickness and number of cell layers when the 
epithelium closes over an unoriented fiber mat suggest that further investigation would 
be worthwhile. Specifically, the observation of epithelial characteristics that are closer 
to those of an unperturbed epithelium motivate higher resolution imaging with antibody 
staining (e.g., against tight junction proteins claudin-1, ZO1 or occludin) and membrane 
staining (e.g., CellTracker from Life Technologies).  
 
 
5.5 Conclusions 
 
We developed two different corneal scaffolds: both made of protein nanofibers and 
either an aECM-PEG hydrogel or a heparin-based hydrogel. Both scaffolds are 
transparent and able to support re-epithelialization of epithelial defects in mice corneas. 
Furthermore, we observed that the regenerated epithelium of mice treated with 
nanofibers (on both types of hydrogel) have a thickness and morphology that was more 
similar to an wounded corneal epithelium than those that did not receive any nanofibers. 
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In relation to clinical translation, we found that aECM-PEG hydrogels at pH 7.0 were 
much easier to handle than those at pH 8.0. For the heparin-based treatment, we 
confirmed that the green light used for photo-crosslinking did not induce any adverse 
effects in epithelial regrowth.  
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Figure 1. Schematic of in vivo mouse epithelial defect model. For each mouse, the 
epithelium is debrided using a corneal Tooke knife to create a surface wound. For treated 
eyes, 1 µL of hydrogel was pipetted onto the wound bed (followed by a layer of isotropic 
nanofibers for the nanofiber-treated group). For control eyes, 1 µL of PBS was pipetted 
onto the wound bed.  
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Figure 2. Treatment application to the wound bed. A) The nanofibers become 
transparent upon addition of PBS, and B) no signs of inflammation are observed 30 
minutes after treatment or the following day (approximately 15 – 18 hours after 
treatment, not shown).  
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Figure 3. A) Representative images of fluorescein staining to visualize wound closure. 
The initial wound area was imaged on day 0. By day 2, re-epithelialization was observed 
in all experimental groups. B) H&E staining of tissue sections from corneas harvested 
on day 4 following the procedure show that the regenerated epithelium show normal 
morphology compared to that of the untreated cornea. C) Quantification of wound area 
observed in A). The rate of re-epithelialization of treated groups are comparable to that 
of untreated controls.   
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Figure 4. The treatment remains in the wound 4 days after the procedure. The aECM-
PEG hydrogel was labeled with NHS-Rhodamine; the nanofibers were labeled with 
NHS-fluorescein.  
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Figure 5. Treatment application to the wound bed. A) The hydrogel and nanofibers are 
transparent upon addition of PBS, and B) the treatment remains in the wound 14 days 
after the procedure. The haprin-based hydrogel was labeled with NHS-Rhodamine; the 
nanofibers were labeled with NHS-fluorescein. 
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Figure 6. Representative images of fluorescein staining to visualize wound closure. The 
initial wound area was imaged on day 0 without fluorescein staining. By day 1, re-
epithelialization was observed in all experimental groups. H&E staining of tissue 
sections from corneas harvested on day 14 following the procedure show that the 
regenerated epithelium show normal morphology compared to that of the untreated 
cornea. 
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Figure S-1. A) Nanofiber substrates are fluorescently labeled with NHS-fluorescein. B) 
Nanofiber substrates become transparent upon wetting.  
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Figure S-2. A) Amino acid sequence of the artificial extracellular matrix (aECM) 
protein and the structure of 4-armed poly(ethylene glycol) with end-terminated 
succinimidyl glutarate groups used in this study. The aECM protein contains an RGD 
binding domain derived from fibronectin and an elastin-like domain. B) The hydrogel 
formed by crosslinking aECM and PEG-S is transparent, and C) is fluorescently labeled 
using NHS-Rhodamine.  
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Figure S-3. The aECM-PEG treatment remains in the wound 4 days after the procedure. 
The aECM-PEG hydrogel was labeled with NHS-Rhodamine; the nanofibers were labeled 
with NHS-fluroescein. The nanofibers can be seen both in the tissue section (cross-section 
of cornea) and in the flat mount (top-down view of cornea).  
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Figure S-4. H&E staining of tissue sections. The corneas from the aECM protein-based 
treatment were harvested on day 4 following the procedure, and those from the heparin-
based treatment were harvested on day 14. Treated corneas that did not receive any 
nanofibers had a corneal morphology similar to that of untreated corneas. Treated corneas 
that received nanofibers (top row, last; bottom row, last two) had a corneal morphology 
similar to that of an unwounded cornea.  
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Figure S-5. The storage modulus of aECM-PEG hydrogels was examined using 
oscillatory rheology. Results of A) a strain sweep from 0.1 to 10%  at 1 rad/s on a strain-
controlled rheometer (ARES RFS) confirm that oscillatory conditions used are in the 
linear viscoelasticity range. A strain of 2% was used for subsequent analysis. B-C) 
aECM-PEG hydrogels prepared at pH 8.0 have a faster gelation time and a lower overall 
modulus (both freshly prepared and swollen) compared to hydrogels prepared at pH 7.0 
and 7.6 (which were indistinguishable from each other). D) The storage modulus of 
aECM-PEG hydrogels did not change with temperature in the range 25 – 37oC.  
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Figure S-6. The light device used for photo-crosslinking heparin-based hydrogels in vivo. 
A single green LED light (525 nm) was placed inside a Teflon holder (1 cm diameter, 2 
cm height). This specific height was chosen such that when the light is turned on, the 
irradiation intensity at the base of the holder is 5 mW/cm2. A) Top down view of light, off 
and on; B) side view of light device, off and on, and C) light device in use during in vivo 
experiments.  
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Table 1. Experimental groups for mice receiving heparin-based treatment. 
 Group 1 Group 2 Group 3 Group 4 
Green light      
Nanofibers     
Hydrogel     
Epidermal growth factor     
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Chapter 6 
 
Development of an ex vivo tissue culture model system 
 
6.1 Introduction 
In Chapter 5, the safety and biocompatibility of our composite scaffold was examined 
in a mouse model for epithelial debridement. We demonstrated that the scaffolds were 
well-tolerated in mice, and supported epithelial regrowth over the wounded area. 
However, most corneal epithelial defects heal quickly and without incident even in the 
absence of any treatment.1-3 Corneal wounds that penetrate into the stromal layer are 
injuries which eventually lead to corneal haze and blindness. Unfortunately, mice 
corneas are thin (~170 microns)4, and we are unable to create reproducible deep wounds 
without the risk of puncture. In order to test the efficacy of our scaffold in treating 
stromal wounds, studies must be carried out in larger animal species (e.g. rabbits).  
 
According to the United States Department of Agriculture, there were approximately 
890,000 animals (excluding mice, rats, birds and fish) used in scientific studies in 2013, 
of which ~169,000 (19%) were rabbits.5 The National Institutes of Health spends ~30 
billion dollars annually on research projects6, where ~40% of them have an animal 
experiment component7. To reduce both the number of animals used and the amount of 
funding spent on animal studies, researchers have been actively finding alternatives to 
animal testing.  
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In recent years, ex vivo organ cultures have proven to be promising substitutes for animal 
experiments. Schmook and coworkers demonstrated that pig skin can be cultured in 
vitro and is a suitable model for human skin.8 Nunes and colleagues showed that trachea 
explanted from a pig can be effectively maintained in organ culture, and can be used to 
study influenza infection.9 Dyer and Patterson have further showed that an excised 
mouse heart can be cultured in a semi-solid, dilute Matrigel, where it remains viable for 
days (evidenced by continued contractions).10  
 
Much work has also been carried out in relation to the cornea. One of the challenges in 
developing an ex vivo corneal culture model is to maintain the curvature of the cornea 
while still being able to deliver nutrients to the endothelial side to keep corneal cells 
alive. Sriram et al. and Castro-Combs et al. separately developed an ex vivo protocol in 
which excised corneas were cultured on dome-shaped supports made from the bottom 
of 50 mL laboratory test-tubes.11,12 In their studies, nutrients from the culture medium 
could not be transported to the corneas; therefore, although they were able to culture the 
corneas for 14 days, results are likely not  good representations of what would be 
observed in vivo. Xu and coworkers cultured excised corneas on top of an 
agarose/collagen gel to study epithelial responses to surfactants.13 However, the corneas 
in their study were only cultured for a short period of time (< 1 hour). Janin-Manificat 
and coworkers were able to keep excised corneas alive for 31 days by placing a sterile 
blotting paper (soaked in culture medium) on the endothelial face of the cornea and 
culturing them on top of a conformer.14 However, it is unclear whether the corneas 
maintained their curvature during the culture period.  
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Here, we describe an ex vivo corneal culture model in which excised animal corneas are 
cultured on an agar-gel to maintain the curvature of the cornea. We show that epithelial 
defects or deeper stromal wounds can be created in the corneas, and that the corneas 
retain their ability to heal and repair wounds. Using this method, corneas can be kept 
alive in a 37oC incubator for up to 21 days with daily culture medium changes. We used 
this ex vivo culture model to test the efficacy of our composite scaffold in treating 
stromal wounds. Results from these studies guided our scaffold selection for subsequent 
in vivo rabbit studies. 
 
6.2 Methods 
Creating wounds on the cornea 
Fresh animal eyes were purchased from vendors (bovine, porcine from Sierra 
Biomedical; rabbit from Pel Freez). Once received, the intact globes were immersed in 
tissue culture medium for 1 hour at 4oC for disinfection. The tissue culture medium used 
here and throughout this study was Dulbecco’s Modification of Eagles Medium/Ham’s 
F-12 (DMEM/F-12) containing 2.5 mM L-glutamine, 120 ug/mL Penicillin, 200 ug/mL 
Streptomycin sulfate and 5 ug/mL Amphotericin B. Excess fat and connective tissue 
was trimmed from the eyeball, and 1 mL of air was injected into the posterior of the eye 
using a 30-gauge needle to provide a firm corneal surface.  
 
To create an epithelial defect, an alcohol pad (80% ethanol, 3 mm diameter) was placed 
on the cornea for 60 seconds to weaken the epithelium. The weakened epithelium was 
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then removed by scraping with a sterile Tooke corneal knife. To create a stromal wound, 
a lamellar keratectomy was performed on the cornea. A corneal trephine (6 mm 
diameter) was used to create a circular wound to a depth of 100 microns. Colibri forceps 
were used to lift edge of the cut tissue such that a crescent knife could be used to remove 
the corneal tissue.  
 
Ex vivo organ culture  
The ex vivo model used here was modified from that of Evans and coworkers.15 After 
creating wounds on the corneal surface, the corneas were excised from the eyeballs 
while keeping part of the scleral rim intact (~ 5mm). The corneas were then placed 
upside down (with the endothelial side up) and filled with an agar-gel to provide support 
and maintain the curvature of the cornea. The agar gel was prepared by mixing the tissue 
culture medium and a 1% agar solution (in PBS) in a 1:1 volume ratio. The corneas 
(with the agar gel support) were then placed (epithelial side up) in a 12-well plate (6-
well plate for bovine corneas). Tissue culture medium was added to the wells such that 
the scleral rim was just immersed in the medium. The corneas were cultured in the 37oC 
incubator (at 5% CO2) with daily medium changes.   
 
Application of corneal scaffold to wound bed  
The nanofiber substrates and hydrogel precursor solutions were prepared and 
characterized as described in Chapter 5. For treated eyes, a layer of nanofibers was first 
placed onto the wound bed, 10 uL of hydrogel solution (either aECM-PEG or heparin-
based) was then pipetted onto the nanofibers, and finally, a second layer of nanofibers 
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was placed on top of the hydrogel. In the case of the heparin-based hydrogels, the cornea 
was then irradiated with a green LED light (525 nm) at 5 mW/cm2 for 5 minutes to 
initiate photo-polymerization of the hydrogel. For untreated eyes, 10 uL of sterile PBS 
was pipetted onto the wound bed.  
 
Fluorescein staining to visualize wound closure  
The area of the epithelial defect was assessed daily using fluorescein staining. Tissue 
culture medium was first removed, and the corneas were then washed twice by pipetting 
PBS over the corneal surface. 15 uL of fluorescein solution (0.25% in PBS, sterile-
filtered) was pipetted onto the surface of each cornea. Excess fluorescein solution was 
removed by pipetting PBS over the corneal surface. The wound area was then imaged 
under blue LED lights, and the extent of wound closure was analyzed using ImageJ.  
 
Transmission electron microscopy to examine corneal nanostructure 
A 2 mm x 5 mm block was cut from the central region of the cornea where the wound 
was originally created. The corneal blocks were fixed with 2.5% glutaraldehyde (in 
PBS) at 4oC overnight and post-fixed with 1% osmium tetroxide (in PBS) for 60 
minutes. Samples were then dehydrated in a graded series of ethanol (30% to 95%) and 
embedded in epoxy resin medium. 100-nm-thick sections were cut with a diamond knife 
on an ultramicrotome (Leica Ultracut UCT) and mounted on standard TEM grids. 
Samples were stained with 5% uranyl acetate and lead citrate prior to imaging (Tecnai 
Transmission Electron Microscope).   
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Histological analysis of corneal sections 
The central region of the corneas (including the wounded area) were cut using a 9.5-
mm-diameter corneal punch. These corneal ‘buttons’ were fixed in 4% 
paraformaldehyde (in distilled water) overnight at 4oC and dehydrated using a graded 
series of sucrose solution (10% for 4 hours, 30% overnight at 4oC). The corneal buttons 
were then embedded in OCT medium (Sakura Finetek, Torrance, CA) and sectioned 
using a cryotome to 7 micron-thick sections. The tissue sections were then processed 
for hematoxylin-eosin staining (H&E staining, described in Chapter 5). 
 
6.3 Results  
Developing ex vivo organ culture for corneal wounds  
In our ex vivo model, corneal wounds were created on fresh animal eyeballs, treated 
with our scaffold and cultured in a standard cell culture incubator (Figures 1 – 2). Using 
this model, we created either a surface wound (where the epithelial layer is debrided) or 
a deeper wound (where part of the stroma is also removed) (Figure 3). After creating 
the wound, we excised the cornea (with a 5 mm scleral rim intact) and cultured the 
cornea on top of an agar gel as described in the Methods section. The agar gel provided 
support for the cornea and helped maintain its curvature. The corneas were then placed 
in tissue culture plates and cultured in a 37oC incubator. Using this method, we were 
able to keep the corneas alive (with no signs of tissue deterioration) for up to 21 days.  
 
To validate that the corneas are indeed alive and retain their ability to heal and repair, 
we created a wound on a bovine cornea that penetrated into the stromal layer (Figure 
6-7 
 
4). Fluorescein staining was used to visualize wound closure. By day 2, the epithelial 
layer had completely regrown over the wound area. We then re-wounded the same 
cornea on day 3 by removing the epithelial layer and tracked epithelial regrowth. By day 
5, we did not see any fluorescein stained areas on the cornea, indicating that the 
epithelial layer was successfully regenerated. In addition to bovine corneas, we also 
validated the ex vivo organ culture model in porcine and rabbit eyes (Figure 5).  
 
Testing composite scaffold with ex vivo organ culture  
We used the ex vivo corneal culture model to test the efficacy of our scaffold in healing 
stromal wounds. For treated eyes, a layer of uniaxially-aligned nanofibers was placed 
onto the wound, followed by a hydrogel layer, and finally a second layer of nanofibers 
(of different orientation) was placed on top of the hydrogel. For untreated eyes, PBS 
was pipetted onto the wound bed as control.  
 
When aECM-PEG was used as the hydrogel layer, we observed that eyes treated with 
isotropic nanofibers had the fastest rate of wound closure (Figure 6). This confirms our 
results in vitro that epithelial cells migrate faster on isotropic nanofibers than on aligned 
ones. We then processed the isotropic nanofiber-treated corneas, along with control 
corneas, for transmission electron microscopy. Results showed that treated corneas had 
a more organized nanostructure compared to untreated eyes (Figure 7).  
 
When heparin-based hydrogels were used as the hydrogel layer, we observed that eyes 
treated with isotropic nanofibers had the fastest rate of wound closure (Figure 8), similar 
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to what we observed for aECM-PEG-hydrogel-treated ones. In a separate experiment, 
we examined the effects of growth factors on the rate of wound closure. In this 
experiment, we added either epidermal growth factor (EGF), fibroblast growth factor 
(FGF) or platelet-derived growth factor (PDGF) at 100 ng/mL to the heparin-based 
hydrogel formulation before application to the wound. We observed that the addition of 
growth factors slightly increased the rate of wound closure compared to those without 
growth factors. There were no observable differences between eyes treated with the 
different growth factors (Figure 9).    
 
To observe the morphology of the corneal tissue during the course of wound repair, we 
processed the corneas for histological analysis at certain time points. Untreated control 
corneas, aECM-PEG treated corneas and heparin-based hydrogel treated corneas were 
fixed with 4% paraformaldehyde on days 1, 3 and 5 following the procedure, dehydrated 
with a graded series of sucrose, and processed for frozen sectioning. H&E staining of 
the tissue sections showed that on day 1, re-epithelialization was not complete on any 
of the corneas (neither untreated or treated) (Figure 10 - 11). By day 3, a regenerated 
epithelial layer was observed in both untreated and treated corneas. There were signs of 
inflammation on corneas treated with the heparin-based hydrogels. On day 5, the 
epithelial layer was completely regrown in the aECM-PEG treated corneas. The 
regenerated epithelium appeared slightly leaky in the untreated control cornea and there 
was further inflammation observed in the heparin-based hydrogel treated corneas. 
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6.4 Discussion 
Developing ex vivo organ culture for corneal wounds  
In this study, we developed an ex vivo organ culture model for corneal wounds. We 
demonstrated that both epithelial defects and stromal wounds can be created in the 
corneas, and that the corneas retain their ability to heal and repair themselves. 
Furthermore, the corneas can be cultured in a 37oC incubator for up to 21 days, providing 
a good method to screen for suitable therapeutics prior to animal studies.  
 
Our system (modified from that developed from Evans et al.15) improves on existing 
models for ex vivo corneal culture in that the explanted cornea is supported by a soft, 
permeable agar gel, which allows the diffusion of nutrients from the culture medium to 
the endothelium of the cornea. This allows the endothelial cells to stay vital and retain 
their ability to pump water from the cornea to avoid swelling. 
 
We have also shown that the ex vivo model can be carried out in eyeballs obtained from 
various animal species (bovine, porcine or rabbits). Each species has their distinct 
advantages: bovine eyes are larger than porcine and rabbit eyes, and are thus easier to 
process and handle; porcine eyes share many structural similarities to human eyes and 
are the closest in dimension16,17; rabbit eyes have the smallest size out of the three 
species, but provide a good representation of results that would be expected in live 
rabbits (which is usually the next step in animal testing after mice).  
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During the development of our ex vivo model, we observed that the success of the 
experiments highly depended on the freshness of the tissue. Fresh eyeballs are firm due 
to their intraocular pressure, while eyeballs that are not fresh are soft and do not retain 
their shape when light pressure is applied. This is a sign that the tissue has started 
deteriorating and connective layers are starting to break down. When these eyeballs are 
used in the ex vivo model, there is a high probability that the cornea will begin rotting 
in the incubator after a few days. In our experiments, for bovine and porcine eyes, the 
eyeballs are harvested locally and shipped on ice for same day delivery. Ex vivo 
experiments are usually carried out within hours upon delivery. Rabbit eyes are harder 
to obtain, and are harvested and shipped from an out-of-state vendor. They are usually 
received the next day, and used immediately upon delivery.  
 
Despite our success in developing the ex vivo model, there is room for improvement. In 
our model, the corneas are cultured in a 37oC incubator with daily changes of media. To 
better simulate the blinking motion of the eye that aids in keeping the outer corneal layer 
moist, the corneas can be placed on a rocker such that the media in the tissue culture 
plate can routinely wash over the eye. Also, to improve nutrient diffusion from the 
culture media to the cornea, microchannels can be introduced in the agar gel base to 
create a perfusion culture system.  
 
Testing composite scaffold with ex vivo organ culture  
We used the ex vivo model to test the efficacy of our corneal scaffold. For both types of 
hydrogels (aECM-PEG and heparin-based), we observed that the rate of re-
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epithelialization was fastest over isotropic nanofibers than aligned ones, thereby 
confirming our in vitro results that epithelial cells migrate faster on isotropic nanofibers 
(Chapter 2).  
 
H&E staining showed that the epithelial layer in corneas treated with aECM-PEG 
hydrogel and nanofibers was completely regenerated, while corneas treated with the 
heparin-based hydrogel and nanofibers were incomplete and showed signs of infection. 
We also note that there was a higher percentage of eyeballs showing signs of rotting in 
the heparin-based hydrogel treatment group compared to the aECM-PEG treated ones 
during the course of the experiments (0-1 out of 10 eyes would show signs of rotting in 
aECM-PEG treated group, with the number increasing to 2-3 out of 10 eyes in the 
heparin-based hydrogel treated group). One possibility is that the eye tissue was already 
starting to deteriorate prior to the experiments; another explanation would be that the 
application of heparin to the wound area elicited an adverse effect that eventually led to 
infection. Although heparin has been associated with rapid endothelial cell repair, it has 
been suggested that heparin may not be beneficial to certain patients.18 Indeed, studies 
have shown that heparin may interfere with wound healing by activating collagenase 
and accelerating collagen degradation, thereby affecting the formation of normal 
collagen.19 It is possible that the application of heparin led to the activation of cytokines 
that are detrimental to corneal wound repair. Further experiments are needed to examine 
effects of heparin in corneal wounds.  
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In view of these results, we chose to test only the aECM-PEG hydrogel formulation in 
subsequent in vivo rabbit studies (Chapter 7). Though the ex vivo model is not a perfect 
model, it was an effective method to screen for potential scaffolds prior to rabbit 
experiments. By our conservative estimation, we were able to greatly reduce the number 
of rabbits needed for in vivo experiments (by over 100 animals).   
 
6.5 Conclusions 
An ex vivo corneal tissue culture is described: a mock wound (either an epithelial 
debridement or a deeper stromal wound) can be created in the cornea of an excised 
animal eyeball, treated with a candidate drug/scaffold, and cultured in a humidified 
incubator (37oC, 5% CO2). Our system improves on existing models for ex vivo corneal 
culture in that the endothelial layer is kept vital by allowing nutrients to diffuse from the 
culture medium through a permeable agar support gel to the endothelium. By allowing 
the endothelium to retain its ability to pump water from the cornea to avoid swelling, 
we can culture the corneas for up to 21 days to observe the effects of the treatment on 
corneal wound healing. We used the ex vivo model to study the efficacy of our two 
corneal scaffolds (nanofibers with either an aECM-PEG hydrogel or a heparin-based 
hydrogel) in treating stromal wounds. We determined that the aECM-PEG hydrogel 
treatment is preferred over the heparin-based treatment, since signs of infection were 
observed in those corneas treated with the heparin-based hydrogel. Using this model, 
we were able to screen for promising scaffolds (and eliminate those that had adverse 
effects) prior to carrying out further in vivo experiments, thereby greatly reducing the 
number of animals that would be needed otherwise. 
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Figure 1. Schematic of ex vivo corneal tissue culture. 1) Fresh animal eyeballs are 
purchased. 2) A wound (either epithelial defect or stromal wound) is created in the cornea. 
3-4) The cornea (with a 5-mm scleral rim intact) is excised from the eyeball. 5) The cornea 
is placed on an agar gel for support and 6) cultured in a tissue culture plate with medium 
at a level just above the scleral rim. 7-11) Corneas in the experimental group are treated 
with our composite scaffold with a layer of uniaxially-aligned nanofibers, followed by a 
layer of hydrogel, and finally a layer of isotropic nanofibers. Corneas treated with heparin-
based hydrogels are then irradiated with green light (525 nm) for 5 minutes for photo-
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polymerization. 12) Corneas are then placed in a 37oC incubator and monitored daily. Steps 
7-11 are skipped for untreated corneas.   
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Figure 2. Photographs of preparing a porcine cornea for ex vivo culture. i) Fresh eyeballs 
are purchased and ii) the fat and connecting tissue are trimmed from the eyeball. iii) A 
wound is created on the cornea and iv) the cornea is excised from the eyeball with 5-mm 
scleral rim intact. v) The iris is removed. vi) The cornea is placed upside down (endothelial 
side up) and vii) filled with the agar gel support. viii) The cornea is then placed right-side 
up into a tissue culture dish (here 12-well plate) and ix) culture medium is filled until the 
level is just above the scleral rim.  
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Figure 3. A) Two types of wounds can be created: an epithelial defect (which is a surface 
wound where only the epithelial layer is removed) or a stromal wound (where a lamellar 
keratectomy is performed such that part of the stroma, in addition to the epithelium, is also 
removed). B) To perform a lamellar keratectomy, a fresh eyeball is first secured onto a 
stable surface. A vacuum corneal trephine (6-mm diameter) is used to cut a circular wound 
of 100 microns deep. A pair of colibri forceps is used to lift edge of the cut tissue such that 
a crescent knife can be used to remove the corneal tissue.  
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Figure 4. Representative images showing the ability of a bovine cornea to repair itself in 
ex vivo culture. On Day 0, a stromal wound was created on the cornea. By Day 2, the 
epithelial layer had regrown over the wounded area. On Day 3, an epithelial defect was 
created on the same cornea, and by Day 5, the epithelial layer was regenerated once again.  
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Figure 5. Representative images demonstrating that our ex vivo corneal culture model can 
be carried out in several different animal species (bovine, top; porcine, middle; rabbit, 
bottom).  
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Figure 6. A) Representative images of wound closure for aECM-PEG treated and untreated 
corneas using fluorescein staining and B) Quantification of results in A). The initial wound 
was 6-mm diameter, 100 microns deep, created using a vacuum corneal trephine. Treated 
eyes were given a layer of uniaxially-aligned nanofibers, followed by a layer of aECM-
PEG hydrogel, and finally, a second layer of nanofibers was placed on top (either isotropic, 
radial or uniaxial). Control eyes were left untreated. Corneas treated with isotropic and 
radial nanofibers had a faster rate of epithelial regrowth compared to those treated with 
uniaxial nanofibers and untreated controls.  
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Figure 7. Transmission electron micrographs of an untreated cornea and a cornea treated 
with our scaffold made of aECM-PEG hydrogel and nanofibers. Results show that the 
collagen nanostructure is more disorganized in untreated corneas compared to those that 
were treated.  
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Figure 8. A) Representative images of wound closure for heparin-based hydrogel treated 
and untreated corneas using fluorescein staining and B) Quantification of results in A). The 
initial wound was 6-mm diameter, 100 microns deep, created using a vacuum corneal 
trephine. Treated eyes were given a layer of uniaxially-aligned nanofibers, followed by a 
layer of heparin-based hydrogel, and finally, a second layer of nanofibers was placed on 
top (either isotropic or uniaxial). Control eyes were left untreated. Corneas treated with 
isotropic nanofibers had a faster rate of epithelial regrowth compared to those treated with 
uniaxial nanofibers and untreated controls. 
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Figure 9. A) Representative images of wound closure for heparin-based hydrogel (loaded 
with growth factors) treated and untreated corneas using fluorescein staining and B) 
Quantification of results in A). The initial wound was 6-mm diameter, 100 microns deep, 
created using a vacuum corneal trephine. Treated eyes were given a layer of uniaxially-
aligned nanofibers, followed by a layer of heparin-based hydrogel, and finally, a second 
layer of isotropic nanofibers. The heparin-based hydrogel was loaded with either epidermal 
growth factor (EGF), fibroblast growth factor (FGF) or platelet-derived growth factor 
(PDGF) at 100 ng/mL. Control eyes were left untreated. Corneas treated with growth 
factors had slightly faster rate of epithelial regrowth compared to those without.   
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Figure 10. Hematoxylin and eosin (H&E) staining of tissue sections from treated and 
untreated corneas on day 1, 3 and 5 after the procedure. Red arrows denote the initial wound 
sites. On day 1, the epithelial layer has not regrown in any of the corneas. On day 3, the 
epithelial layer has regrown in the aECM-PEG-hydrogel treated cornea, while the heparin-
based hydrogel-treated cornea showed signs of infection. On day 5, the epithelial layer of 
the control corneas has mostly regrown.  
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Figure 11. Higher magnification pictures of those shown in Figure 10 of hematoxylin and 
eosin (H&E) staining of tissue sections from treated and untreated corneas on day 1, 3 and 
5 after the procedure.  
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Chapter 7 
 
In vivo study of corneal scaffold in a rabbit model 
 
7.1 Introduction 
In the first two chapters, we studied the effects of topological and biochemical cues on 
corneal epithelial cells, fibroblasts and myofibroblasts. We identified that gelatin 
nanofibers of isotropic orientation can promote epithelial cell migration, while those that 
are uniaxially aligned increase fibroblast migration and modulate the myofibroblast 
phenotype. We also demonstrated that growth factors (EGF, FGF and PDGF at 50 - 100 
ng/mL) can further decrease α-SMA expression. In Chapter 4, we developed a visible-
light photo-crosslinkable heparin-based hydrogel that can bind and release bioactive 
growth factors.  
 
We confirmed that our corneal scaffold, comprised of nanofibers and the heparin-based 
hydrogel, as well as the photo-crosslinking light dosage, are well-tolerated in a mouse 
model for epithelial defects (Chapter 5). In addition, we also fabricated and tested a 
different hydrogel material that is made of artificial extracellular matrix (aECM) 
proteins. To test the cellular response to our scaffold in corneal stromal wounds, we 
developed an ex vivo corneal tissue culture where the corneas can be kept alive for up 
to 21 days and retain their ability to heal and repair wounds (Chapter 6). In these studies, 
we observed that a scaffold that contains the aECM-based hydrogel is more favorable 
than one with the heparin-based hydrogel in treating corneal wounds.  
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Here, in collaboration with Dr. Bala Ambati at the University of Utah Moran Eye Center, 
we tested these scaffolds in stromal wounds created on rabbit corneas in vivo. Although 
the anatomy of rabbit eyes is slightly different from that of human eyes (in particular, 
rabbit eyes do not have Bowman’s layer)1,2, rabbit experiments have been the “gold 
standard” in testing candidate treatments for corneal wound repair3-6.  
 
For a given eye, a lamellar keratectomy was performed to make a 6-mm diameter, 100 
micron deep corneal wound, which was then treated with our aECM-based scaffold or 
left untreated as control. The rate of epithelial regrowth was compared between 
experimental and control groups. The number of myofibroblasts and immune cells were 
analyzed by immunostaining of tissue sections from harvested corneas. Results show 
that our aECM-based scaffold shows promise in promoting a more orderly corneal 
wound response.  
 
7.2 Methods 
Fabrication of scaffold  
Fabrication of nanofibers 
Gelatin (type A, porcine, Sigma Aldrich, St. Louis, MO) was dissolved in a mixture of 
2:3:5 distilled water/ethyl acetate/acetic acid at 12% w/w and stirred overnight at 37oC. 
Electrospun nanofibers were fabricated from the gelatin solution using a 22-gauge 
needle, +15 kV voltage and 8 cm needle-to-collector distance. Isotropic nanofibers were 
collected on a metal ring (6 mm diameter) placed on a planar electrode, and uniaxially-
aligned nanofibers were made using a pair of split electrodes (6 mm apart). 
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Fabrication of aECM-PEG hydrogels  
Artificial extracellular matrix proteins (aECM, 34.6 kDa) were synthesized and 
characterized using established protocols described elsewhere. To fluorescently label 
aECM proteins (aECM-f), aECM protein (2.5 mg/mL in PBS) was mixed with NHS-
rhodamine (7 molar excess) for one hour at room temperature. Excess dye was removed 
by fluorescent dye removal columns (Thermo Scientific). aECM-f proteins were then 
lyophilized for storage until use. aECM protein solutions were prepared by dissolving 
aECM in PBS (34% aECM, 2% aECM-f w/v) overnight at 4oC. Four-arm poly(ethylene 
oxide) terminated with succinimidyl glutarate groups (PEG-S, Polymer Source, 
Montreal, Canada) was dissolved in PBS (25% w/v) just prior to hydrogel fabrication. 
The aECM solution and PEG-S solution were mixed together in a 1:1 ratio to prepare 
the aECM-PEG precursor solution (final concentration: 18% aECM, 12.5% PEG-S). 
The precursor solution was used immediately after preparation.  
 
Characterization of aECM-PEG hydrogels  
To determine the pore characteristics of fabricated aECM-PEG hydrogels, the hydrogels 
were first swollen in PBS for 2 days at 37oC, and then flash-frozen in liquid nitrogen for 
10 minutes. The frozen hydrogels were then lyophilized for 2 days. Cross-sections of 
the hydrogels were prepared by cutting with a cold razor blade, and mounted onto 
aluminum stubs. Samples were sputter-coated with 10 nm palladium and observed in a 
field emission scanning electron microscope (SEM, Zeiss 1550 VP) at an accelerating 
voltage of 5 kV.  
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Animal experiments  
The experiments in a rabbit model were performed in the Moran Eye Center according 
to the Association for Research in Vision and Ophthalmology Statement of Use for 
Animals, and were approved by the Institutional Animal Care and Use Committee of 
the University of Utah. All drugs used were pharmaceutical-grade ophthalmic solutions. 
All scaffold components were sterilized as follows prior to use. Nanofiber mats were 
first immersed in 70% ethanol (twice, 10 minutes each) and then placed under UV light 
for 30 minutes. Hydrogel precursor solutions were sterile filtered through a 0.2 micron 
filter. All procedures were carried out in a sterile operating room following standard 
aseptic techniques: all personnel wore sterile surgical gown, mask and gloves. Between 
consecutive rabbits all personnel changed gloves. Each rabbit was covered with a sterile 
drape (with an opening for access to the animal’s eye) during the procedure. All supplies 
needed (e.g., forceps, trephines, etc) were autoclaved under high temperature and 
pressure in between procedures.  
 
Lamellar keratectomy in rabbits 
Rabbits (New Zealand white, female, ~3.5 kg) were anesthetized with ketamine (35 
mg/kg) and xylazine (5 mg/kg). Betadyne was applied to the rabbit eyes prior to surgery. 
Droplets of proparacaine (0.5%, Bausch & Lomb), tropicamide (1%, Bausch & Lomb), 
cyclopentolate (1%, Akorn) and phenylephrine hydrochloride (2.5%, Falcon) were then 
applied to the rabbit eyes. A corneal trephine (6 mm diameter) was used to create a 
circular wound to a depth of 100 microns. A crescent knife was then used to remove the 
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corneal tissue. For each rabbit, the left eye was untreated to serve as a control and the 
right eye was treated with our scaffold. Our treatment involved placing a layer of 
nanofibers gently onto the wound bed, applying a layer of aECM-PEG hydrogel (10 
µL), followed by placing an additional layer of nanofibers on top of the hydrogel. 
Following surgery, erythromycin ointment was applied to both treated and untreated 
eyes. The rabbits were allowed to recover from surgery, and their eyes were observed 
daily for signs of inflammation. Six rabbits were used in each experimental group. A 
surgical error occurred in one eye of the aECM-PEG treated experimental group (the 
trephine was not properly zeroed and the resulting incisions were too deep) and the 
rabbit was euthanized. No data was recorded for that animal.  
 
Tracking epithelium regrowth following procedure 
The surface area of the epithelial defect was assessed on days 6 and 13 after surgery. To 
observe the wound boundary, 1 µL of fluorescein solution (0.25% in PBS) was pipetted 
onto the surface of each eye. Excess fluorescein solution was rinsed with 0.9% sodium 
chloride solution and removed by gently touching a sterile cotton swab to the side of the 
eye. The wound area was then imaged under blue LED lights, and the extent of wound 
closure was analyzed using ImageJ.  
 
Staining and immunolabeling of corneal sections  
Rabbits were euthanized (3 from each group on day 6 and remaining 3 on day 13), and 
their corneas were harvested. Frozen sections were prepared by first fixing the excised 
corneas with 4% paraformaldehyde for 2 hours, and then placing in two sucrose 
7-6 
 
solutions (10% for 2 hours, 30% overnight). The corneas were then embedded in OCT 
medium and sectioned using a cryotome to 7-micron-thick sections. For 
immunofluorescence, frozen sections were blocked with 5% (w/v) fetal bovine serum 
(FBS) in phosphate-buffered saline with 0.2% tween. The sections were probed with 
mouse anti-αSMA conjugated to FITC (1:400 dilution, Sigma Aldrich, St. Louis, MO) 
or mouse anti-neutrophil (1:200 dilution, Hycult Biotech) or mouse anti-macrophage 
(1:200 dilution, Abcam) antibodies overnight at 4oC. The secondary antibody Alexa-
Fluor 647 goat anti-mouse IgG (Life Technologies) was used at 1:1000 dilution for 1 
hour. Nuclei was stained with DAPI.  
 
Paraffin sections were prepared by fixing excised corneas with 4% paraformaldehyde 
for 2 hours, dehydrating them through a graded ethanol series, and finally embedding 
them in paraffin. Sections were cut (7 microns) and processed for hematoxylin-eosin 
(H&E) and Masson’s trichrome staining. In Masson’s trichrome, blue staining 
represents collagen. To quantify fibrosis, ImageJ software was used to calculate the 
number of highest-intensity blue pixels, which was then divided by the total number of 
pixels per corneal section.  
 
 
7.3 Results  
To study the efficacy of our scaffold in treating corneal wounds that penetrate into the 
stroma, we chose a rabbit model and performed a lamellar keratectomy to create a 6-
mm diameter, 100 micron deep wound (Figure 1). As in the mouse experiments in 
Chapter 5, the wound in the left eye was treated with PBS followed by topical antibiotic 
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(“untreated”) to serve as a control, while the right eye was “treated” with our scaffold: 
a layer of uniaxially-aligned nanofibers at the base of the wound bed (Figure S-1), a 
hydrogel to fill the wound, and a top layer of unoriented nanofibers. Two hydrogels 
were compared: (i) aECM-PEG hydrogel and (ii) aECM-PEG hydrogel with 3.5% 
pluronic F-127 added as a porogen (“aECM-PEG-F127”). 
 
The rabbits showed no signs of distress during the recovery period after surgery. The 
cornea was observed to be transparent post-op and in the daily examinations thereafter. 
No differences in inflammation were observed between treated and control, indicating 
that our treatment was well-tolerated in rabbits.  
 
The extent of epithelial closure was visualized on Days 1, 6 and 13 with fluorescein 
staining (Figure 2). We observed that treated rabbit eyes (in both aECM-PEG and 
aECM-PEG-F127 experimental groups) had similar rates of epithelial regrowth 
compared to untreated control eyes: Day 1, the epithelial defects had decreased in size; 
Day 6, treated eyes had slightly smaller epithelial defects than the untreated controls; 
and Day 13, treated eyes showed very small epithelial defects (point-like) and untreated 
control eyes showed diffuse update of fluorescein over an area similar to that of the 
initial wound.  
 
Three rabbits from the aECM-PEG-F127 group and two from the aECM-PEG group 
(one animal was lost, see Methods) were sacrificed on Day 6; and the remaining three 
from each group were sacrificed on Day 13. Their corneas were harvested and processed 
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for histological examination. In accord with observations of epithelial closure by 
fluorescein staining, H&E staining of tissue sections showed that the epithelial layer had 
not fully regrown in either treated or untreated corneas on Day 6 (Figure 2, S-2 to S-4). 
Interestingly, epithelial defects could not be found in H&E stained sections of specimens 
taken on Day 13, despite the fact that some fluorescein stain penetrated the epithelium 
(Figure 2, S-2 to S-4). The regenerated epithelium of corneas treated with aECM-PEG 
had a morphology closest to that of a healthy unwounded cornea (based on prior 
literature and tissue sections from the corneas of fresh rabbit eyes purchased from 
vendor, Figure S-5).  
 
Immunolabeling of αSMA protein (a cell marker for the hyperactive myofibroblast 
repair phenotype) in the tissue sections showed that there were less myofibroblast cells 
in treated corneas compared to controls that received no treatment (Figure 3, S-6). There 
were no measurable differences in the number of myofibroblasts between the two treated 
groups.  
 
In addition, there were also fewer macrophages and neutrophils in treated corneas 
compared to controls (Figure 4, S-7, S-8), with the largest decrease in corneas treated 
with aECM-PEG-F127. Masson’s trichrome staining showed a decrease of blue color in 
the repaired stroma of treated corneas compared to controls (Figure 5), indicating that 
there was less collagen formation in the scaffold-treated corneas.   
 
7.4 Discussion 
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In these studies, we tested the aECM-PEG hydrogel treatment, since we observed more 
favorable results using this treatment than the heparin-based hydrogels in the ex vivo 
corneal culture experiments (Chapter 6). In particular, we chose to use aECM-PEG 
hydrogel at pH 7, since we observed no measurable differences between the effects of 
the pH 7 and 8 formulations in the mice experiments. In addition, NHS-groups 
hydrolyze at a slower rate at pH 7, thus allowing more time between preparing the 
precursor solution and applying it to the wound (the half-life of hydrolysis for NHS-
groups is ~4 hours at pH 7 and 0oC, while the half-life is only 10 minutes at pH 8.6 and 
4oC7). 
 
A key concern in using our scaffold to treat deeper corneal wounds is whether the 
aECM-PEG hydrogel layer would allow cell infiltration. To address this concern, 
pluronic F-127 was added to the formulation as a porogen to induce the formation of 
larger pores. This strategy has been employed in PLLA porous foams to enhance pore 
size and improve the interconnectivity among pores.8,9 Indeed, the addition of pluronic 
F-127 into our aECM-PEG hydrogels (aECM-PEG-F127) resulted in the formation of 
larger pores compared to those without (Figure S-9). Live/dead staining of corneal 
fibroblasts encapsulated in the aECM-PEG hydrogels showed that the addition of 
pluronic F-127 did not affect cell viability in vitro (Figure S-10). Using a scratch wound 
assay in vitro, we observed that the migration rate of fibroblasts into the ‘mock wound’ 
containing aECM-PEG-F127 was slightly faster than that with aECM-PEG (Figure S-
11).  
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The rabbit studies were divided into two experimental groups: one treated with aECM-
PEG, and the other with aECM-PEG-F127. In both groups, a layer of uniaxially-aligned 
nanofibers was first placed onto the wound bed, followed by the addition of a hydrogel 
layer, and finally, a layer of isotropic nanofibers was placed on top of the hydrogel.  
 
Rabbit study results confirm observations from mice experiments that our scaffold is 
well-tolerated in animals, and supports epithelial regrowth. There were no measurable 
differences in the rate of epithelial closure between the two treatments. Interestingly, the 
epithelium in most control eyes were not fully restored after 13 days, evidenced by the 
large area stained with fluorescein. H&E staining of tissue sections showed the area that 
stains is not de-epithelialized, but rather, the epithelium is leaky. Elevated cytokines 
associated with inflammatory response tend to make epithelia and endothelia leaky10-12; 
perhaps the restoration of the epithelial barrier in treated eyes results from reduced 
cytokine levels evident in the decreased production of αSMA and fewer numbers of 
macrophages and neutrophils.  
 
Immunostaining of tissue sections showed that the population of myofibroblasts and 
inflammatory cells (macrophages and neutrophils) were greatly reduced in the wound 
bed treated with our scaffolds relative to untreated controls, indicating that our treatment 
was effective in promoting a calmer wound response. This confirms our observations in 
vitro that fewer myofibroblasts are observed on oriented nanofibers than on planar 
surfaces. In addition, Masson’s trichrome staining of tissue sections showed that there 
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is less collagen formation in treated corneas than in untreated ones, indicating our 
treatment is effective in reducing fibrosis.  
 
There were no significant differences in cellular response to the scaffolds between the 
two experimental groups, suggesting that the addition of pluronic F-127 and thus size 
of pores in the scaffold is not a major factor in orchestrating orderly wound repair. 
Rather, we speculate that both hydrogel formulations allow repair myofibroblasts to 
infiltrate and migrate onto the uniaxially-aligned nanofibers. The topographical and 
biochemical cues from the nanofibers induce the myofibroblasts to express lower levels 
of αSMA and initiate a calmer wound response, which results in fewer activated immune 
cells and less formation of disorganized collagen. Guillemette and coworkers' 
hypothesis that cells which respond to physical cues on an underlying substrate can 
induce other cell layers to behave in a similar fashion may also hold true in the present 
study13: myofibroblasts on the oriented nanofibers may influence myofibroblasts 
throughout the scaffold to reduce their αSMA expression levels.  
 
In the current study, the rabbits were only kept alive for 14 days after surgery. Jester and 
colleagues have shown that after full thickness stromal wounds, αSMA expression in 
myofibroblasts can be detected as early as 3 days in the anterior stroma and at 7 days 
throughout the thickness of the stroma. Thus, a time scale of 14 days is sufficiently long 
to observe effects of our scaffold treatment in modulating αSMA expression.14 
However, a longer duration rabbit study is still needed evaluate effects of the scaffold 
on the morphology of regenerated tissue (e.g., collagen fiber diameter, collagen 
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orientation, ratio of proteoglycans to collagen, lamellar superstructure). Indeed, Wang 
and colleagues have shown that a study of 3 months is required to evaluate corneal haze 
development, and confirm morphology and transparency of a healed stroma.15  
 
Here, based on the results from the ex vivo corneal tissue cultures, both of the treated 
groups in the present rabbit studies received nanofibers. In view of the favorable 
response to nanofiber/aECM-PEG/nanofiber scaffolds, future work evaluating the role 
of each of the three layers is warranted. Specifically, experimental groups that are treated 
with the aECM-PEG hydrogel alone, aECM-PEG and an underlayer of oriented 
nanofibers, and aECM-PEG hydrogel with an overlayer of unoriented nanofibers should 
be compared. It is possible that the aECM-PEG hydrogel acts as a buffer for cytokines 
released upon corneal injury and is sufficient to mediate a calmer wound response in the 
stroma without the use of nanofibers. The incremental benefit of the nanofibers might 
be greater for the unoriented overlayer than for the underlayer. Simplifying the treatment 
to hydrogel alone or hydrogel with only an overlayer of nanofibers would greatly 
simplify the treatment.  
 
 
7.5 Conclusion 
We tested the efficacy of our corneal scaffold (nanofibers with an aECM-PEG hydrogel) 
in vivo using a rabbit model for stromal wounds. As expected from observations made 
in the in vivo mice and ex vivo culture experiments, our treatment supported epithelial 
regrowth over the scaffold. Immunostaining of tissue sections revealed that there was a 
decreased expression of αSMA protein in treated corneas than in untreated ones. To our 
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knowledge, this is the first study which has demonstrated in vivo that the expression of 
αSMA can be modulated by topological and biochemical cues presented on nanofibers. 
In addition, we found that there were fewer immune cells (macrophages and neutrophils) 
in treated corneas than untreated corneas. Further experiments are needed to fully 
examine whether the repaired cornea remains transparent in the long term, but in this 
short-term study, our  corneal scaffold shows promise in promoting a calmer wound 
response. 
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Figure 1. Schematic of in vivo rabbit model for stromal wounds. For each rabbit eye, a 
lamellar keratectomy was performed to create a 6-mm diameter, 100 micron deep wound. 
For treated eyes, a layer of uniaxially-aligned nanofibers were placed in the wound bed, 
followed by a layer of aECM-PEG hydrogel, and finally, a layer of isotropic nanofibers 
was placed on top of the hydrogel. For control eyes, 15 µL of PBS was pipetted onto the 
wound bed.  
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Figure 2. Representative images of fluorescein staining to visualize wound closure. The 
wound area was imaged on day 1, 6 and 13. Tissue sections from corneas harvested on day 
6 and 13 were also subjected to H&E staining. Epithelial regrowth was faster in treated 
corneas than untreated ones. The corneal morphology for treated corneas also appeared 
more normal and organized than untreated controls.   
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Figure 3. A) Representative images of immunolabeling of myofibroblasts and B) 
quantification of results. Corneas were harvested on day 14, fixed, dehydrated and 
embedded in optimum cutting temperature (O.C.T. compound). The samples were then 
sectioned using a cryotome. The 7-micron-thick tissue sections were labeled with FITC-
conjugated anti-αSMA. Treated corneas had significantly fewer αSMA-positive 
myofibroblasts than untreated ones. There were no measurable differences between the two 
treated groups.  
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Figure 4. Representative images of immunolabeling of immune cells  and quantification 
of results. Corneas were harvested on day 14, fixed, dehydrated and embedded in optimum 
cutting temperature (O.C.T. compound). The samples were then sectioned using a 
cryotome. The 7-micron-thick tissue sections were labeled with antibodies against 
macrophages  (A) and neutrophils (B). Alexa-Fluor 647 goat anti-mouse antibodies were 
used as the secondary antibodies. Treated corneas had significantly fewer macrophages and 
neutrophils than untreated ones, with the most significant decrease in the aECM-PEG-
F127-treated eyes.   
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Figure 5. A) Representative images of Masson’s Trichrome staining of tissue sections and 
B) quantification of results. Corneas were harvested on day 14, fixed and processed for 
paraffin embedding. The samples were then sectioned into 7-micron-thick sections and 
subjected to Masson’s Trichrome staining.  Treated corneas had less collagen formation 
than untreated ones.  
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Figure S-1. Scanning electron micrographs showing the isotropic and uniaxially-aligned 
nanofibers used in this study.  
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Figure S-2. Quantification of epithelial closure as observed from fluorescein staining. 
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Figure S-3. H&E staining of tissue sections from all rabbits used in the aECM-PEG 
experimental group. For each rabbit, their left eye was left untreated, and their right eye 
was treated with our composite scaffold. Three rabbits were sacrificed on Day 6, and the 
remaining three were sacrificed on Day 13. Red arrows denote the initial wound site.  
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Figure S-4. H&E staining of tissue sections from all rabbits used in the aECM-PEG-F127 
experimental group. For each rabbit, their left eye was left untreated, and their right eye 
was treated with our composite scaffold. Three rabbits were sacrificed on Day 6, and the 
remaining three were sacrificed on Day 13. Red arrows denote the initial wound site. 
  
7-24 
 
 
Figure S-5. For comparison purposes, we also prepared tissue sections from rabbit corneas 
(using fresh rabbit eyeballs purchased from Pel Freez). Corneas were either left unwounded 
(to show the morphology of a healthy cornea) or wounded using the same protocol as the 
in vivo studies (these corneas were processed immediately after creation of the wound to 
show the morphology of a freshly-wounded cornea). 
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Figure S-6. Immunolabeling of myofibroblasts in tissue sections of corneas harvested on 
day 13 (all three rabbits represented here, extension of Figure 3). Treated corneas had 
significantly fewer αSMA-positive myofibroblasts (green) than untreated ones. There were 
no measurable differences between the two treated groups. 
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Figure S-7. Immunolabeling of macrophages in tissue sections of corneas harvested on 
day 13 (all three rabbits represented here, extension of Figure 4A-B). Treated corneas had 
significantly fewer macrophages (red) than untreated ones. There were no measurable 
differences between the two treated groups. 
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Figure S-8. Immunolabeling of neutrophils in tissue sections of corneas harvested on day 
13 (all three rabbits represented here, extension of Figure 4C-D). Treated corneas had 
significantly fewer neutrophils (red) than untreated ones. There were no measurable 
differences between the two treated groups. 
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Figure S-9. Scanning electron micrographs of the cross-sections of aECM-PEG (left 
column) and aECM-PEG-F127 (right column) hydrogels. Hydrogels were swollen for 2 
days in PBS at 37oC, lyophilized and processed for SEM imaging. Results show that the 
addition of 3.5% Pluronic F-127 increased the pore size of the hydrogel.  
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Figure S-10. Live/dead staining of encapsulated corneal fibroblasts in aECM-PEG and 
aECM-PEG-F127 hydrogels show that cells are viable. Live cells are stained green.   
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Figure S-11. Using a scratch wound assay in vitro, we observed that corneal fibroblasts 
were able to migrate into the ‘mock wound,’ which was filled with either the aECM-PEG 
or the aECM-PEG-F127 hydrogel. There were slightly more infiltrated cells in the hydrogel 
with added Pluronic F-127 than that without. Corneal fibroblasts are stained green using 
acridine orange.  
 
